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Investigating depression in patients with cancer and patients with myocardial infarc­
tion using systematic reviews and meta-analytic techniques 
Anna Meijer 
1. Het systematisch screenen voor depressie bij patienten met kanker kan op basis 
van de huidige literatuur niet warden aanbevolen en moet daarom voorlopig 
warden afgeraden. 
2. Screenen voor depressie en distress bij patienten met kanker heeft mogelijk 
schadelijke effecten. 
3. De uitkomsten van systematische literatuurstudies moeten beter warden 
geTntegreerd in nieuw wetenschappelijk onderzoek en in klinisch beleid. 
4. Sommige symptom en van depressie na een hartaanval kunnen een cardioprotectief 
effect hebben. 
5. Effectieve behandeling van depressie na een hartaanval levert mogelijk een 
betere prognose op. 
6. In de psychosomatische wetenschap wordt te veel belang gehecht aan de 
resultaten van individuele studies. 
7. De resultaten van systematische reviews en meta-analyses bevatten meer 
informatie dan de resultaten van de individuele studies die ze omschrijven. 
8. "Like fire, the X2 test is an excellent servant and a bad master"1 
9. "For in much wisdom is much grief: and he that increaseth knowledge increaseth 
sorrow."2 
1Sir Bradford Hill {1965}. The environment and disease: association or causation. Proceedings of 
the Royal Society of Medicine; 58: 295-300. 
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In this thesis, the focus will be on systematic reviews and meta-analytic techniques, and their 
strengths and limitations, in addressing a number of key issues in relation to depression in 
medical patients. Two types of non-communicable medical illness, cancer and myocardial 
infarction (Ml), were studied as examples of the problems encountered in investigating 
depression in medical patients. In these areas of research, both scientists and health care 
professionals disagree amongst each other on causes, effects, and treatment of depression. 
Key issues concerning depression for each type of disease are investigated, and meta­
analytic research methods are applied. 
Systematic review and meta-analysis 
The main purpose of this thesis is to critically review the existing evidence on depression 
research within cancer and Ml patients. In both areas of depression investigation, results 
of existing research are often conflicting and difficult to integrate. Therefore, methods of 
systematic review and meta-analysis are used to investigate the conclusions, quality, and 
reliability of existing evidence, as well as the heterogeneity among studies. All meta-analytic 
techniques start with a systematic search and selection of relevant literature, and a critical, 
narrative review of the evidence (systematic review). When the relevant quantitative data 
are sufficiently similar and available, such as odds ratios or effect sizes, these data can be 
used in a combined analysis of quantitative data to calculate an overall estimate of the 
strength of an association or effect (meta-analysis). In addition to common systematic 
reviews and meta-analyses, which are typically based on summary data reported in journal 
articles, a technique called individual patient data (IPD) meta-analysis can also be applied. In 
IPD meta-analysis, original, raw data is collected and combined for analysis. This technique 
is already being used in medical research, for example in drug trials, but its utilization in 
psychosomatic research is increasing. It not only allows for more uniform analyses and more 
detailed subgroup analyses, but also provides more power for performing such analyses. 
In this thesis, these three techniques (systematic review, summary data meta-analysis, and 
IPD meta-analysis) are applied and evaluated. First, evidence on screening for depression and 
distress in cancer patients was investigated in three papers, which was done in systematic 
reviews. Second, research on the association between post-Ml depression and (cardiac) 
prognosis was also systematically reviewed and in addition quantitatively summarized in two 
summary data meta-analyses, one on the association between depression and inflammation 
in post-Ml patients and one on the association between post-Ml depression and prognosis. 
Finally, the most comprehensive technique is demonstrated in the final chapter, which is 
an IPD meta-analysis of post-Ml depression and (cardiac) prognosis. These techniques are 
thus applied in the context of depression in medical patients, which will be introduced in 
the following section. 
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Chapter 1 
Depression in medical patients 
Depression is one of the most common mental disorders, with a 1-year prevalence of 
around 4-7% in the general population 2, 3, 4• The World Health Organization (WHO) expects 
that by 2020, depression will be the second highest ranking disorder for burden of disease 5, 
and by 2030 the highest in high income countries 6• Its core symptoms are either depressed 
mood or loss of interest, or both, and a number of other symptoms, such as sleeping 
and concentration difficulties (see Text Box 1 7). Typically, however, symptom profiles of 
depression tend to vary widely across patients. The causes of depression are most likely 
a combination of genetic factors, as heritability of lifetime depression is estimated to be 
around 36% 8• 9, and environmental factors, such as stressful life events 10• 11. 
Text Box 1: Major depressive disorder 
Major depression has been defined as follows in the Diagnostic and Statistical Manual-IV 7: 
A. Five (or more) of the following symptoms have been present during the same 2-week period and represent 
a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss 
of interest or pleasure. 
Note: do not include symptoms that are clearly due to a general medical condition, or mood incongruent 
delusions or hallucinations. 
(1) Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., feels 
sad or empty) or observation made by others (e.g., appears tearful). Note: In children and adolescents, 
can be irritable mood. 
(2) Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day 
(as indicated by either subjective report or observation made by others) 
(3) Significant weight loss when not dieting or weight gain (e.g. a change of more than 5% of body weight in 
a month), or decrease or increase in appetite nearly every day. Note: In children, consider failure to make 
expected weight gains. 
(4) Insomnia or hypersomnia nearly every day 
(5) Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective 
feelings of restlessness or being slowed down) 
(6) Fatigue or loss of energy nearly every day 
(7) Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day 
(not merely self-reproach or guilt about being sick) 
(8) Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective 
account or as observed by others) 
(9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or 
a suicide attempt or a specific plan for committing suicide 
B. The symptoms do not meet criteria for a Mixed Episode 
C. The symptoms cause clinically significant distress or impairment in social, occupational, or other important 
areas of functioning 
D. The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse, a 
medication) or a general medical condition (e.g., hypothyroidism) 
The symptoms are not better accounted for by bereavement, i.e., after the loss of a loved one, the symptoms 
persist for longer than 2 months or are characterized by marked functional impairment, morbid preoccupation 
with worthlessness, suicidal ideation, psychotic symptoms, or psychomotor retardation. 
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Depression occurs more often in people with serious medical conditions than in people who 
are otherwise healthy. The prevalence of major depression in medical patients, depending 
on the type of illness, is estimated to be between 10% and 30% 3• 12• 
On top of the negative impact on patients' quality of life in general, depression in the 
medically ill appears to be consistently associated with poorer outcomes. Depressed patients 
are rehospitalized more often, have more adverse disease-related events, and even die 
earlier than non-depressed patients 12• The causal mechanisms underlying this association 
are difficult to investigate, but the association is most likely bidirectional. That is, depression 
is a risk factor for the development and course of physical disease, and physical disease is a 
risk factor for the development of depression. 
Biological and psychological (cognitive, behavioral and emotional) mechanisms are involved 
in these associations. Biologically, depression may be associated with worsened disease 
outcomes through physiological processes that are directly causal. Physiological mechanisms 
are, for example, vascular disease, changes to the autonomic nervous system (ANS), or to 
hypothalamic-pituitary-adrenal (HPA)-axis activity 12• 13• Conversely, biological processes 
involved in medical diseases have also been implicated in the development of depression. 
In addition, increased inflammatory markers have been found in depressed patients 14• 
Unhealthy behaviors associated with depression are, for example, lack of exercise, poor diet, 
smoking, and poor medication adherence 12• For example, depressed medical patients have 
up to three times higher non-adherence rates 15• These mechanisms may also be common 
underlying factors causing both depression and medical disease, resulting in an indirect 
association. Cognitively and emotionally, functional loss, fear of dying and the impact of 
having a serious medical condition can also result in elevated symptoms of depression. 
This complex interaction between physical and psychological processes is reflected in the 
problems encountered when diagnosing depression in medical patients. According to the 
(DSM)-IV, depression cannot be diagnosed when the symptoms are a result of "the direct 
physiological effects of ... a medication ... or a general medical condition" 7• Depression 
is defined in part by somatic symptoms, such as fatigue, sleeping difficulties, and eating 
problems. However, these symptoms are not unique to depression, but are non-specific 
and occur in a large number of diseases, and it is hard to determine to what extent these 
symptoms are due to depression or to the medical illness. The association between 
depression and poorer outcomes in medical patients may therefore be partly confounded 
by the symptoms of the medical disease itself. 
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Screening for depression and distress in patients with cancer 
Cancer is a process of unregulated cell division, in which tumors form and invade surrounding 
bodily tissues, causing damage and loss of function, as well as potentially spreading 
malignant cells to other parts of the body. Cancer is among the top 10 main causes of death 
worldwide (causing 13% of deaths) 16• 17• 
In cancer patients, depression prevalence is estimated to be on average around 25%, but rates 
vary widely across different types and stages of cancer 18-20• Depression in cancer patients is 
associated with elevated all-cause and cancer mortality 21• In addition to major depression, 
a concept used often in oncological practice and research is distress. Distress encompasses 
elevated symptoms of psychological problems, ranging from mild to severe, and can include 
anxiety, adjustment disorder, and major depression. There is no standard definition and 
therefore no gold standard or cut-off for the diagnosis of distress, and multiple instruments 
and methods are used to assess distress. In this thesis, the definition of distress as provided 
by the National Comprehensive Cancer Network is used: " ... a multi-determined unpleasant 
emotional experience of a psychological (cognitive, behavioral, and emotional), social, and/ 
or spiritual nature that may interfere with the ability to cope effectively with cancer, its 
physical symptoms and its treatment. Distress extends along a continuum, ranging from 
common normal feelings of vulnerability, sadness and fears to problems that can become 
disabling, such as depression, anxiety, panic, social isolation, and spiritual crisis" 22• As the 
concepts of depression and distress overlap, but are different nonetheless, both will be 
investigated in this thesis. 
In oncology, awareness of the adverse consequences of depression and distress for patients 
with cancer has increased greatly, and there are calls for improved psychosocial treatment. 
Many institutions recommend routine screening for depression or distress in an attempt to 
better help cancer patients with psychological problems. However, the scientific basis for 
these recommendations is not always clear. In current medicine and psychiatry practice, 
treatment should be based on empirical evidence, and benefits, risks, and costs of routine 
screening should be assessed carefully before recommendations can be made. 
Instating routine screening for distress or depression appears attractive, as it is relatively 
fast, easy and low-cost, and many cancer centers already use screening instruments to 
assess patients at high-risk of psychological problems. However, methods of screening that 
are ineffective are not necessarily harmless. First, patients incorrectly diagnosed as being 
depressed may be submitted to stressful and expensive treatments that are not helpful, 
and patients incorrectly diagnosed as not-depressed may be deprived from necessary 
treatment. Therefore, screening instruments need to be accurate. Second, screening can 
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only be effective when patients who screen positive are provided with effective treatment. 
Although in general it is believed that pharmacological and psychological anti-depressant 
treatment is effective, high quality evidence based on RCTs in cancer patients is still scarce 
and inconclusive. In addition, patients may not be provided with the necessary follow­
up psychosocial support when such support is not available as an integrated part of a 
screening program. Evaluating the current evidence on treatment effectiveness is essential 
in establishing whether or not routine screening will be useful in cancer patients. Third, 
patients enrolled in routine depression or distress screening programs need to have better 
outcomes than those receiving treatment as usual for screening to be useful. 
Regarding screening for depression or distress in cancer patients, essential empirical 
evidence on these issues has not yet been summarized and evaluated. The evidence was, 
therefore, systematically reviewed to provide scientific grounds for recommendations either 
against or for routine screening for depression and distress in cancer patients. In addition, 
one chapter was added that assesses the risk of bias involved in investigating screening for 
depression and distress. 
Depression in patients with myocardial infarction 
The belief in a link between the heart and affect is so entrenched in most cultures that it 
seems a natural fact. In language, the word "heart" is often used to describe mood states 
or emotions. The statement made by a 17th century English scholar, allegedly suffering from 
depression himself, illustrates how the interaction between mood and the heart has been 
the object of study for a long time: 
"The bad (affections) are simple or mixed: simple for some bad object present, as 
sorrow, which contracts the heart, macerates the soul, subverts the good estate of 
the body, hindering all the operations of it, causing melancholy, and many times 
death itself" 23 
Ml is characterized by the dying of heart muscle tissue as a result of lack of oxygen, usually 
caused by atherosclerosis 24, in which plaques form, damaging and blocking the arteries. In 
the previous paragraph, it was noted that depression is expected to be the number 2 most 
important cause of disease burden in 2020. lschemic heart disease is number 1 25, and it is 
the leading cause of death worldwide 26• In The Netherlands, for example, the incidence of 
first Ml is estimated to be 234 (234 new cases of Ml per 100,000 people per year), and 40% 
of the people with a first Ml die before reaching the hospital 27• Similar numbers have been 
found in studies of other countries 28• 29• 
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Depression is both a risk factor for the development of coronary heart disease (CHD), as 
well as for a worsened prognosis in patients with existing cardiac disease. Many studies have 
found that depressed people in the general population are at a higher risk of developing 
ischemic heart disease, including Ml 30• 31• Meta-analyses of this association find a relative 
risk of around 1.9 31• 32• In patients with existing CHD, the relative risk for depression of 
mortality is around 1.8 31• In Ml patients, previous studies have found an OR of 2.0 to 2.6 for 
mortality 31, 33, 34. 
In hospitalized Ml patients, the prevalence of major depression is estimated to be around 
20% 35, which is comparable to the prevalence of depression in patients with other medical 
diseases. In the year after a Ml, patients are 4 times more likely to develop depression than 
people without an Ml 36• Moreover, in Ml patients, depression and elevated symptoms of 
depression are associated with poorer cardiac prognosis and early mortality. 
Potential physiological mechanisms are, for example, elevated inflammation 12• 37, altered 
functioning of the autonomic nervous system, or an overactive HPA-axis 12• 38 in depressed 
Ml patients. Carney et al. found decreased heart rate variability in depressed Ml patients 39, 
indicating changes to the ANS that affect the heart. In addition, increased platelet reactivity 
in depressed patients, a process strongly involved in ischemic heart disease, is a potential 
mechanism 12• 40• 41• 
Behavioral mechanisms are likely to be involved as well. Depressed CHD and Ml patients 42-44 
are less adherent to medications 45, less compliant with cardiac rehabilitation 46 and stress 
reduction, and display more unhealthy behaviors, such as a high-fat diet, smoking, and lack 
of physical exercise than non-depressed patients 47-49_ This will result in worsened health 
outcomes. In fact, Horwitz et al. found that non-adherence in Ml patients was associated 
with a 2.6 times higher risk of dying within a year of the Ml 50• 
The direction of causality of the association between post-Ml depression and prognosis has 
been much investigated and debated. One of the ways to find out whether depression causes 
worsened outcomes is to investigate the effects of depression treatment on prognosis. If 
depression is truly causal for worsened outcomes, effective depression treatment would 
have to result in improved outcomes. A number of randomized controlled trials (RCTs) have 
investigated the effectiveness of depression treatment in patients with CHD or Ml, and in 
general, studies find moderate effect sizes for depression improvement 51-54 _ In a meta­
analysis on the effects of depression treatment on mental health related quality of life (QOL) 
in Ml and unstable angina (UA) patients, O'Neill et al. found an effect size of 0.29 in favor 
of treatment 55• However, even when treatment of depression was moderately effective, no 
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improvements in cardiac prognosis were found 32, 51-54• 56• This suggests that either depression 
is not causally involved in worsened prognosis, or that depression treatment effects are not 
large enough to improve prognosis. 
In summary, most researchers agree there is an association between post-Ml depression 
and prognosis. Two of the main questions, however, are what the strength of this association 
is, and whether depression is an independent, potentially causal predictor of worsened 
outcomes. Although, in cohort studies, causality cannot be proven, it can be considered 
plausible, if adjustment for confounders does not remove the association. Potential 
confounders in this association are comorbidities, health behaviors, and, most importantly, 
cardiac disease severity. 
A number of studies across the world have already investigated the association between 
post-Ml depression and prognosis, but results are mixed. First of all, it would be useful 
to find all relevant studies and to summarize the effect sizes of these associations, and to 
investigate the causes of different findings across studies (between-study heterogeneity). 
This can be done in a meta-analysis based on summary data. 
Second, it is important to systematically investigate the extent to which disease severity as a 
confounder explains the association between post-Ml depression and prognosis. However, 
reported data from different studies are not sufficient for that purpose. Establishing a 
summary of the strength of the association adjusted for important confounders by using 
reported data only is limited, as studies either do not report any adjusted associations, 
adjust for different confounders each, or adjust for a large number of confounders at the 
same time. This makes it impossible to establish a reliable estimate of the potentially 
confounding role of specific variables. Therefore, the only way to reliably investigate the 
role of disease severity in the association between post-Ml depression and prognosis is to 
perform an individual patient data meta-analysis, combining raw data from as many studies 
as possible, and then to systematically analyze these data adjusted for markers of cardiac 
disease severity. This method allows for more consistency in analyses as well as more power 
and reliability of the results due to larger numbers of subjects and events. In addition, it 
creates the possibility to establish the effects of individual factors on the association. 
Hence, in this thesis, both meta-analyses based on summary data and individual patient data 
meta-analyses are performed to investigate the association between post-Ml depression 
and prognosis. Results of both types of analyses are compared and commented on. 
15 
Chapter 1 
Research questions and thesis outline 
This d issertation is not written to s u pport or deny any specific hypothesis or theory. Instead, 
its ma in  aim is to eva luate the evidence on depression and medica l  d isease as objective ly 
as possib le.  Fi rst, we eva luate the evidence on the effectiveness of treatment of depression 
and d istress in  cancer patients and  consequently on whether or not routi ne screen ing for 
depression and distress is effective. The results a re meant to i nform researchers and c l in ica l 
practice and pol icy makers of the state of the current evidence, and to provide an evidence­
base for existing and future pol icy. Second, i n  i nvestigating post-Ml  depression, this thesis 
summarizes, combi nes, and critica l ly  eva luates, by means of summary data meta-a na lyses, 
the fa i rly su bstantia l  body of existi ng evidence. F ina l ly, orig ina l  patient data is used to 
perform an I PD meta-a na lysis as a more systematic method to i nvestigate the potentia l ly 
confound ing role of disease severity and a number of other factors in the association 
between depression and adverse o utcomes. 
I: General Introduction 
Part I: Screening for depression and distress in patients with cancer: systematic reviews 
II: Depression screening and patient outcomes in cancer: a systematic review 
I l l :  Distress screening and patient outcomes in cancer: a systematic review 
IV: Risk of bias from inclusion of patients who already have diagnosis of or are undergoing treatment for 
depression in diagnostic accuracy studies of screening tools for depression: systematic review 
Part II: Depression and myocardial infarction: meta-analyses 
V: More than the sum of its parts: meta-analysis and its potential to discover sources of heterogeneity in 
psychosomatic medicine 
VI: Depression and inflammation in patients with acute and stable coronary heart disease: a meta-analysis 
VII: Prognostic association of depression following myocardial infarction with mortality and cardiovascular 
events: a meta-analysis of 25 years of research 
VIII: Prognostic association of depression following myocardial infarction with mortality and cardiovascular 
events: an individual patient data meta-analysis 
IX: General Discussion 
Chapter 2 is a systematic review of depression screen ing i n  patients with cancer. It eva luates 
the d iagnostic accu racy of i nstruments used to screen for depression, the effectiveness of 
depression treatment in cancer patients, and the evidence on the effectiveness of depression 
screen ing in  patients with cancer. 
Chapter 3 systematica l ly reviews the l iterature on d istress screen ing in cancer  patients. It 
conta ins  a broader definition of d istress, inc lud ing any kind of psychological d istress, such as 
elevated symptoms of depression, major depression, a nd anxiety. 
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Chapter 4 is an evaluation of methods of screening for depression. It points out the high risk 
of bias when studies assessing the effectiveness of screening for depression include patients 
who were already diagnosed with depression before the screening took place. This results in 
an overestimation of the actual effectiveness of screening methods. 
Chapter 5 discusses a summary of the essential elements involved in meta-analysis, and 
its usefulness in psychosomatic medicine. Each step, from formulating a clear research 
question, searching the literature, study selection, data extraction, effect size pooling, 
different statistical techniques, to interpretation of the results, is described. Throughout the 
chapter, the strengths as well as limitations of meta-analyses are discussed. 
Chapter 6 is a meta-analysis of studies on the role of inflammation in depression in patients 
with acute and stable coronary heart disease. Inflammation is a physiological mechanism 
that potentially explains the association between post-Ml depression and prognosis. 
Chapter 7 is a meta-analysis of studies on the association between post-Ml depression and 
prognosis, and is based on summary data as reported by the study authors. It summarizes 25 
years of research and forms the basis for the individual patient data meta-analysis reported 
in chapter 8. It highlights some of the main unresolved issues concerning depression in Ml 
patients. 
Chapter 8 is an individual patient data meta-analysis of the association between post-Ml 
depression, consisting of data of over 10,000 Ml patients, provided by the authors of 16 
individual studies across the world. Its main aim is to investigate to what extent post-Ml 
depression predicts prognosis independent of cardiac disease severity and a number of 
other health related risk factors. 
Chapter 9 is the general discussion of this thesis. It summarizes and integrates the findings 
on screening for depression and distress in patients with cancer, and on the association 
between post-Ml depression and prognosis. Tying this all together, it finally discusses the 
usefulness of systematic review, summary data meta-analysis, and individual patient data 




1. Systematic reviews. Available at: http://www.senseaboutscience.org/pages/systematic-reviews.html. 
Accessed July/9, 2012. 
2. Waraich P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic 
review of the literature. Can J Psychiatry 2004; Feb;49(2}:124-38. 
3. World Health Organization. Investing in Mental Health. Geneva: World Health Organization; 2003. 
4. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental 
disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmaco/ 2011; Sep;21(9} :655-
79. 
5. Depression. Available at : http://www.who.int/mental health/management/depression/definition/en/. 
Accessed 06/Monday, 2012. 
6. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 
2006; Nov;3(11):e442. 
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Dsm-lV-Tr. 4th ed. 
Washington DC :  American Psychiatric Association; 2000. 
8. Kendler KS, Gatz M, Gardner CO, Pedersen NL. A Swedish national twin study of lifetime major depression. Am 
J Psychiatry 2006;163(1) :109-14. 
9. Sullivan P F, Neale MC, Kendler KS. Genetic epidemiology of major depression :  review and meta-analysis. Am 
J Psychiatry 2000; Oct;157(10):1552-62. 
10. Kessler RC. The effects of stressful life events on depression. Annu Rev Psycho/ 1997;48:191-214. 
11. Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of 
major depression. Am J Psychiatry 1999; Jun;156(6):837-41. 
12. Evans D L, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, et al. Mood disorders in the medically ill: 
scientific review and recommendations. Biol Psychiatry 2005; Aug 1;58(3): 175-89. 
13. Carney RM, Freedland KE, Rich MW, Jaffe AS. Depression as a risk factor for cardiac events in established 
coronary heart disease: a review of possible mechanisms. Ann Behav Med 1995; Spring;17(2} :142-9. 
14. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. 
Trends lmmunol 2006; Jan;27(1}:24-31. 
15. Di Matteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: 
meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; Jul 
24;160(14):2101-7. 
16. Cancer. Available at : http://www.who.int/mediacentre/factsheets/fs297 /en/. Accessed July/6, 2012. 
17. Alwan A. Global status report on noncommunicable diseases 2010: Description of the global burden of NCDs, 
their risk factors and determinants. Geneva: World Health Organization; 2011.  
18.  Ng CG, Boks MP, Zainal NZ, de Wit NJ. The prevalence and pharmacotherapy of depression in cancer patients. 
J Affect Disord 2011; Jun;131(1-3): 1-7. 
19. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004;(32)(32):57-71. 
20. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. Biol 
Psychiatry 2003; Aug 1;54(3):283-94. 
21. P inquart M, Duberstein PR. Depression and cancer mortality :  a meta-analysis. Psycho/ Med 2010; 
Nov;40{11) :1797-810. 
22. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: distress management. v.1 
ed.Nationonal Comprehensive Cancer Network Inc.; 2008. 
23. Burton R. The anatomy of melancholy. 2009th ed. http://www.exclassics.com/anatomy/anatomyl.pdf : The 
Ex-Classics Project; 1652. 
24. Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mahonen M, Ngu Blackett K, et al. World Health Organization 
definition of myocardial infarction: 2008-09 revision. Int J Epidemio/ 2011; Feb;40(1}: 139-46. 
25. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998; Nov;4(11}: 1241-3. 




27. Koek HL, de Bruin A, Gast A, Gevers E, Kardaun JW, Reitsma JB, et al. Incidence of first acute myocard ia l  
infarction in the Netherlands. Neth J Med 2007; Dec;65(11):434-41. 
28. Manuel DG, Lim JJ, Tanuseputro P, Stukel TA. How many people have had a myocardial infarction? Prevalence 
estimated using historical hospital data. BMC Public Health 2007; Jul 24;7:174. 
29. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of 
acute myocardial infarction. N Engl J Med 2010; Jun 10;362(23) :2155-65. 
30. Glassman AH, Shapiro PA. Depression and the course of coronary artery d isease. Am J Psychiatry 1998; 
Jan;155(1) :4-11. 
31. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart 
disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 
2006; Dec;27(23) :2763-74. 
32. Kuper H, Nicholson A, Kivimaki M, Aitsi-Selmi A, Cavalieri G, Deanfield J E, et al. Evaluating the causal relevance 
of diverse risk markers: horizontal systematic review. BMJ 2009; Nov 5;339:b4265. 
33. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary 
heart disease: a meta-analysis. Psychosom Med 2004; Nov-Dec;66(6):802-13. 
34. Van Melle JP, De Jonge P, Spijkerman TA, Tijssen JG, Ormel J, Van Veldhuisen DJ, et al. Prognostic association 
of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. 
Psychosom Med 2004; Nov-Dec;66(6):814-22. 
35. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, et al. Prevalence of depression in survivors of 
acute myocardial infarction. J Gen Intern Med 2006; Jan;21(1) :30-8. 
36. Kendler KS, Gardner CO, Fiske A, Gatz M. Major depression and coronary artery disease in the Swedish 
twin registry: phenotypic, genetic, and environmental sources of comorbidity. Arch Gen Psychiatry 2009; 
Aug;66(8) :857-63. 
37. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta­
analysis. Psychosom Med 2009; Feb;71(2): 171-86. 
38. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, 
biology, and treatment. Arch Gen Psychiatry 1998; Jul;55(7) :580-92. 
39. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, et al. Depression, heart rate variability, 
and acute myocardial infarction. Circulation 2001; Oct 23;104(17) :2024-8. 
40. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, et al. Exaggerated platelet reactivity 
in major depression. Am J Psychiatry 1996; Oct;153(10) : 1313-7. 
41. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta­
thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997; Aug 
15;42(4) :290-5. 
42. Rieckmann N, Kronish IM, Haas D, Gerin W, Chaplin WF, Burg MM, et al. Persistent depressive symptoms lower 
aspirin adherence after acute coronary syndromes. Am Heart J 2006; Nov;152(5) :922-7. 
43. May HT, Sheng X, Catinella AP, Horne BD, Carlquist J F, Joy E. Antilipidemic adherence post-coronary artery 
disease diagnosis among those with and without an ICD-9 diagnosis of depression. J Psychosom Res 2010; 
Aug;69(2) : 169-74. 
44. Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly 
patients with coronary artery disease. Health Psychol 1995; Jan;14(1) :88-90. 
45. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease 
outcomes. A critical review. Arch Intern Med 1997; Sep 22;157(17):1921-9. 
46. Blumenthal JA, Williams RS, Wallace AG, Williams RB,Jr, Needles TL. Physiological and psychological variables 
predict compliance to prescribed exercise therapy in patients recovering from myocardial infarction. 
Psychosom Med 1982; Dec;44(6):519-27. 
47. Myers V, Gerber Y, Benyamini Y, Goldbourt U, Drory Y. Post-myocardial infarction depression: increased hospital 
admissions and reduced adoption of secondary prevention measures--a longitudinal study. J Psychosom Res 
2012; Jan;72(1):5-10. 
48. Kronish IM, Rieckmann N, Halm EA, Shimbo D, Vorchheimer D, Haas DC, et al. Persistent depression affects 
adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med 2006; 
Nov;21(11) : 1178-83. 
19 
Chapter 1 
49. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less 
likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch 
Intern Med 2000; Jun 26;160(12) :1818-23. 
50. Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, et a l. Treatment adherence and risk 
of death after a myocardial infarction. Lancet 1990; Sep 1;336(8714):542-5. 
51. Lesperance F, Frasure-Smith N, Koszycki D, Laliberte MA, van Zyl LT, Baker B, et al. Effects of citalopram and 
interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac 
Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; Jan 
24;297(4):367-79. 
52. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT,Jr, et al. Sertraline treatment of 
major depression in patients with acute Ml or unstable angina. JAMA 2002; Aug 14;288(6):701-9. 
53. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Effects of treating depression 
and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in 
Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; Jun 18;289(23):3106-16. 
54. Van Melle J P, De Jonge P, Honig A, Schene AH, Kuyper AM, Crijns HJ, et al . Effects of antidepressant treatment 
following myocardial infarction. Br J Psychiatry 2007; Jun;190:460-6. 
55. O'Neil A, Sanderson K, Oldenburg B, Taylor CB. Impact of depression treatment on mental and physical 
health-related quality of life of cardiac patients: a meta-analysis. J Cardiopulm Rehabil Prev 2011; May­
Jun;31(3):146-56. 
56. Thombs BD, de Jonge P, Coyne JC, Whooley MA, Frasure-Smith N, Mitchell AJ, et al. Depression screening and 
patient outcomes in cardiovascular care: a systematic review. JAMA 2008; Nov 12;300(18):2161-71. 
20 
Pa rt I 
Screening for depression and distress in patients 
with cancer: systematic reviews 

Chapter 2 
Depression screening and patient outcomes in 
cancer: a systematic review 
Anna Meijer, Michelle Roseman, Katherine Milette, James C. Coyne, 
Michael E. Stefanek, Roy C. Ziegelstein, Erin Arthurs, Allison Leavens, 
Steven C. Palmer, Donna E. Stewart, Peter de Jonge, Brett D. Thombs 
P/oS One, November 2011, Volume 6, Issue 6, e27181 
Chapter 2 
Abstract 
Context: Several practice guidelines recommend screening for depression in cancer care, but 
no systematic reviews have examined whether there is evidence that depression screening 
benefits cancer patients. 
Objective: To evaluate the potential benefits of depression screening in cancer patients by 
assessing the (1) accuracy of depression screening tools; (2) effectiveness of depression 
treatment; and (3) effect of depression screening, either alone or in the context of 
comprehensive depression care, on depression outcomes. 
Data sources: CINAHL, Cochrane, EMBASE, IS i ,  MEDLINE, PsyclNFO and SCOPUS databases 
through January 24, 2011; manual journal searches; reference lists; citation tracking; trial 
registry reviews. 
Study selection: Articles on cancer patients were included if they (1) compared a depression 
screening instrument to a valid criterion for major depressive disorder (MDD); (2) compared 
depression treatment with placebo or usual care in a randomized controlled trial (RCT); (3) 
assessed the effect of screening on depression outcomes in a RCT. 
Data extraction: Two investigators independently extracted methodological characteristics 
and outcomes from included studies. 
Results: There were 19 studies of screening accuracy, 1 MDD treatment RCT, but no RCTs 
that investigated effects of screening on depression outcomes. Screening accuracy studies 
generally had small sample sizes (median=17 depression cases) and used exploratory 
methods to set sample-specific cut-off scores that varied substantially across studies. A 
nurse-delivered intervention for MDD reduced depressive symptoms moderately (effect 
size=0.37). 
Conclusions: The one treatment study reviewed reported modest improvement in depressive 
symptoms, but no evidence was found on whether or not depression screening in cancer 
patients, either alone or in the context of optimal depression care, improves depression 
outcomes compared to usual care. Depression screening in cancer should be evaluated in a 
RCT in which all patients identified as depressed, either through screening or via physician 
recognition and referral in a control group, have access to comprehensive depression care. 
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Introduction 
Over 40% of people will be diagnosed with cancer in their lifetime with two-thirds living at 
least 5 years 1, 2• Cancer treatment is often arduous and may include surgery, radiotherapy, 
or chemotherapy that can last for months or years. Cancer patients and survivors often 
experience decreased quality of life, reduced capacity to perform daily activities, and mental 
health problems. Distress is common, ranging from "normal" distress in reaction to cancer 
and its treatment to symptoms that meet criteria for a psychiatric disorder 3• 4• Prevalence 
of major depressive disorder (MOD} is estimated to be approximately 11% among cancer 
patients, compared to 5-6% in the general population, although rates may vary depending 
on the type of cancer 5• 6• 
Many cancer patients report that their psychosocial needs are not addressed adequately, 
and improving supportive and palliative care has been prioritized 3A,7 _ A 2002 US National 
Institutes of Health (NIH} State-of-the Science Conference Statement 8 called for the routine 
use of screening tools to identify untreated depression among cancer patients. Similarly, 
among gaps in psychosocial care, a 2007 report from the Institute of Medicine (IOM} noted 
low rates of recognition and treatment for depression 4• The IOM report 4 and guidelines from 
the UK National Institute for Clinical Excellence (NICE} 7 and the National Comprehensive 
Cancer Network (NCCN} 3 recommend screening for psychological "distress," including 
depression, in cancer patients. 
The term screening has been used, sometimes inaccurately, to describe a number of 
activities that involve the use of depression symptom questionnaires, including using the 
questionnaires to monitor symptom severity or treatment effects, to detect relapse in 
patients who have undergone treatment, to identify patients who are receiving suboptimal 
treatment, or to inform the delivery of psychosocial services that are provided to all 
patients, regardless of symptom severity scores. Although these activities are potentially 
useful applications of depression symptom questionnaires, none constitutes screening 9• 
Screening, as defined by the UK National Screening Committee, is "a public health service 
in which members of a defined population, who do not necessarily perceive they are at 
risk of, or are already affected by, a disease or its complications, are asked a question or 
offered a test to identify those individuals who are more likely to be helped than harmed 
by further tests or treatment to reduce the risk of disease or its complications" (page 6} 10• 
Thus, screening for MOD involves using questionnaires to identify patients who may have 
depression, but who are not seeking treatment for symptoms and whose depression is 
not otherwise recognized. Patients who screen positive should be further assessed using 
a clinical interview to determine if a diagnosis of MOD is warranted, and, if appropriate, 
treated. In addition to evidence from well-designed and conducted screening randomized 
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controlled trials (RCTs), established criteria for when recommendations for screening should 
be considered 10-12 emphasize the need to assess whether accurate screening tests with only 
a tolerably small risk of false positive results are available and whether there are effective 
treatments for patients identified through screening. 
No systematic reviews have specifically evaluated the effects of screening for MDD in 
cancer patients on depression outcomes. Thus, the objective of this systematic review was 
to evaluate whether evidence supports recommendations for systematic screening for 
depression in cancer care. We used the US Preventive Services Task Force (USPSTF) 13• 14 
analytic framework for evaluating evidence for or against screening programs to develop 
review questions (see Figure 1). The USPSTF framework recognizes the need for RCTs to 
directly assess links between screening programs and patient outcomes. When direct 
evidence from RCTs is not available or is of low quality, the USPSTF framework assesses key 
links that are necessary for screening to benefit patients, focusing on the need for accurate 
screening tools and effective treatments 14• Thus, we identified the following key questions 
for the current review: 
Key Question # 1: What is the accuracy of depression screening instruments among cancer 
patients? 
Key Question # 2: Does treatment of depression improve symptoms of depression in cancer 
patients? 
Key Question # 3: Is depression screening of cancer patients, either alone or in the context of 
enhanced depression care, more effective than usual care in reducing depressive symptoms 
or diagnoses of MDD? 
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The CINAHL, Cochrane, EMBASE, ISi , MEDLINE, PsyclNFO and SCOPUS databases were 
searched through January 24, 2011. One search was conducted to identify articles that 
compared a screening instrument with a valid MDD criterion standard (Key Question #1) 
or that assessed outcomes from depression screening, either alone or in the context of 
enhanced depression care (Key Question #3). A second search was done for depression 
treatment studies (Key Question #2). Manual searching was done on reference lists of 
included articles, relevant systematic reviews, and 45 selected journals (August 2010 to 
January 2011). We tracked citations of included articles using Google Scholar 15, surveyed 
authors of included treatment and screening trials, and searched the trial registries 
ClinicalTrials.gov 16 and the International Standard Randomized Controlled Trial Number 
Register 17 to attempt to identify unpublished treatment or screening RCTs. 
Identification of eligible studies 
Eligible articles included studies in any language on cancer patients with any type of 
malignancy at any disease stage that reported original data, excluding case series or case 
reports. Translators assisted reviewers to evaluate titles/abstracts and articles for languages 
not covered by investigators, who were able to independently review material in English, 
Dutch, French, and Spanish. Multiple articles on the same cohort were treated as a single 
study. Studies with mixed populations were included if cancer data were reported separately. 
Studies on the accuracy of depression screening tools (Key Question #1) were included 
if they compared screening results to a Diagnostic and Statistical Manual of Mental 
Disorders (DSM) or International Classification of Diseases (!CD) diagnosis of MDD based 
on a validated structured or semi-structured interview (e.g., Structured Clinical Interview 
for DSM-IV [SCIO-IV] 18, Composite International Diagnostic Interview [CIDI] 19, Diagnostic 
Interview Schedule [DIS] 20) administered within 2 weeks of the screening tool and reporting 
data allowing determination of sensitivity, specificity, positive predictive value, and negative 
predictive value. 
Eligible articles on depression treatment (Key Question #2) were RCTs comparing 
pharmacological, psychotherapeutic, or other interventions with placebo or usual care 
controls among cancer patients diagnosed with MDD based on a validated diagnostic interview 
and DSM or ICD criteria. We required a valid diagnostic interview because unassisted clinician 
diagnoses have poor reliability 21 and because a large proportion of patients scoring above 
cutoffs on self-report questionnaires do not have MDD 22• Head-to-head trials of different 
interventions without a comparison to usual care or placebo were not eligible. 
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E l igib le artic les for Key Question #3 were RCTs that com pared depression outcomes between 
cancer patients who underwent depression screening and those who d id not. We searched 
for both screening stud ies that inc luded the provis ion of com prehensive depression care 
for patients with depression as part of the screen ing program and stud ies that screened 
patients, but did not provide such ca re. Cha nges in  rates of depression recognition and 
treatment were noted, but  not inc luded as depression outcomes. Th is  is because increased 
treatment without improved depression outcomes wou ld  expose patients to costs and 
potentia l harms without benefit. Screening was defined per the UK National  Screen ing 
Committee's defin ition 10• Thus, e l ig ib le screen ing tria ls  had to i nc lude a case identification 
strategy based on an a priori defi ned cut-off score on a depression screening tool  to make 
d ecisions regard ing further assessment or treatment. Studies i n  which both i ntervention 
a nd control groups received the same psychosocia l  services, but service providers in  the 
i ntervention group had access to resu lts from psychosocia l  questionna ires that may have 
i nformed their i nteractions, but d id n ot necessari ly determine service a l location decisions, 
were not incl uded . Stud ies in which q uestionna ire resu lts were provided to c l in icia ns without 
gu idance on cut-off scores to determine positive screen ing status were a l so exc luded.  
F ina l ly, stud ies that admin istered m u ltiple screen ing tools for m u ltip le  problems were not 
inc luded, since determin ing whether depression screen ing infl uenced depression outcomes 
wou ld  not be poss ib le .  
Two investigators independently reviewed artic les for e l igi b i l ity. If  either deemed a n  article 
potentia l ly e l igible based on title/abstract review, then a fu l l -text review was completed .  
Disagreements after ful l.:fext review were resolved by consensus. 
Evaluation of eligible studies 
Two investigators i ndependently extracted and entered data into a standard ized spreadsheet. 
D iscrepa ncies were resolved by consensus. For Key Question #1 (diagnostic accu racy), the 
Qua l ity Assessment for Diagnostic Accuracy Studies tool (QUADAS) 23 was used for qua l ity 
a ssessment. Risk of bias in stud ies inc luded for Key Question #2 (treatment) and  Key 
Question #3 (screen ing) was assessed with the Cochra ne Risk of Bias tool 24• Study qua l ity 
a n d  risk of b ias were assessed by 2 investigators with d iscrepancies resolved by consensus. 
Data presentation and synthesis 
I n  stud ies included for Key Question #1 (diagnostic accuracy), for each screen ing instrument, 
sensitivity, specificity, positive predictive va lue, and negative predictive va lue with 95% 
confidence i nterva ls (Cls) 25 were extracted based on primary cut-offs identified by study 
a uthors. For Key Questions #2 (treatment) and #3 (screen ing), when mu lti p le depression 
o utcomes were reported, designated primary outcomes for each study were prioritized, 
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followed by observer-rated scales, then self-report measures. Post-intervention effect sizes 
were reported using the Hedges' g statistic 26, which represents a standardized difference 
between 2 means, as well as r2, which is statistically equivalent 27•28, but presents results in 
terms of percent of variance in depression change scores due to treatment. Response and 
remission were presented as relative risk ratios using study definitions. 
Eligible studies for each key question were evaluated to determine whether there was 
sufficient clinical and methodological similarity to support pooling of results. For Key 
Question #1, studies were heterogeneous in terms of patient samples, screening tools 
and cut-offs, criterion standards, and whether they used a priori-defined, standard scoring 
thresholds versus sample-specific thresholds based on exploratory receiver operating 
characteristic (ROC) curve methods. Only 1 eligible study was identified for Key Question #2 
and none for Key Question #3. Thus, results were not pooled quantitatively. 
A review protocol was not published or registered for this study. However, a protocol was 
followed for searching, data extraction, and data synthesis with all methods determined a 
priori. 
Resu lts 
Key question #1: Diagnostic accuracy of depression screening tools 
The database search for Key Questions #1 (diagnostic accuracy) and #3 (screening) generated 
2,302 unique citations (Figure 2). For Key Question #1 (diagnostic accuracy), 2,193 were 
excluded after title/abstract review and 91 after full-text review. Two additional eligible 
articles 29•30 were identified through alternative sources, resulting in 20 included articles 29•45_ 
Two of these articles 37•38 reported on the same cohort, leaving 19 unique studies for review. 
The 20 studies (19 cohorts) reviewed included 8 studies of breast cancer patients 
29,3o,33,35A0A1A4A6 and 11 of patients with mixed cancer sites 31•32•34•36·39A2,43,45A7,45 across the 
spectrum of cancer stages (Table 1). Sample sizes in the 19 patient cohorts ranged from 16 
to 381 (median=128), and the number of cases of MDD from 6 to 74 (median=17). In 12 
studies 31·39A1,44,47A8, diagnostic accuracy data were reported using an optimal cut-off score 
that maximized accuracy based on exploratory ROC methods; 1 study 46 used exploratory 
methods for the study's primary screening tool and compared results to literature-based 
cut-offs for 2 other screening tools; 1 study 45 used exploratory methods to identify an 
optimal cut-off among a small set of possible cut-offs from the literature; and 5 studies 
29,3o,4o,42A3 reported on standard cut-off scores from the screening literature. 
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Figure 2: PRISMA flow diagram of study selection process for Key Question #1 
2302 Unique titles/abstracts 
30 
identified and screened for 
potential eligibi lity 
,, 
109 Articles selected for full-text 
review 
2193 Titles/abstracts excluded : 
• No original data or case report (470) 
• Not cancer (545) 
• Not major depression (415) 
• No comparison of screening results to diagnostic 
interview for major depression (763) 
91 Articles excluded: 
• No original data or case report (2) 
• Not cancer (5) 
• Sample selected based on presence of depression 
or distress (10) 
• No comparison of screening results to diagnostic 
interview for major depression (74) 
18 Articles meeting eligibility 
criteria Eligible articles identified from other 
I sources 
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Question #1 
19 Unique cohorts for Key 
Question #1 
Table 1: Summary of studies of diagnostic accuracy of depression screening tools in cancer 
First Cancer Site/ N Mean Males Major Derivation Sensitivity Specificity Positive Negative 
Author, Description Age (%) Depression N (%) Instrument/ of Cut-off % (95% CI) % (95% Cl) Predictive Predictive 
Year, (Years) Criterion Major Cut-off Value Value 
Country Standard Depression % (95% Cl) % (95% Cl) 
Akechi 31 Mixed/ 209 61 66 SCIO 14 (7%) 1 item, "Depressed?"• NA 79 (52-92) 92 (87-95) 41 (25-59) 98 (95-99) 
2006, Terminal 
Japan 
1 item, "Lost interest?"• NA 93 (68-99) 92 (87-95) 45 (28-62) 99 (97-100) 
1 item, "Depressed" or NA 100 (78-100) 86 (81-90) 34 (22-49) 100 (98-100) 
"Lost Interest?"• 
HADS � 17 Exploratory 71 (45-88) 77 (71-83) 19 (10-31) 97 (93-99) 
HADS-D � 9 Exploratory 86 (60-96) 69 (62-75) 17 (10-27) 99 (95-100) 
Alexander Breast/ 200 58 0 SCIO 18 (9%) EPDS � 13 Literature 72 (49-88) 90 (85-94) 42 (26-59) 97 (93-99) 
30 Stage I-l ib 
2010, (disease-
UK  free) 
HADS-D � 11 Literature so (29-71) 97 (94-99) 64 (39-84) 95 (91-97) 
Coyne 29 Breast/ 113 56 0 SCIO 10 (9%) HSCL-25 � 44 Literature 70 (40-89) 75 (66-82) 21 (11-38) 96 (90-99) 
2004, Stage I-IV ro 




Breast/ 103 56c 0 SCIO 3 (3%) HSCL-25 � 44 67 (21-94) Literature 74 (65-82) 7 (2-23) 99 (93-100) 
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H A D S  �  1 9  E x p l o r a t o r y  6 8  ( 4 7 - 8 4 )  6 7  ( 5 6 - 7 6 )  3 7  ( 2 4 - 5 2 )  8 8  ( 7 7 - 9 4 )  
W i l l i a m s  L i f e -
3 7 , 3 8  
e x p e c t a n c y  
2 0 0 0 ,  < 6  m o n t h s  
2 0 0 1 ,  
U K  
H A D S - D  �  1 1  
E x p l o r a t o r y  5 5  ( 3 5 - 7 3 )  
7 4  ( 6 4 - 8 3 )  3 8  ( 2 3 - 5 5 )  8 5  ( 7 5 - 9 2 )  
H A D S - A  �  1 0  E x p l o r a t o r y  5 9  ( 3 9 - 7 7 )  6 8  ( 5 7 - 7 7 )  3 4  ( 2 1 - 5 0 )  8 5  ( 7 5 - 9 2 )  
E P D S  �  1 3  E x p l o r a t o r y  8 2  ( 6 1 - 9 3 )  7 9  ( 6 9 - 8 7 )  5 3  ( 3 7 - 6 9 )  9 4  ( 8 5 - 9 8 )  
Table 1 (continued) 
First Cancer Site/ N Mean Males Major Derivation Sensitivity Specificity Positive Negative 
Author, Description Age (%) Depression N (%) Instrument/ of Cut-off % (95% CI) % (95% Cl) Predictive Predictive 
Year, (Years) Criterion Major Cut-off Value Value 
Country Standard Depression % (95% Cl) % (95% Cl) 
Lloyd- M ixed/ 246 62 43 PSE 74 (30%) EPDS .!: 12 Exploratory 72 (60-81) 74 (67-80) 54 (44-64) 86 (79-91) 
Wil l iams Life-
39 expectancy 
2007, <6 months 
UK  
Brief EPDS .!: 6 Exploratory 72 (60-81) 83 (77-88) 65 (54-74) 87 (81-91) 
Love 40 Breast/ 303 N R  0 MILP 29 ( 10%) HADS-D .!: 11 Literature 7 (2-22) 98 (95-99) 25 (7-59) 91 (87-94) 
2002, Stages 1-llb 
Australia (excluding 
T3, NO, MO) 
Love 41 Breast/ 227 52 0 M ILP 16 (7%) HADS-D � 7 Exploratory 81 (57-93) 80 (74-85) 24 ( 14-36) 98 (95-99) 
2004, Stage IV 
Austral ia 
BD I-SF .!: 5 Exploratory 94 (72-99) 63 (56-69) 16 (10-25) 99 (96-100) 
Meyer 42 Mixed/ 45 NR  42 SCID 9 (20%) MEQ .!: 90 Literature 56 (27-81) 94 (82-98) 71 (36-92) 89 (76-96) 
2003, Terminal 0 
UK 
Murphy 4 3  N R/ 16 68 50 SCID 6 (38%) EPDS .!: 13 Literature• 67 (30-90) 100 (72- 100 (51- 83 (55-95) 5· 
2006, Advanced 100) 100) 
UK  metastatic 
n> 
n> 
cancer in  3· 
pal l iative 3· 
care 
!:t. 
Ozalp 44 Breast/ 204 51 0 SCIO 17 (8%) HADS .!: 17 Exploratory 71 (47-87) 80 (74-85) 24 ( 15-38) 97 (93-99) n> 
2008, M ixed � � 
Turkey ;::;: 
HADS-D .!: 5 Exploratory 88 (66-97) 59 (52-66) 16 (10-25) 98 (94-100) 





T a b l e  1  ( c o n ti n u e d )  
F i r s t  C a n c e r  S i t e /  N  
M e a n  M a l e s  M a j o r  
D e r i v a ti o n  S e n s i ti v i t y  S p e c i fi c i t y  P o s i ti v e  N e g a ti v e  
A u t h o r ,  D e s c r i p ti o n  A g e  ( % }  D e p r e s s i o n  N  ( % }  I n s t r u m e n t /  o f  C u t - o ff  % ( 9 5 % C I }  
%  ( 9 5 %  C l )  P r e d i c ti v e  P r e d i c ti v e  
Y e a r ,  ( Y e a r s )  C r i t e r i o n  
M a j o r  C u t - o ff  
V a l u e  
V a l u e  
C o u n t r y  
S t a n d a r d  D e p r e s s i o n  %  ( 9 5 %  C l }  %  ( 9 5 %  C l }  
P a s s i k  
4 5  
M i x e d /  6 0  5 8  4 7  
M I N I  2 4 ( 4 0 % )  Z S D S  �  4 8  L i t e r a t u r e /  6 7  ( 4 7 - 8 2 )  8 6  ( 7 1 - 9 4 )  7 6  ( 5 5 - 8 9 )  
7 9  ( 6 4 - 8 9 )  
2 0 0 1 ,  U S A  N R  
E x p l o r a t o r y
1  
B Z S D S  <!:  2 2  L i t e r a t u r e /  9 6  ( 8 0 - 9 9 )  4 2  ( 2 7 - 5 8 )  
5 2  ( 3 8 - 6 6 }  
9 4  ( 7 2 - 9 9 )  
E x p l o r a t o r y
1  
P a t e l  
4 6  
B r e a s t /  
1 0 0  5 3  
0  
C I D I  
8 ( 8 % )  B C - V I �  2  E x p l o r a t o r y  8 8  ( 5 3 - 9 8 )  5 9  ( 4 8 - 6 9 )  1 7  ( 8 - 3 0 )  
9 8  ( 9 0 - 1 0 0 )  
2 0 1 0 ,  M i x e d  
A u s t r a l i a  ( e x c l u d i n g  
S t a g e  I V )  
H A D S - D  �  8  L i t e r a t u r e  1 7  ( 3 - 5 6 )  9 4  ( 8 7 - 9 8 )  
2 0  ( 4 - 6 2 )  
9 3  ( 8 5 - 9 7 )  
P S Y C H - 6  �  2  L i t e r a t u r e  8 0  ( 3 8 - 9 6 )  6 8  ( 5 6 - 7 8 )  
1 5  ( 6 - 3 4 )  
9 8  ( 8 9 - 1 0 0 )  
S m i t h  
4
7  
M i x e d /  3 8 1  5 6  
s o  
S C A N /  P S E  4 0  ( 1 0 % )  H A D S - D  <!:  7  E x p l o r a t o r y  7 3  ( 5 7 - 8 4 )  6 4  ( 5 9 - 6 9 )  1 9  ( 1 4 - 2 6 )  
9 5  ( 9 2 - 9 7 )  
2 0 0 6 ,  U K  N R  
H A D S - D  m i n u s  m i s fi tti n g  E x p l o r a t o r y  7 0  ( 5 5 - 8 2 )  6 0  ( 5 5 - 6 5 )  1 7  ( 1 2 - 2 4 )  9 4  ( 9 1 - 9 7 )  
i t e m s �  5  
W a l k e r  
4 8  
M i x e d /  3 6 1  6 2  2 4  S C I O  3 0 ( 8 % )  H A D S  �  1 5  E x p l o r a t o r y  8 7  ( 7 0 - 9 5 )  8 5  ( 8 1 - 8 8 )  3 4  ( 2 5 - 4 5 )  
9 9  ( 9 6 - 9 9 )  
2 0 0 7 ,  U K  M i x e d  
H A D S - D  <!:  7  E x p l o r a t o r y  9 0  ( 7 4 - 9 7 )  8 8  ( 8 4 - 9 1 )  4 0  ( 2 9 - 5 2 )  
9 9  ( 9 7 - 1 0 0 )  
H A D S - A  <!:  
9  
E x p l o r a t o r y  8 7  ( 7 0 - 9 5 )  8 3  ( 7 9 - 8 7 )  3 2  ( 2 3 - 4 2 )  
9 9  ( 9 6 - 9 9 )  
A b b r e v i a t i o n s :  B C - V I  =  B r e a s t  C a n c e r  - V u l n e r a b i l i t y  I n d e x ;  B D I - S F  =  B e c k  D e p r e s s i o n  I n v e n t o r y  S h o r t  F o r m ;  B Z S D S  =  B r i e f  Z u n g  S e l f  R a t i n g  D e p r e s s i o n  S c a l e ;  C I D I  =  C o m p o s i t e  I n t e r n a t i o n a l  
D i a g n o s t i c  I n t e r v i e w ;  C I S  =  C l i n i c a l  I n t e r v i e w  S c h e d u l e ;  D T  =  D i s t r e s s  T h e r m o m e t e r ;  E P D S  =  E d i n b u r g h  P o s t n a t a l  D e p r e s s i o n  S c a l e ;  G A D  =  G e n e r a l  A n x i e t y  D i s o r d e r ;  G H Q =  G e n e r a l  H e a l t h  
Q u e s t i o n n a i r e ;  H A D S  =  H o s p i t a l  A n x i e t y  a n d  D e p r e s s i o n  S c a l e  t o t a l  s c o r e ;  H A D S - A  =  A n x i e t y  s u b s c a l e  o f  H o s p i t a l  A n x i e t y  a n d  D e p r e s s i o n  S c a l e ;  H A D S - D  =  D e p r e s s i o n  s u b s c a l e  o f  H o s p i t a l  
A n x i e t y  a n d  D e p r e s s i o n  S c a l e ;  H S C L - 2 5  =  2 5 - i t e m  v e r s i o n  o f  t h e  H o p k i n s  S y m p t o m  C h e c k l i s t ;  M D D  =  M a j o r  D e p r e s s i v e  D i s o r d e r ;  M E Q  =  M o o d  E v a l u a t i o n  Q u e s t i o n n a i r e ;  M I L P  =  M o n a s h  
I n t e r v i e w  f o r  L i a i s o n  P s y c h i a t r y ;  M I N I  =  M i n i - I n t e r n a ti o n a l  N e u r o p s y c h i a t r i c  I n t e r v i e w ;  N A =  N o t  a p p l i c a b l e ;  N R  =  N o t  r e p o r t e d ;  P C M  =  P a t i e n t  C a r e  M o n i t o r ;  P S E  =  P r e s e n t  S t a t e  E x a m i n a t i o n ;  
P S Y C H - 6  =  6 - i t e m  s u b s c a l e  m e a s u r i n g  s y m p t o m s  o f  d e p r e s s i o n  a n d  a n x i e t y  f r o m  t h e  S o m a t i c  a n d  P s y c h o l o g i c a l  H e a l t h  R e p o r t  ( S P H E R E ) ;  S A D S :  S c h e d u l e  f o r  A f f e c ti v e  D i s o r d e r s  a n d  
S c h i z o p h r e n i a ;  S C A N  =  S c h e d u l e  f o r  C l i n i c a l  A s s e s s m e n t  i n  N e u r o p s y c h i a t r y ;  S C I D  =  S t r u c t u r e d  C l i n i c a l  I n t e r v i e w  f o r  D S M ;  Z S D S  =  Z u n g  S e l f  R a t i n g  D e p r e s s i o n  S c a l e .  
•  I t e m s  w e r e  e m b e d d e d  i n  t h e  d i a g n o s t i c  i n t e r v i e w,  a n d  a t  l e a s t  1  o f  2  w a s  r e q u i r e d  f o r  a  d i a g n o s i s  o f  m a j o r  d e p r e s s i o n .  b  S t u d y  r e p o r t e d  d i a g n o s ti c  a c c u r a c y  d a t a  f o r  a l l  1 1 3  w o m e n  i n  t h e  
s t u d y ,  a n d  a l s o  a f t e r  e x c l u d i n g  w o m e n  w i t h  M D D  a l r e a d y  t r e a t e d  w i t h  a n t i d e p r e s s a n t s  a n d  w o m e n  w i t h  G A D  a l r e a d y  t r e a t e d  w i t h  a n t i d e p r e s s a n t s  o r  a n x i o l y t i c s  ( N  =  1 0 3 ) .  c  M e a n  a g e  b a s e d  
o n  a l l  1 1 3  w o m e n  i n  t h e  s t u d y .  d  D e m o g r a p h i c  d a t a  a r e  b a s e d  o n  f u l l  s t u d y  s a m p l e  o f  1 0 9  p a ti e n t s ,  r a t h e r  t h a n  t h e  7 9  p a ti e n t s  i n c l u d e d  i n  t h e  a n a l y s e s  r e p o r t e d  i n  t h e  t a b l e .  T h e  a u t h o r s  
e x c l u d e d  3 0  p a t i e n t s  w i t h  a n x i e t y  o r  a d j u s t m e n t  d i s o r d e r s ,  b u t  n o t  M D D ,  f r o m  d i a g n o s t i c  a c c u r a c y  a n a l y s e s .  •  A  c u t - o f f  o f  1 3  o r  g r e a t e r  o n  t h e  E P D S  i s  s t a n d a r d ,  a l t h o u g h  t h e  a u t h o r s  d i d  n o t  
i n d i c a t e  t h i s  e x p l i c i t l y .
1  
A u t h o r s  u s e d  s e v e r a l  d i f f e r e n t  c u t - o ff s  f r o m  t h e  l i t e r a t u r e  a n d  t e s t e d  t o  d e t e r m i n e  o p t i m a l  c u t - o ff  i n  t h e i r  s a m p l e .  
n  
N  
Depression screening in patients with cancer 
There were 6 studies 31•32•36-38A4A8 of the Hospital Anxiety and Depression Scale (HADS). The 
6 studies included between 14 and 30 MDD cases. All used exploratory ROC methods, and 
they identified optimal screening cut-offs that ranged from 15 to 20. Nine studies 31,33,35-
38·41'44,47,48, with 14 to 40 MDD cases per study, used ROC methods with the HADS depression 
subscale (HADS-D) and reported optimal cut-off scores from 5 to 11. Only 3 studies 3o,4o,46 
used a priori defined standard cut-offs, 8 46 or ll 3°A0, to assess diagnostic accuracy with the 
HADS-D and reported sensitivities of 7% to 50%. Two studies 37-39 used ROC methods with 
the Edinburgh Postnatal Depression Scale (EPDS) and identified optimal cut-off scores of 12 
and 13, similar to the standard cut-off of 13 used in two other studies 3o,43 . Excluding a study 
with only 6 MDD cases 43, sensitivity with the EPDS ranged from 72% to 82%, specificity 
from 74% to 90%, positive predictive value from 42% to 54%, and negative predictive value 
from 86% to 97%. Apart from the HADS anxiety subscale, no other screening tool was used 
in more than one study (see Table 1). One study 29 assessed the yield of screening with 
and without excluding patients with psychiatric disorders already treated with psychotropic 
medications and found that the true positive rate of depression screens fell from 21% to 7% 
after excluding patients who were already receiving treatment prior to screening. 
As shown in Table 2, the methodological quality of the 19 diagnostic accuracy studies was 
generally adequate for using an appropriate reference standard, which was an inclusion 
criterion; for administering the same reference test to all patients in the study; for the 
reference being independent of the screening test; and for adequately describing the 
screening and diagnostic tests. However, 17 of 19 studies failed to exclude patients who 
were already diagnosed or receiving depression treatment and who would not be newly 
identified through screening. In addition, 6 studies were rated 'no' or 'unclear' for clear 
sample selection criteria, 10 for timing of the screening tool and diagnostic interview 
administration, 11 for blind interpretation of the diagnostic interview, 19 for description of 
handling of missing data, and 8 for explanation of study withdrawals. 
35 
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T a b l e  2 :  Q u a l i t y  a s s e s s m e n t  o f  s t u d i e s  o f  d i a g n o s ti c  a c c u r a c y  ( Q U A D A S )  
Q U A D A S  I t e m s •  
�  
N  
F i r s t  # 1  # 2  #3 # 4  # 5  # 6  # 7  # 8  # 9  # 1 1  # 1 3  # 1 4  
A u t h o r ,  R e p r e s e n t a ti v e  S e l e c ti o n  R e f e r e n c e  T i m i n g  o f  
W h o l e  
A l l  R e f e r e n c e  I n d e x  T e s t  R e f e r e n c e  R e f e r e n c e  M i s s i n g  D a t a  S t u d y  
Y e a r ,  P a ti e n t  C r i t e r i a  S t a n d a r d  R e f e r e n c e  S a m p l e  P a ti e n t s  I n d e p e n d e n t  D e s c r i b e d  D e s c r i b e d  I n t e r p r e t e d  H a n d l e d  
W i t h d r a w a l s  
C o u n t r y  S p e c t r u m
b  
C l e a r  A p p r o p r i a t e '  a n d  I n d e x  R e c e i v e d  w i t h  S a m e  o f  I n d e x  T e s t  A d e q u a t e l y  A d e q u a t e l y  B l i n d  t o  A p p r o p r i a t e l y •  E x p l a i n e d  
T e s t
d  
R e f e r e n c e  R e f e r e n c e  
I n d e x  
A k e c h i  
3 1  
N o  Y e s  Y e s  Y e s  Y e s  Y e s  Y e s  ( H A D S )  Y e s  Y e s  U n c l e a r  U n c l e a r  
N o  
2 0 0 6 ,  J a p a n  
N o  ( s i n g l e  ( H A D S )  
i t e m )  N o  ( s i n g l e  
i t e m )  
A l e x a n d e r  
N o  Y e s  Y e s  U n c l e a r  Y e s  Y e s  Y e s  Y e s  Y e s  U n c l e a r  U n c l e a r  
Y e s  
3 0  
2 0 1 0 ,  U K  
C o y n e  
2 9  
Y e s  Y e s  Y e s  
U n c l e a r  
Y e s  
Y e s  Y e s  Y e s  Y e s  U n c l e a r  U n c l e a r  U n c l e a r  
2 0 0 4 , U S A  
G r a s s i  
3 2  
N o  Y e s  Y e s  Y e s  Y e s  Y e s  Y e s  Y e s  Y e s  Y e s  U n c l e a r  
N o  
2 0 0 9 ,  I t a l y  
H o p w o o d  
3 3  
N o  Y e s  Y e s  U n c l e a r  N o  Y e s  Y e s  Y e s  N o  Y e s  U n c l e a r  
Y e s  
1 9 9 1 ,  U K  
H o u t s  
3 4  
N o  N o  Y e s  Y e s
1  
Y e s  Y e s  Y e s  Y e s  Y e s  Y e s  U n c l e a r  
Y e s  
2 0 1 0 , U S A  
K r e s p i  
N o  U n c l e a r  Y e s  
Y e s  
Y e s  Y e s  Y e s  Y e s  
N o  Y e s  U n c l e a r  
N o  
B o o t h b y  
3 5  
2 0 1 0 ,  U K  
K u g a y a  
3 6  
N o  N o  Y e s  Y e s  Y e s  Y e s  Y e s  Y e s  Y e s  Y e s  U n c l e a r  
N o  
1 9 9 8 ,  J a p a n  
L l o y d - Y e s  Y e s  Y e s  U n c l e a r  Y e s  Y e s  Y e s  
Y e s  Y e s  Y e s  U n c l e a r  
Y e s  
W i l l i a m s  
3 7 , 3 8  
2 0 0 0 ,  2 0 0 1 ,  
U K  
L l o y d -
N o  Y e s  Y e s  U n c l e a r  Y e s  Y e s  Y e s  Y e s  Y e s  Y e s  U n c l e a r  
Y e s  
W i l l i a m s
3 9  
2 0 0 7 ,  U K  
L o v e  
4 0  
N o  Y e s  Y e s  U n c l e a r  Y e s  Y e s  
Y e s  
Y e s  Y e s  U n c l e a r  U n c l e a r  U n c l e a r  
2 0 0 2 ,  
A u s t r a l i a  
L o v e  
4 1  
N o  Y e s  Y e s  U n c l e a r  Y e s  Y e s  Y e s  Y e s  Y e s  U n c l e a r  U n c l e a r  
U n c l e a r  
2 0 0 4 ,  
A u s t r a l i a  
Table 2 (continued) 
QUADAS Items• 
First #1 #2 #3 #4 #5 #6 #7 #8 #9 #11 #13 #14 
Author, Representative Selection Reference Timing of Whole All Reference Index Test Reference Reference Missing Data Study 
Year, Patient Criteria Standard Reference Sample Patients Independent Described Described Interpreted Handled Withdrawals 
Country Spectrumb Clear Appropriate< and Index Received with Same of Index Test Adequately Adequately Blind to Appropriately• Explained 
Test' Reference Reference Index 
Meyer 42 No Yes Yes Yes Yes Yes Yes Yes Yes Unclear Unclear Yes 
2003, UK 
Murphy 43 No Unclear Yes Yes Yes Yes Yes Yes Yes Unclear Unclear Yes 
2006, UK 
Ozalp 44 No Yes Yes Yes Yes Yes Yes Yes Yes Yes Unclear Yes 
2008, 
Turkey 
Passik 45 No No Yes Unclear Yes Yes Yes Yes Yes No Unclear Yes 
2001, USA 
Patel 46 No Yes Yes No1 Yes Yes Yes Unclear Yes Unclear Unclear Yes 
2010, 
Australia 
Smith 47 Unclear No No Yes Yes Unclear Yes Yes Yes Yes Unclear Unclear 
"O 
2006, UK 
� Walker 48 No Yes Yes No Yes Yes Yes Yes Yes Unclear Unclear Yes a· 
2007, UK :::i 
V, 
• Items are rated 'yes', 'no' and 'unclear' based on the user's guide19 and reflecting the likel ihood of being free of bias. Items #10 (blind interpretation of test results) 
and #12 (same clin ical data available as in practice) were not evaluated because scoring of all self-report depression screening tools is fully automated and does not s· 
require judgment. b Item #1 scored 'no' if patients with already diagnosed or treated depression were not excluded from study sample as they would not constitute (lQ s· 
newly identified cases in clinical practice. Studies were not downgraded for only sampling one type or stage of cancer. c Item #3 was scored 'yes' for all studies as the "O 
systematic review inclusion criteria required the reference standard to be a standardized structured or semi-structured diagnostic interview based on DSM or ICD 
QJ 
!:t. 
criteria. d Item #4 scored 'yes' if index test and reference standard were administered within 1 week of each other, 'no' if longer, and 'unclear' if not specified. Studies 
in which a significant number of patients received assessments more than 2 weeks apart were not included in the systematic review. e Item #13 originally was "Were :E 
uninterpretable, indeterminate or intermediate test results reported?" This item was adapted as "Were missing data on the index test handled correctly?" 1 Authors ;:;: 
clarified that most patients received the index test and reference standard on the same day and all within 5 days. 8 Authors clarified that 67% of interviews were QJ 
UJ conducted w ith in one week and 93% within 2 weeks. n 
.....J � 
Chapter 2 
Key question #2: Effect of depression treatment 
For Key Question #2, 2,923 unique citations were identified. As shown in Figure 3, 2,870 
were excluded after title/abstract review, and 52 after full-text review, leaving 1 eligible 
RCT. That study 49 of patients with MOD based on the SCIO-IV randomized 99 patients to 
usual cancer care and 101 to usual care plus a nurse-delivered collaborative care depression 
intervention. The intervention involved up to 10 one-to-one sessions (mean=7) over 
3 months. Sessions included education about depression and its treatment, problem­
solving and coping strategies, and communication with physicians about depression 
management. Study nurses reviewed each patient's progress with a psychiatrist weekly 
and communicated with the patient's primary care physician regarding patient progress 
and psychiatrist recommendations. Post-intervention depression scores were significantly 
reduced compared to the usual care group (Hedges' g=0.37) (see Table 3). Study quality was 
high (Table 4). 
Figure 3: PRISMA flow diagram of study selection process for Key Question #2 
2923 Unique titles/abstracts 
identified and screened for 
potential eligibility 
2870 Titles/abstracts excluded: 
• No original data or case report (644) 
• Not cancer (518) 
� • Not major depression (1575) � • Not an RCT of major depression treatment 
(131) 
• No placebo or usual care control (2) 
1• 
53 Articles selected for full-text 
review 
52 Articles excluded: 
• No original data or case report (6) 
• � Not cancer (2) � • Not major depression (41) 
• Not an RCT of major depression treatment (2) 
• No placebo or usual care control (1) 
1, 
1 Study included in systematic 




Table 3: Summary of Randomized Controlled Trial of Pharmacological or Psychotherapeutic Treatment of Depression in Cancer 
Depression Outcomes• 
First 




Treatment Males (%) Treatment 





(%) Lost to Duration 
Country Follow-up 
Remission:b Response:< Primary Secondary 
N (%) and N (%) and Outcome: Outcome(s): 
Relative Relative Hedges' g Hedges' g 
Risk Ratio Risk Ratio (95% Cl) (95% CI) 
(95% CI) (95% CI) and r2 and r2 
Strong 49 Non- Mixed/ Nurse Total: 200 Total: 57 Total :  Total: 4 Mean of (a) Txd 28 (a) Txd 51 SCL-20 NR  
2008, Industry Mixed Intervention Tx : 101 Tx : 57 30% (2%) 7 sessions (28%) (50%) depression' 
UK  vs. UC UC: 99 UC: 57 Tx: 31% Tx : 0 (0%) over UC: 14 UC: 34 g=0.37 
UC: 28% UC: 4 (4%) 3 months (14%) (34%) (0.09 to 
R R=2.0 (1.1 RR=l.5 0.65) 
to 3.5) (1.1 to 2.1) r2=0.03 






Abbreviations: Cl = confidence interval; NR = not reported; RR = relative risk ratio; SCL-20 depression = depression subscale derived from the Symptom Checklist-90; 
Tx = treatment; UC = usual care. 
• Depression outcomes were assessed at the end of the treatment period. Continuous outcomes that favored the treatment group are reported in this table as positive 
numbers. b Remission defined as (a) <0.75 on the SCL-20 and (b) no longer having major depression based on the SCIO-IV. c Response defined as a 50% reduction in 
SCL-20 score from baseline. d Publication included remission and response data for 97 patients in the intervention group and 99 in the usual care group. In this table, 
patients lost to follow-up are counted as non-remitters and non-responders. • Publication included remission data for 96 patients in the intervention group and 98 in 
the usual care group. In this table, patients lost to follow-up are counted as non-remitters. 1 Unadjusted effect size g calculated from mean SCL-20 scores 3 months 






















Table 4: Assessment of Risk of Bias in Randomized Controlled Trials in Key Question #2 (Treatment) 
Cochrane Risk of Bias Tool Items• 





Key Question #2 (Treatment): 
Strong 49 
2008, 






Outcome Data Outcome 
Reporting 
uncertain low low 
#6 #7 
Other Sources Overall Risk of 
of Bias Bias Rating 
low low 
• Items are scored as 'high', 'low', or 'uncertain' risk of bias. 
Key question #3: Effect of depression screening 
Of 2,302 unique titles/abstracts from the database search, 5 were selected for full-text 
review, and no RCTs of depression screening met review eligibility criteria (Figure 4). 
Figure 4: PRISMA flow diagram of study selection process for Key Question #3 
2302 Unique titles/abstracts 
identified and screened for 
potential eligibil ity 
2297 Titles/abstracts excluded: 
• No original data or case report (470) 
� • Not cancer (545) � 
• No screen for major depression (441) 
• No RCT or other contro l led tria l  of 
,, depression screen ing (841) 
5 Articles selected for fu l l -text 
review 
5 Articles excluded : 
� • No RCT of depression screening (5) � 
,, 
o Studies included in 
systematic review of Key 
Question #3 
40 
Table 5: Excluded studies for effect of screening on depression outcomes (Key Question #3) 
First Author, Cancer N Comparison Depression Outcomes Reason(s) for exclusion 
Year, Site Consented/ 
Country Randomized• 
Boyes 69 Mixed 80 Intervention: Results from a computer survey No significant difference after Screening of multiple problems 
2006, completed prior to each v isit were provided to 4 visits between groups for and perceived care needs did 
Australia the patient's oncologist. The survey included an change in HAOS-0 scores and not allow assessment of the 
assessment of 12 physical symptoms associated with proportion of patients with effect of depression screening. 
chemotherapy, symptoms of anx iety and depression HAOS-0 � 11. 
{HAOS), and perceived supportive care needs (31 
items), along with computer-generated suggested 
strategies to manage each identified issue. 
Control : Results from computer survey not made 
available to oncologist. 
Carlson 70 Lung 1,134 Full Screening Intervention: Results from OT, problem No difference between full Screening of multiple problems 
2010, and checklist, fatigue and pain thermometers, and screening intervention, triage did not allow assessment 
Canada breast PSSCAN depression and anxiety sections, along with intervention, or usual care of the effect of depression 
personalized feedback report placed on patient's groups on PSSCAN depression screening. 
electronic medical record at initial visit. scores 3 months post-
randomization. 
Triage Intervention: Ful l  screen ing, as described above, � 
along with an offer to speak to a member of the study 5· 
psychosocial team about any of the assessed issues. 
::J 
rt) 
Control: OT completed, but results were not disclosed 5· 
to patient or placed on electronic medical record. OQ 
5· 
"O 
Oetmar 71 Mixed 273b Intervention: Patients completed a quality of l ife No difference between A positive depression screen �-rt) 
2002, questionnaire, the EORTC QLQ-C30, at 3 successive groups in SF-36 Mental Health based on a defined cut-
Netherlands outpatient visits with results made available to patient subscale after 4th visit. off score was not used to � 
and physician prior to consultation. determine who received 
;;.: 
n 
further assessment or 
� Control: Usual care. treatment. ""' 
.i::,.  
T a b l e  5  ( c o n ti n u e d )  
N  
F i r s t  A u t h o r ,  C a n c e r  N  C o m p a r i s o n  D e p r e s s i o n  O u t c o m e s  R e a s o n ( s )  f o r  e x c l u s i o n  
�  
Y e a r ,  S i t e  
C o n s e n t e d /  
N  
C o u n t r y  
R a n d o m i z e d •  
H i l a r i u s  
7 2  
M i x e d  2 9 8  
I n t e r v e n ti o n :  P a t i e n t s  c o m p l e t e d  a  q u a l i t y  o f  l i f e  N o  d i f f e r e n c e  b e t w e e n  N o t  a  r a n d o m i z e d  c o n t r o l l e d  
2 0 0 8 ,  
q u e s t i o n n a i r e ,  t h e  E O R T C  Q L Q - C 3 0 ,  a t  4  o u t p a t i e n t  
g r o u p s  i n  S F - 3 6  M e n t a l  H e a l t h  t r i a l  ( s e q u e n ti a l  c o h o r t  
N e t h e r l a n d s  
v i s i t s ,  w i t h  s u m m a r i e s  g i v e n  t o  p a t i e n t s  a n d  n u r s e s  s u b s c a l e  a f t e r  4
t h  
v i s i t .  d e s i g n ) .  I n  a d d i t i o n ,  a  p o s i t i v e  
p r i o r  t o  c o n s u l t a t i o n .  
d e p r e s s i o n  s c r e e n  b a s e d  o n  
a  d e f i n e d  c u t - o f f  s c o r e  w a s  
C o n t r o l :  S t a n d a r d  c o n s u l t a t i o n s  w i t h  p h y s i c i a n s  a n d  
n o t  u s e d  t o  d e t e r m i n e  w h o  
n u r s e s .  r e c e i v e d  f u r t h e r  a s s e s s m e n t  o r  
t r e a t m e n t .  
M a u n s e l l  
7
3  
B r e a s t  
2 6 1  I n t e r v e n ti o n :  U s u a l  c a r e +  t e l e p h o n e  s c r e e n i n g  D i s t r e s s  l e v e l s  o n  t h e  P S I  
S c r e e n i n g  w a s  f o r  d i s t r e s s ,  
1 9 9 6  b e g i n n i n g  2 1  d a y s  p o s t - r a n d o m i z a ti o n  a n d  r e p e a t e d  a t  d e c r e a s e d  f o r  b o t h  g r o u p s .  N o  b r o a d l y ,  n o t  M D D  a n d  t h e  
C a n a d a  
2 8 - d a y  i n t e r v a l s  w i t h  t h e  2 0 - i t e m  G H Q .  S o c i a l  w o r k e r s  
b e t w e e n - g r o u p  d i f f e r e n c e s  a t  3  f o l l o w - u p  i n t e r v e n t i o n  f o r  
m a d e  f o l l o w - u p  t e l e p h o n e  c a l l s  t o  a l l  p a ti e n t s  w i t h  
a n d  1 2  m o n t h s .  p o s i t i v e  s c r e e n s  w a s  g e a r e d  
G H Q �  5  t o  a s s e s s  p s y c h o l o g i c a l  d i s t r e s s  a n d  o f f e r  t o w a r d s  d i s t r e s s ,  n o t  M D D  
p s y c h o s o c i a l  i n t e r v e n t i o n .  
s p e c i f i c a l l y .  
C o n t r o l :  U s u a l  c a r e ,  w h i c h  i n c l u d e d  m i n i m a l  
p s y c h o s o c i a l  i n t e r v e n ti o n  a s  p a r t  o f  i n i t i a l  c a n c e r  c a r e .  
M c l a c h l a n  
7
4  
M i x e d  
4 5 0  I n t e r v e n ti o n :  P a t i e n t s  a t  t h e i r  f i r s t  c o n s u l t a t i o n  N o  s i g n i f i c a n t  d i f f e r e n c e  A  p o s i ti v e  d e p r e s s i o n  s c r e e n  
2 0 0 1 ,  
c o m p l e t e d  a  s e r i e s  o f  s e l f - r e p o r t  q u e s ti o n n a i r e s  v i a  b e t w e e n  g r o u p s  a t  b a s e d  o n  a  d e f i n e d  c u t -
A u s t r a l i a  
t o u c h - s c r e e n  c o m p u t e r ,  i n c l u d i n g  t h e  C N Q ,  E O R T C  2 - m o n t h s  o r  6 - m o n t h s  p o s t - o f f  s c o r e  w a s  n o t  u s e d  t o  
Q L Q - C 3 0 ,  a n d  B D I - S F .  A  s u m m a r y  o f  q u e s t i o n n a i r e  r a n d o m i z a ti o n  f o r  t h e  C N Q  d e t e r m i n e  w h o  r e c e i v e d  
r e s u l t s  w a s  m a d e  a v a i l a b l e  t o  p h y s i c i a n s  p r i o r  t o  p s y c h o l o g i c a l  d o m a i n ,  B D I - S F  f u r t h e r  a s s e s s m e n t  o r  
c o n s u l t a t i o n ,  w h i c h  w e r e  i n t e n d e d  t o  b e  u s e d  t o  i n f o r m  s c o r e s  o r  E O R T C  Q L Q - C 3 0  t r e a t m e n t .  A d d i t i o n a l l y ,  
a n  i n d i v i d u a l i z e d  m a n a g e m e n t  p l a n .  E m o t i o n a l  F u n c t i o n i n g . c  s c r e e n i n g  o f  m u l ti p l e  p r o b l e m s  
d i d  n o t  a l l o w  a s s e s s m e n t  
C o n t r o l :  Q u e s t i o n n a i r e  r e s p o n s e s  w e r e  n o t  m a d e  o f  t h e  e f f e c t  o f  d e p r e s s i o n  
a v a i l a b l e  t o  h e a l t h  c a r e  t e a m  p r i o r  t o  c o n s u l t a t i o n .  s c r e e n i n g .  
Table 5 (continued) 
First Author, Cancer N Comparison Depression Outcomes Reason(s) for exclusion 
Year, Site Consented/ 
Country Randomized• 
Rosenbloom Mixed 213 Assessment, Interview, and Discussion Intervention: No significant difference A positive depression screen 
75 At baseline, 1 and 2 months, patients completed FLIC  between groups at based on a defined cut-
2007, and FACT-G, and FACT-G scores elaborated through an 3-months or 6-months post- off score was not used to 
USA interview and discussion, the results of which were randomization for Brief POMS determine who received 
shared with treatment nurse prior to visit. negative mood subscale or FLIC further assessment or 
psychological subscale scores. treatment. Additional ly, 
Assessment Intervention: At baseline, 1 and 2 months, screening of multiple problems 
patients completed FLIC and FACT-G, and FACT-G scores did not allow assessment of 
were shared with treatment nurse prior to visit. effect of depression screening. 
Control: Patients completed FLIC at baseline. 
Questionnaire data not shared with treatment nurse. 
Shimizu 76 Mixedd 1,065 Intervention: Patients completed 11-point D IT (score Only number of positive Not a randomized controlled 
2010, range 0-10), and those with a distress score <!: 4 and an screens and number diagnosed trial (sequential cohort design). 
Japan impact score <!: 3 were referred by their oncologist for a and treated, but no depression In addition, outcomes included 
psycho-oncology service consultation. outcomes, were assessed. number of positive screens 
and number treated, but no 
Control: Usual care with referral to psycho-oncology depression outcomes were � 





Taenzer 77 Lung 57 Intervention: At a single clinic visit, patients completed Only number of quality Not a randomized controlled 3· 
2000, the EORTC QLQ-C30, which was provided to clinic staff of l ife issues addressed in  trial (sequential cohort CTQ 3· 
Canada prior to clinic appointment with no specific instructions appointment and patient design). In addition, a positive 
for use. satisfaction, but no depression depression screen based on !:t. 
outcomes, were assessed. a defined cut-off score was � 
Control : Patients completed the EORTC QLQ-C30 not used to determine who 
;:;: 
following their clinic appointment. received further assessment or ::, 
n 
treatment and no depression 
� outcomes were assessed. n lJJ � 
.i:,.  
.i,,.  
T a b l e  5  ( c o n ti n u e d )  
F i r s t  A u t h o r,  
Y e a r, 
C o u n t r y  
T h e w e s  
7 8  
2 0 0 9 ,  
A u s t r a l i a  
V e l i k o v a  
7
9  
2 0 0 4 ,  
U K  
C a n c e r  
N  
S i t e  C o n s e n t e d /  
R a n d o m i z e d •  
M i x e d  8 3  
M i x e d  
2 8 6  
C o m p a r i s o n  
I n t e r v e n ti o n :  P a t i e n t s  c o m p l e t e d  t h e  O T ,  a n d  n u r s i n g  
s t a f f  w a s  e n c o u r a g e d  t o  a s s e s s  p r o b l e m s  a n d  d i s c u s s  
p s y c h o s o c i a l  r e f e r r a l  f o r  p a t i e n t s  w i t h  O T  s c o r e �  5 .  
C o n t r o l :  U s u a l  c a r e  w i t h  n o  s c r e e n i n g .  
A s s e s s m e n t  a n d  F e e d b a c k  I n t e r v e n ti o n :  F o r  6  m o n t h  
s t u d y  p e r i o d ,  p r i o r  t o  c l i n i c  v i s i t s ,  p a t i e n t s  c o m p l e t e d  
E O R T C  Q L Q - C 3 0  a n d  H A D S  w i t h  r e s u l t s  p r o v i d e d  t o  
p h y s i c i a n s  p r i o r  t o  v i s i t .  
A tt e n t i o n  C o n t r o l :  F o r  6  m o n t h  s t u d y  p e r i o d ,  p r i o r  t o  
c l i n i c  v i s i t s ,  p a t i e n t s  c o m p l e t e d  E O R T C  Q L Q - C 3 0  a n d  
H A D S  w i t h  n o  r e s u l t s  p r o v i d e d  t o  p h y s i c i a n s .  
U s u a l  C a r e  C o n t r o l :  P a t i e n t s  d i d  n o t  c o m p l e t e  E O R T C  
Q L Q - C 3 0  o r  H A D S .  
D e p r e s s i o n  O u t c o m e s  
C o n t r a r y  t o  h y p o t h e s i s ,  
p a t i e n t s  i n  t h e  s c r e e n e d  g r o u p  
r e p o r t e d  s i g n i f i c a n t l y  h i g h e r  
l e v e l  o f  u n m e t  p s y c h o l o g i c a l  
n e e d s  6  m o n t h s  a ft e r  i n i t i a l  
c l i n i c  c o n t a c t .  
S c o r e s  o n  F A C T- e m o ti o n a l  
s u b s c a l e  w e r e  b e t t e r  i n  t h e  
i n t e r v e n t i o n  g r o u p  t h a n  t h e  
u s u a l  c a r e  c o n t r o l  g r o u p ,  
b u t  n o t  d i f f e r e n t  f r o m  t h e  
a t t e n t i o n  c o n t r o l  g r o u p .  
R e a s o n ( s )  f o r  e x c l u s i o n  
N o t  a  r a n d o m i z e d  c o n t r o l l e d  
t r i a l  ( s e q u e n t i a l  c o h o r t  
d e s i g n ) .  O u t c o m e  o f  u n m e t  
p s y c h o l o g i c a l  n e e d s ,  b u t  n o t  
d e p r e s s i o n .  
A  p o s i t i v e  d e p r e s s i o n  s c r e e n  
b a s e d  o n  a  d e f i n e d  c u t -
o f f  s c o r e  w a s  n o t  u s e d  t o  
d e t e r m i n e  w h o  r e c e i v e d  
f u r t h e r  a s s e s s m e n t  o r  
t r e a t m e n t .  A d d i t i o n a l l y ,  
s c r e e n i n g  o f  m u l t i p l e  p r o b l e m s  
d i d  n o t  a l l o w  a s s e s s m e n t  o f  
e f f e c t  o f  d e p r e s s i o n  s c r e e n i n g .  
A b b r e v i a t i o n s :  O T  =  D i s t r e s s  T h e r m o m e t e r ;  B D I - S F  =  B e c k  D e p r e s s i o n  I n v e n t o r y  - S h o r t  F o r m ;  C N Q  =  C a n c e r  N e e d s  Q u e s t i o n n a i r e ;  D I T  =  D i s t r e s s  a n d  I m p a c t  
T h e r m o m e t e r ;  E O R T C  Q L Q - C 3 0  =  E u r o p e a n  O r g a n i z a t i o n  f o r  R e s e a r c h  a n d  T r e a t m e n t  o f  C a n c e r  Q u a l i t y  o f  L i f e  Q u e s t i o n n a i r e  - C o r e  3 0 ;  F A C T - e m o t i o n a l  =  F u n c t i o n a l  
A s s e s s m e n t  o f  C a n c e r  T h e r a p y - e m o t i o n a l ;  F A C T - G  =  F u n c t i o n a l  A s s e s s m e n t  o f  C a n c e r  T h e r a p y - G e n e r a l ;  F L I C  =  F u n c t i o n a l  L i v i n g  I n d e x  - C a n c e r ;  G H Q  =  G e n e r a l  
H e a l t h  Q u e s t i o n n a i r e ;  H A D S  =  H o s p i t a l  A n x i e t y  a n d  D e p r e s s i o n  S c a l e ;  H A D S - D  =  D e p r e s s i o n  s u b s c a l e  o f  H o s p i t a l  A n x i e t y  a n d  D e p r e s s i o n  S c a l e ;  M O D  =  M a j o r  
d e p r e s s i v e  d i s o r d e r ;  P O M S  =  P r o f i l e  o f  M o o d  S t a t e s ;  P S I  =  P s y c h i a t r i c  S y m p t o m  I n d e x ;  P S S C A N  =  P s y c h o l o g i c a l  S c r e e n  f o r  C a n c e r ;  S F - 3 6  =  S h o r t  F o r m  3 6  H e a l t h  S u r v e y  
Q u e s t i o n n a i r e .  
•  N u m b e r  c o n s e n t e d  f o r  n o n - r a n d o m i z e d  c o n t r o l l e d  t r i a l s  a n d  n u m b e r  r a n d o m i z e d  f o r  r a n d o m i z e d  c o n t r o l l e d  t r i a l s .  
b  
P h y s i c i a n s ,  r a t h e r  t h a n  p a r t i c i p a n t s ,  w e r e  
r a n d o m i z e d .  T h i s  n u m b e r  i s  t h e  n u m b e r  o f  e l i g i b l e  p a t i e n t s  w h o  a g r e e d  t o  p a r t i c i p a t e .  c  T h e  a u t h o r s  r e p o r t e d  a  p o s t - h o c  s u b g r o u p  a n a l y s i s  t h a t  f o u n d  s i g n i f i c a n t l y  
i m p r o v e d  B 0 I - S F  s c o r e s  f o r  t h e  4 4  p a ti e n t s  i n  t h e  i n t e r v e n ti o n  g r o u p  w i t h  b a s e l i n e  B 0 I - S F  s c o r e s  �  8  c o m p a r e d  t o  t h e  1 9  c o n t r o l  p a t i e n t s  w i t h  B 0 I - S F  �  8 .  H o w e v e r ,  
p a t i e n t s  w e r e  n o t  r a n d o m i z e d  b a s e d  o n  B 0 I - S F  s c o r e s ,  a n d  t h e  r e l e v a n c e  o f  t h e s e  r e s u l t s  f o r  s c r e e n i n g  a r e  n o t  c l e a r ,  s i n c e  s c r e e n i n g  i s  a p p l i e d  t o  a l l  p a ti e n t s ,  n o t  o n l y  
p a t i e n t s  i d e n t i f i e d  t h r o u g h  s c r e e n i n g  w i t h  h i g h  s c o r e s .  
d  







Depression screening in patients with cancer 
A number of other studies (see Table 5) described by their authors or in other reviews 
as related to screening were excluded from the present systematic review. Several were 
excluded because they did not use a positive depression screen based on a pre-specified 
cut-off score to determine which patients would receive further assessment or treatment. In 
those studies, a range of screening tools was often made available for clinical consultations, 
but scores on a depression screening tool did not determine referral for psychosocial 
evaluation or treatment. Studies were also excluded because they (1) were not RCTs; (2) 
included multiple screening tools for many different problems, not allowing the effect of 
depression screening to be evaluated separately; or (3) did not report depression symptom 
or diagnosis outcomes. 
Discussion 
One of the most important functions of systematic reviews is to identify areas where there 
is not sufficient evidence and where clinical trials are needed 50• The main finding of this 
systematic review was that there are no RCTs that have evaluated whether screening for 
depression among cancer patients would improve depression outcomes. This is important 
because reports from an NIH panel 8 and the IOM 4 and clinical guidelines from the NCCN 3 and 
N ICE 7 have recommended that screening for psychological distress, including depression, 
be part of standard supportive and palliative cancer care. The results of this systematic 
review show that these recommendation statements are not supported by evidence from 
RCTs that screening cancer patients for depression would improve patients' mental health 
beyond existing psychosocial services that are offered in oncology settings. 
As described in well-established criteria for evaluating the potential benefit of screening 
programs 10•12 and methods developed by the USPSTF 14, in the absence of evidence from 
well-conducted RCTs on the benefits versus harms of screening it is important to examine 
whether evidence on the performance of screening tools and the efficacy of treatment is 
sufficiently robust as to warrant recommendations for screening and where there are gaps 
in the process that require more research. 
With respect to the accuracy of depression screening tools in cancer settings, most studies 
that we reviewed used exploratory methods that identify cut-off scores that maximize 
diagnostic accuracy in a particular sample. These methods tend to yield inflated estimates of 
screening accuracy that do not replicate consistently in other samples 51• In addition, sample 
sizes were generally small for the purpose of assessing diagnostic accuracy with a median of 
17 MOD cases per study. Not surprisingly, optimal cut-off scores for the two instruments that 
were used most frequently, the HADS and HADS-D, varied too widely to provide guidance 
45 
Chapter 2 
to clinicians on their optimal use. Optimal cut-offs ranged from 15 to 20 for the HADS and 
5 to 11 for the HADS-D. Three studies that used a priori defined standard cut-offs for the 
HADS-D reported very low sensitivity (7% to 50%). The accuracy of the EPDS was better, with 
cut-offs of 12 and 13 producing reasonably high sensitivity (72-82%) and specificity (74-90%) 
estimates, although only one study included more than 22 patients with MDD. All studies 
for Key Question #1 were based on samples that included already diagnosed and treated 
patients. This would be expected to generate inflated estimates of screening sensitivity and 
exaggerate the number of previously undetected cases that would be identified through 
screening in clinical practice as described in a recent overview 52• 
With respect to depression treatment, we identified 1 high-quality RCT of a nurse­
delivered collaborative care intervention for MDD 49• That study found that cancer patients 
randomized to the intervention experienced a small to moderate reduction in depressive 
symptoms (Hedges' g=0.37), similar to the estimated effect reported in a meta-analysis 
of collaborative care interventions in primary care (standardized mean effect size=0.25) 53• 
A number of studies have used psychosocial interventions to address a range of clinical 
domains associated with cancer, but not MDD, and were not included in this review 54• A 
collaborative care intervention 55 and several antidepressant trials for depression 54 were also 
excluded because they defined MDD based on non-validated clinician interviews or scores 
on self-report questionnaires. Results from those studies generally support the conclusion 
that depression treatment is similarly effective for patients with and without cancer 54• 55• 
The nurse-delivered collaborative care intervention trial reported by Strong et al. 49 tested 
the kind of integrated depression care that might be considered for patients identified 
as depressed in a screening program. This trial was included in the review of treatment 
effects, but not the effects of screening, because it only enrolled patients who had been 
diagnosed with MDD. Thus, the results of the trial suggest that collaborative care would 
improve outcomes for patients already identified as depressed. They do not, however, 
address the important question of whether patients from a cancer setting who are screened 
would have better outcomes than patients who are not screened, but who could receive 
collaborative depression care after referral by a healthcare provider outside of the context 
of screening. Per standard criteria for evaluating screening programs 10-12, RCTs of screening 
assess outcomes for patients screened versus patients not screened. Thus, an important 
limitation of our review was that there were no RCTs that compared depression outcomes 
among patients screened for depression compared to patients not screened for depression. 
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Depression screening in context 
Depression screening is only useful to the degree that it leads to improved outcomes above 
and beyond existing care. Thus, to be successful, a screening program would need to identify 
a meaningful number of patients as depressed out of those who have opted not to utilize 
available psychosocial supports; successfully enroll those patients in treatment; and achieve 
positive treatment results. As illustrated by one study from Germany 56, however, the desire for 
psychosocial support to cope with cancer may not be correlated with distress levels, and nearly 
as many patients with low levels of distress may desire supportive care as patients above the 
cut-off criterion on a screening tool. To provide incremental benefit to patients, depression 
screening programs in cancer must be able to uncover and address unmet needs 57• 
As described in the recently updated NICE guidelines for depression care in general medical 
settings, it should not be assumed that screening programs would necessarily meet currently 
unmet care needs. The NICE guidelines noted a lack of evidence for benefit from depression 
screening and, therefore, rather than routine screening of all patients, recommended 
strategies to identify depression among high-risk groups of patients or patients otherwise 
identified by physicians as possibly having depression 58• In addition to the overall lack of 
evidence for benefits from screening, the authors of the NICE report cited a number of other 
important considerations, including the relatively small proportion of patients who screen 
positive on screening tools who actually have depression. They noted that many patients who 
screen positive are mildly depressed and are likely to recover without formal intervention, 
and that ineffective screening could divert scarce resources from more seriously depressed 
patients who may receive inadequate treatment as a result 58•59• 
Based on existing evidence from other patient groups, it is clear that screening without 
comprehensive systems for depression assessment and management does not improve 
depression outcomes. There are at least 11 trials in primary care 60, for instance, that have 
tested whether screening and referral for depression treatment improves depression 
outcomes, and all have been negative. Some of these primary care trials have found that 
screening increases the number of patients treated for depression, but increasing treatment 
without symptom reduction would be costly and could expose patients to unnecessary harms 
from treatment without benefit 60• Thus, the USPSTF recommends depression screening in 
primary care only when supported by integrated, staff-assisted depression management 
programs 61• However, it is not clear whether screening in the context of staff-assisted, 
collaborative care depression management programs would benefit patients 62, and it is 
important to differentiate between the effectiveness of screening and the effectiveness of 
collaborative care. The results of the collaborative care treatment trials reviewed by the 
USPSTF suggest that providing collaborative depression care is better than not providing 
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this care. They do not, however, demonstrate that patients who receive screening will have 
better depression outcomes compared to patients who are not screened when the same 
treatment and care resources are made available to both groups 9• This is because, as in the 
Strong et al. study 49, in the studies reviewed by the USPSTF, patients were required to have 
depressive symptoms or a diagnosis of depression to be eligible for the trial. In addition, 
only patients with depression in the intervention groups received a collaborative care 
intervention for depression, whereas depressed patients in the control groups received only 
standard care. In actual clinical settings, patients receive the optimal treatment available, 
whether they are identified through a screening program or via physician recognition. Thus, 
these trials do not address the issue of whether screening would benefit patients with 
previously unrecognized depression. Underlining this issue, in the largest of the trials cited 
by the USPSTF a substantial portion of patients were already recognized and being treated 
for depression prior to enrolling in the trial and receiving augmented care 9• 
Potential harms from depression screening in cancer care 
In the absence of demonstrated benefit, potential harms from depression screening 
for cancer patients should be considered carefully, as outlined in standard evaluative 
frameworks 10•12 and in the USPSTF methodology 14• The degree to which routine depression 
screening of patients with cancer might lead to inappropriate labeling and treatment 
on the one hand, or to extraordinary and impractical overuse of important health care 
resources, on the other, has not been examined. Routine depression screening would 
increase the number of cancer patients diagnosed with depression and treated with 
antidepressant drugs 29•63• As a consequence, more patients with cancer would be exposed 
to potentially harmful drug-drug interactions between antidepressants and either cancer 
chemotherapeutic agents 53•57 or anti-emetics 68• Interactions between anti-cancer drugs 
and antidepressants are of particular concern because small alterations in the plasma 
concentrations of certain members of either drug class can lead to either subtherapeutic 
effects or drug toxicity 64• Perhaps of greatest importance is the potential interaction between 
certain antidepressants and tamoxifen, commonly used as adjuvant therapy for women with 
breast cancer. The hepatic enzyme CYP2D6 is the principal enzyme that converts tamoxifen to 
its active metabolite, endoxifen 67• Some antidepressants, particularly paroxetine, fluoxetine, 
and bupropion, are strong inhibitors of CYP2D6 and may diminish the therapeutic effect 
of tamoxifen 29•65•66• Indeed, one study estimated that there would be 1 additional breast 
cancer death within 5 years of stopping adjuvant treatment for every 20 women who used 
paroxetine approximately 40% of the time they took tamoxifen 63• 
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Conclusions 
In summary, this systematic review did not identify any RCTs that compared the benefits 
versus harms of depression screening in patients with cancer. In the absence of such RCTs, 
there currently is not evidence to support recommendations for the incorporation of routine 
depression screening into standard cancer care. Depression treatment appears to be as 
effective in cancer care as in other settings, but important limitations in the evidence base 
on screening tools in this population were identified, and research is needed to address 
these limitations. In order to inform health care providers who must decide whether or not 
to screen cancer patients for depression and developers of guidelines for cancer care, well­
designed and executed RCTs that investigate depression screening programs are needed. 
Specifically, screening for depression in a cancer treatment setting should be tested in a 
trial where all patients identified as depressed via screening or by physician recognition and 
referral in a control group have access to high-quality, integrated depression care. Given the 
current absence of evidence on the effectiveness of screening in cancer, and the absence 
of positive results from any trial in other patient groups, however, recommendations for 
depression screening among patients with cancer are at this point premature. 
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ABSTRACT 
Objective: Severa l practice gu idel ines recommend routine screening for psychological 
distress i n  cancer care. The objective was to eva luate the effect of screen ing cancer patients 
for psychological d istress by assessing the (1 )  effectiveness of interventions to reduce 
distress a mong patients identified as distressed; and (2 )  effects of screening for d istress on 
distress outcomes. 
Methods: Cl NAHL, Cochrane, EM BASE, IS i ,  MEDLI N E, Psyc lN FO, and SCOPUS databases were 
sea rched through Apri l 6, 2011 with manual sea rches of 45 relevant journa ls, reference l ist 
review, citation tracking of incl uded articles, and tria l registry reviews through June 30, 2012. 
Articles i n  a ny language on cancer patients were inc luded if they (1) compared treatment for 
patients with psychological d istress to p lacebo or usua l  ca re in a randomized contro l led tria l  
(RCT); or (2 )  assessed the effect of provid ing screen ing on  psychologica l d istress i n  a RCT. 
Results: There were 14 e l igib le RCTs for treatment of d istress, and 1 RCT on the effects 
of screen ing on patient distress. Pharmacological, psychotherapy and col l aborative 
ca re interventions genera l ly reduced distress with sma l l  to moderate effects. One study 
investigated effects of d istress screening on  psychologica l outcomes, and it found no 
improvement. 
Conclusion: Treatment stud ies reported modest improvement in  distress symptoms, but 
only a single e l igib le study was found on the effects of screening cancer patients for distress, 
and distress d id not improve in screened patients versus those receiving usual ca re. Because 
of the lack of evidence of beneficia l  effects of screen ing cancer patients for distress, it is 
prematu re to recommend or mandate implementation of routine screening. 
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Introduction 
Emotional distress is common among cancer patients as a result of the diagnosis of a life­
threatening disease, the direct effects of the tumor, aggressive medical treatments, and the 
changes in lifestyle that occur 1-3 _ Increasingly, attention is being paid to the psychological 
consequences of cancer, with recognition of not only psychiatric disorders such as major 
depressive disorder (MDD) or anxiety disorders, but also of subsyndromal symptoms 
of depression and anxiety. In addition, attention is being paid to the broader and more 
inclusive concept of emotional or psychological distress, as indicated by an elevated score 
on a one-item distress thermometer or another psychological symptom questionnaire. A 
number of major cancer organizations have recommended routine screening for distress, 
broadly defined, and several accrediting agencies mandate routine distress screening on 
the assumption that identification of distress will result in increased uptake of services and 
reductions in distress 4-6• 
Well-accepted, standard definitions of medical screening describe it as an intervention that 
involves the application of a screening tool to individuals who are not otherwise aware they 
are at risk, in order to detect a medical condition that can be alleviated through intervention 
7•8• Screening for MOD, for instance, involves the use of depression symptom questionnaires 
or small sets of questions about depression to identify patients who may have depression, 
but who have not sought treatment and whose depression has not already been recognized 
by healthcare providers. Patients identified as possible cases based on a positive screen 
need to be further assessed to determine if they have depression and, if appropriate, 
offered treatment 9• 
Screening for "distress" is less well-defined since it does not seek to identify patients with a 
medical condition, and the meaning of a positive screen is less clear. If screening for "distress" 
is to be done, nonetheless, consistent with well-established definitions of screening 7•8, 
it would involve using scores above a pre-defined cut-off on a distress screening tool to 
identify patients to be offered an intervention to reduce psychological distress. Distress 
screening would be potentially useful if it could improve patient outcomes beyond existing 
standard care in which patients had access to the same services without being screened. 
Three previous reviews 10, 11,12 have sought to evaluate whether there is evidence that routine 
screening for psychological distress improves psychosocial outcomes among patients with 
cancer. The reviews have concluded that screening may improve communication between 
patients and health care providers and may stimulate discussions of psychosocial and 
mental health issues. The reviews agreed, however, that there is not conclusive evidence 
that screening for distress improves patient outcomes. One concern about these reviews 
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is that they included studies that would not be considered "screening" based on standard 
definitions of screening. For example, studies in which psychosocial questionnaires were 
used to inform psycho-oncology consultations were included, even though screening, by 
definition, would involve using a psychosocial questionnaire to actually determine which 
patients would receive a psychosocial consultation and potentially be offered psychosocial 
services 7-9 • 
In a previous systematic review, we considered the evidence on screening for MOD in cancer 
patients 13, but did not find evidence to support recommendations of systematic screening 
for depression. Compared to depression, the target of recommendations for screening for 
psychological distress is broader in scope, but less clearly defined in terms of targeting a 
specific medical condition. The objective of the present systematic review was to evaluate 
the evidence on screening for psychological distress in cancer. Review questions were 
developed based on the U.S. Preventive Services Task Force (USPSTF) 14•15 analytic framework 
for evaluating screening programs. The USPSTF framework recognizes the need for RCTs 
to directly assess links between screening programs and patient outcomes. When direct 
evidence from RCTs is not available or is of low quality, the USPSTF framework assesses key 
links that are necessary for screening to benefit patients, focusing on the need for accurate 
screening tools and effective treatments 14•15• 
Screening for distress per se differs from other medical screening programs in that there 
is not a clear, defined medical condition, such as MOD, that screening tools seek to detect. 
Thus, although reviews of screening usually assess screening tool accuracy compared to a 
gold standard 14•15, we were not able to do this. Nonetheless, an important prerequisite if 
screening of psychological distress is to improve patient outcomes is that distress can be 
reduced through intervention for patients identified as distressed. Thus, consistent with 
USPSTF methods, Review Question #1 was, "What are the effects of interventions to reduce 
distress among cancer patients who have been selected for treatment based on a minimum 
threshold of psychological distress, as would be done in a screening program?" 
If screening is to be actually recommended as policy, there should be consistent evidence 
from well-conducted randomized controlled trials (RCTs) 16•17 that screening benefits patients 
in excess of any possible harms. Thus, Review Question #2 was, "Is routine screening 
for psychological distress of cancer patients more effective than usual care in reducing 
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The CINAHL, Cochrane, EMBASE, IS i, MEDLINE, PsyclNFO, and SCOPUS databases were 
searched through April 6, 2011. A search was conducted for studies of interventions designed 
to reduce psychological distress among cancer patients identified as having distress (Review 
Question #1) and for studies that assessed outcomes of psychological distress screening 
interventions (Review Question #2). Manual searches were done on relevant systematic 
reviews, reference lists of included articles, and 45 selected journals (March 2011 to May 
2012). We also tracked citations of included articles using Google Scholar 18 and searched 
the trial registries ClinicalTrials.gov 19 and the International Standard Randomized Controlled 
Trial Number Register 20 to attempt to identify unpublished treatment or screening RCTs. 
Identification of eligible studies 
Eligible articles included studies in any language on cancer patients with any type of 
malignancy at any disease stage that reported original data, excluding abstracts, case series, 
or case reports. Translators assisted reviewers to evaluate titles and abstracts and full-length 
articles for languages not covered by investigators, who were able to independently review 
material in English, Dutch, French, and Spanish. Multiple articles from the same cohort were 
treated as a single study. Studies with mixed populations were included only if cancer data 
were reported separately. 
For Review Question #1, eligible articles were RCTs that compared interventions designed 
to reduce psychological distress to placebo, usual care, or attention controls in adult cancer 
patients with elevated distress. Only RCTs that limited inclusion to patients with high levels 
of distress, rather than all patients with cancer, were included because this is what would 
occur in a screening program. Furthermore, psychosocial interventions in cancer appear 
to be beneficial among patients with high initial distress, but produce negligible effects 
for patients with low pre-intervention distress 21• Small, underpowered studies are often 
of poor quality, and significant publication bias is a major problem among these studies 
22-24• A number of proposals have been made regarding setting thresholds for minimum 
number of patients for studies to be included in systematic reviews 23•24• In the present 
review, we included trials that randomized at least 25 patients to each group 25• Head-to­
head comparisons of different interventions without a comparison to usual care or placebo 
were not eligible. 
Eligible articles for Review Question #2 were RCTs that compared outcomes between cancer 
patients who underwent screeningfor psychological distress and those who did not. Screening 
was defined according to the UK  National Screening Committee's definition 7• Thus, eligible 
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screening trials had to include a strategy to identify patients with high levels of psychological 
distress based on an a priori-defined cut-off score on a measure of distress. Furthermore, 
in eligible studies, positive versus negative results of the screening test had to be used to 
make decisions about further assessment, referral, or treatment. Studies were excluded if 
healthcare providers for patients in the intervention group had feedback from psychosocial 
questionnaires to inform their communication with patients, whereas healthcare providers 
for patients in the control group did not, but a cut-off score on a screening instrument did not 
determine referral for psychosocial services. In such instances, psychosocial questionnaires 
are used to inform and structure conversations, not to determine which patients receive 
services to address distress. Studies in which questionnaire results were provided to 
clinicians without guidance about cut-off scores to determine positive screening status 
were also excluded. Finally, studies that involved administering multiple screening tools 
for multiple problems were not included, since patients in these studies could have been 
deemed in need of services due to reasons other than psychological distress (e.g., issues 
related to drug coverage by insurance, transportation and parking, or nutritional needs) 
26, and determining whether the psychological distress component of screening influenced 
distress outcomes would not be possible. 
Two investigators independently reviewed articles for eligibility. If either deemed an article 
potentially eligible based on title and abstract review, then a full-text review was undertaken. 
Disagreements after full-text review were resolved by consensus. 
Evaluation of eligible studies 
Two investigators independently extracted and entered data into a standardized spreadsheet. 
Discrepancies were resolved by consensus. Risk of bias in studies included for both review 
questions was assessed with the Cochrane Risk of Bias tool 27, including assessment of 
financial conflicts of interest as has been recommended 28•29• Risk of bias was assessed by 
two investigators, with discrepancies resolved by consensus. 
Data presentation and synthesis 
Psychological distress outcomes reported in each eligible study were classified as primary or 
secondary for the purposes of the review. For both review questions, when multiple measures 
of psychological distress were assessed as outcomes, designated primary outcomes for 
each study were prioritized. If there were no designated primary outcomes, the distress 
measure that was used to determine eligibility for the trial (Review Question #1) or as the 
screening tool for psychological distress (Review Question #2) was selected. If there were 
no observer-rated instruments, and there was more than 1 self-rating instrument, all were 
reported as secondary outcomes. When outcomes were assessed at multiple time points, 
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the assessment point that followed the end of treatment most closely was reported. Post­
intervention effect sizes were reported using the Hedges' g statistic 30, which represents a 
standardized difference between 2 means, as well as r2, which is statistically equivalent 31•3 2, 
but presents results in terms of percent of variance in distress outcome or change scores 
due to treatment. Dichotomous outcomes {e.g., response, remission) were not extracted 
since there is no agreed upon gold standard or definition for caseness in the context of 
psychological distress. 
Eligible studies for each review question were evaluated to determine whether there was 
sufficient clinical and methodological similarity to support pooling of results. For Review 
Question #1 {treatment), studies were heterogeneous in terms of patient samples, 
therapeutic interventions, outcome measures, and treatment duration. Only 1 eligible 
study was identified for Review Question #2 {screening). Therefore, results were not pooled 
quantitatively. A review protocol was not published or registered for this systematic review. 
However, a written protocol was developed and followed for searching, data extraction, and 
data synthesis with all methods determined a priori. 
Results 
Review question #1: effect of treatment of psychological distress 
The combined database search for Review Questions #1 {treatment) and #2 {screening) 
generated 4,167 unique citations. As shown in Figure 1, for Review Question #1 {treatment), 
3,754 were excluded after title/abstract review and 399 after full-text review, leaving 14 
eligible studies for review. No additional studies were identified through alternative sources, 
such as hand searching of journals, forward citation of included articles, and review of trial 
registries. 
As shown in Table 1, the 14 studies of interventions to reduce psychological distress we 
reviewed included 12 studies of patients with mixed cancer sites 33-44, 1 study with patients 
with breast or cervical cancer 45, and 1 study with patients with breast cancer only 46• Total 
sample size per study ranged from 55 to 472. Of the 14 studies, 7 randomized at least 
64 patients per group 34•35-39A3A4, which would provide adequate {80%} power to detect a 
medium effect size {standardized mean difference = 0.50) 47• 
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Figure 1: PRISMA flow diagram of study selection process for Review question #1 
4,167 Unique titles/abstracts 
identified and screed 
for potentia l  el igibi l ity 
3,754 Titles/abstracts excluded: 
... . No origina l  data or case report (266) . No cancer (668) . N ot an RCT of d istress treatment (2,740) . < 25 randomized per group (80) 
� r 
413 Articles selected for 
ful l-text review 
399 Articles excluded: 
. No origina l  data or case report (10) 
� . No cancer (12) . N ot an RCT of distress treatment (202) . No min imum level of distress (167) . < 25 randomized per group (7) 
� r . I ncomplete outcome data (1)  
14 Studies included in  
systematic review of 
Key Question #1 
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Table 1: Characteristics and outcomes of randomized controlled trials of distress treatment 
First Author, Study Cancer Type/ Distress Treatment vs. Number Mean Males (%) Treatment Primary Distress Secondary Distress 
Vear, Funding Description Inclusion Control of Patients Age Duration Outcome:• Outcome(s):• Hedges' g 
Country Source Criterion Randomized (Years) Hedges' g (95% Cl) (95% Cl) and r2 
and r2 
Costa, NR Mixed/ Depression Mianserin vs. Total :  73 Tx: 49 Tx: 0% 4 weeks HAMD-17: ZSRDS: 
1985, Mixed diagnosis; and placebo Tx: 36 Placebo: Placebo: 0.60 (0.13-1.07) 0.64 (0.17-1.11) 





Dwight- Non- Breast or Symptoms Collaborative Total : 55 Tx: 48 Tx: 0% Minimum NRd fl FACT-G emotional:< 
Johnson, industry cervical/ consistent care vs. UC Tx: 28 UC: 47 UC: 0% of 8 0.58 (0.04-1.12) 
2005, Mixed with major UC: 27 weeks< r2 = .08 





baseline and 1 
month later 
El l, Non- Mixed/ Mixed Sadness or Collaborative Total :  472 NR  Tx: 16% 12 months PHO-9:l FACT-G emotional:1 
2008, industry anhedonia care vs. Tx: 242 UC: 14% 0.17 (-0.07-0.42) 0.29 (0.05-0.54) 
United States34 more than enhanced UC• UC: 230 r2 = .01 r2 =.02 
half the days, 0 
plus PHQ-9 SF-12 mental:1 � 
� 10 and/or 0.21 (-0.04-0.46) � dysthymia r2 = .011 V, 
Evans, Non- Mixed/ CES-D � 16 CBT vs. SS1 Total : 78 CBT: 54 CBT: 63% 8 weeks CES-D: SCL-90-R GSI: rt) 
1995, industry Stage I I  vs .  UC CBT: 29 UC: 54 UC: 67% 0.54 (-0.02-1.10) r2 0.59 (0.03-1.15) rt) 
United States35 SS: 231 =.07 r2 = .08 ::i" 
UC: 26 ::i" 
Non- Mixed/ MDD or Col laborative Total: 215 Tx: 72 Tx: 37% 12 months SCL-20 depression: NA Fann, !:t. 
2009, industry NR  dysthymia care vs. UC Tx: 112 UC: 72 UC: 42% 0.47 (0.20-0.74) 
United States36 diagnosis UC: 103 r2 = .OS 
Fisch, Non-industry Mixed/ TQSS � 2 Fluoxetine vs. Total : 163 Tx: 61 Tx: 55% 12 weeksh BZSDS:h NA ;::.· 
2003, with drug Advanced, placebo Tx: 83 Placebo: Placebo: 0.23 (-0.21-0.66) r2 :::, 
United States37 supplied by incurable Placebo: 80 59 45% = .01 llJ ::J 
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Razavi, Industry Mixed/ Mixed MDD or Fluoxetine vs. Total :  91 Tx: 53 Tx: 18% 5 weeks HADS: SCL-90-R GSI: 
1996, adjustment placebo Tx: 45 P lacebo: Placebo: 0.36 (-0.12-0.84) r2 0.22 (-0.26-0.69) r2 = .01 
Belg ium and  d isorder Placebo: 46 53 23% = .03 MADRS: 
France42 d iagnosis, plus 0.17 (-0.31-0.65) r2 = .01 
HADS ;,: 13 HAS: 
0.21 (-0.26-0.69) r2 = .01 
Strong, Non- M ixed/ M ixed HADS ;,: 15; Nurse Total :  200 Tx: 57 Tx:31% Mean of SCL-20 degression: SCL-10 anxiet�: 
2008, industry MDD d iagnosis; i ntervention Tx: 101 UC: 57 UC: 28% 7 sessions 0.37 (0.09-0.65) 0.24 (-0.04-0.52) r2 = .01 
U nited SCL-20 vs. UC UC: 99 over 3 r2 = .03 
Kingdom43 d epression ;,: months 
1.75 
Van Industry Breast/ Depression M ia nserin vs. Total: 55 Tx: 51  Tx: 0% 6 weeks fl HAMD-21: NA 
Heeringen, Stages d iagnosis and  placebo Tx: 28 P lacebo: Placebo: 0.77 (0.23-1.32) 
1996, 1-11, non- HAMD-21 ;,: 16 Placebo: 27 53 0% r2 = .13 
Belg ium46 metastatic 
Wilkinson, Non- Mixed/ Mixed Depression Aromatherapy Total :  288 Tx: 52 Tx: 14% 4 weeks0 N R1 fl SAl:0 
2007, industry or a nxiety massage Tx: 144 UC: 53 UC: 13% 0.22 (-0.01-0.46) r2 = .01 
United d iagnosis vs. UC UC: 144 fl CES-D:0 
Kingdom« 0.17 (-0.06-0.41) r2 = .01 
Abbreviations: BSI-GSI = Global Severity Index of the Brief Symptom Inventory; BZSDS = Brief Zung Self-Rating Depression Scale; CBT = cognitive behavior therapy; CGI-S = Clinical Global 
Impression Scale for Severity of Illness; CES-D = Center for Epidemiologic Studies Depression Scale; Cl = confidence interval; FACT-G emotional = emotional well-being subscale of Functional 
Assessment of Cancer Therapy - General; HADS = Hospital Anxiety and Depression Scale total score; HADS-A = Anxiety subscale of Hospital Anxiety and Depression scale; HADS-D = Depression 
subscale of Hospital Anxiety and Depression Scale; HAMD-17 = 17-item Hamilton Depression Rating Scale; HAMD-21 = 21-item Hamilton Depression Rating Scale; HAS = Hamilton Anxiety 
Scale; HSCL-20 = 20-item Hopkins Symptom Checklist depression scale; MAC anxious preoccupation = anxious preoccupation subscale of Mental Adjustment to Cancer scale; MAC fighting 
spirit = fighting spirit subscale of Mental Adjustment to Cancer scale; MAC helplessness = helplessness subscale of Mental Adjustment to Cancer scale; MADRS = Montgomery-Asberg 
Depression Rating Scale; MDD = major depressive disorder; NA = not applicable; NR = not reported; PAIS psychological = psychological distress subscale of Psychosocial Adjustment to 
I llness Scale; PHQ-9 = 9-item Patient Health Questionnaire; POMS = Profile of Mood States; PST = problem-solving therapy; PST-SO = problem-solving therapy with significant other; RSCL 
psychological = psychological symptoms subscale of Rotterdam Symptom Checklist; SAi = State Anxiety Inventory; SCL-10 anxiety = anxiety subscale derived from the Symptom Checklist-90; 
SCL-20 depression = depression subscale derived from the Symptom Checkl ist-90; SCL-90-R GSI = Global Severity Index of revised Symptom Checklist-90; SF-12 mental = mental component 
summary of 12-item Short Form Health Survey; SF-36 MHI depression: depression severity subscale of the 36-item Short Form Health Survey Mental Health Inventory; SS = social support; 
TQSS = Two-Question Screening Survey; Tx = treatment; UC = usual care; WL = waiting list control; ZSRDS = Zung Self-Rating Depression Scale. 
• Continuous outcomes that favored the treatment group are reported as positive numbers. b Assessed using PHQ-9 and 3 additional questions from PRIME-MD. ' Treatment components 
received varied between study participants. Effects of collaborative intervention were assessed after 8 months. d The PHQ-9 was used to determine eligibil ity for the trial and was thus 
classified as the primary outcome, but continuous outcome data were not reported for the PHQ-9. • Enhanced usual care consisted of standard oncology care, educational pamphlets, 
and a listing of center and community resources. ' Results adjusted for sex, race, years in the US, dysthymia, baseline depression severity, baseline anxiety, cancer stage, cancer type, and 
treatment status. 1 Results from social support group were not included in this review, as fewer than 25 patients were randomized to this group. h The fourth assessment visit (mean 12.3 
weeks post-randomization) was closest to the end of the treatment period. However, only 33/163 patients completed the fourth visit. Outcome data presented here were assessed at the 
fifth visit (mean 14.9 weeks post-randomization). 1 Planned treatment duration was 8 weeks, but 28 patients (39%) received additional therapy sessions between 8 weeks and 4 months. 1 No 
primary outcome could be identified. k Eligible participants met study criteria for depression, cancer-related pain, or both. Results are reported only for the 309 participants meeting eligibility 
criteria for depression. 1 Age and sex were reported for the whole sample (N = 405), and not only the 309 participants enrolled for depression. m Treatment duration was not explicitly stated 
in the article, but 16 weeks was the last assessment timepoint. " HADS-A and HADS-D were identified in the article as primary outcomes, but insufficient information was provided to extract 
continuous outcome data. The authors reported that anxiety was significantly reduced in the treatment group at 16 weeks, but not depressive symptoms. 0 Anxiety and depression outcomes 



















Four studies were pharmacological interventions designed to treat depression, 2 with 
mianserin 33•46 and 2 with fluoxetine 37A2• The other 10 studies included collaborative care 
interventions 34•36•39.43,45, cognitive behavior therapy 35•38.4°, problem solving therapy 41, 
and aromatherapy massage 44• Among the drug trials, there was 1 study 37 with at least 
64 patients per group, and that study found a small effect size reduction on self-reported 
depressive symptoms with fluoxetine (Hedges' g = 0.23): Three other smaller trials 33A2A5 
reported somewhat larger effects for fluoxetine (Hedges' g = 0.36) 42 and mianserin {Hedges' 
g = 0.60 to 0.77) 33A5_ Among collaborative care trials, effect sizes were small to moderate 
for adequately powered trials (Hedges' g = 0.17 to 0.47) 34,35,39.43 and moderate too large 
for a smaller study (Hedges' g = 0.60) 45• The effect sizes for outcomes reported in a trial 
of problem-solving therapy 41, comparing problem-solving therapy to a wait-list control 
(Hedges' g = 3. 76 ) or problem-solving therapy with a significant other to the wait-list control 
(Hedges' g = 4.30) were exceedingly large. The effect sizes on 2 outcome measures from 
aromatherapy with massage 44 were small (Hedges' g = 0.17 to 0.22) and not statistically 
significant. Effect sizes for each individual study are shown in Table 1. 
Risk of bias ratings are shown in Table 2, and specific explanations for all ratings are available 
from the authors. Among the 4 trials of antidepressants, all had unclear or high risk of bias 
for the majority of rating categories 33,37A2A6• Specifically, all had unclear or high risk related 
to industry funding and author-industry financial ties, and all were conducted prior to the 
availability of clinical trial registries. Thus, selective outcome reporting was rated as unclear 
for all of these trials. Among non-pharmacological treatments, all were rated as high risk 
for blinding of patients and personnel and for blinding of outcome assessment due to the 
nature of the interventions and outcome assessments. Generally, quality was mixed in these 
studies. Not including blinding, only 1 non-pharmacological intervention trial 43 was rated 
as low risk of bias across all categories, including being registered with sufficiently precise 
outcome registration to compare to those described in the published trial report. One trial 
of problem-solving therapy 41 was rated as high risk of bias for Other Sources of Bias. This 
was due to the unrealistically high effect sizes, approximately 10 times those of other non­
pharmacological studies, which were reported for the primary outcome variable. Other 
meta-analyses have excluded this study as an extreme outlier 4s-so. 
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Table 2: Assessment of risk of bias in randomized controlled trials in Key Question #1 (treatment) and Key Question #2 (screening) 
Cochrane Risk of Bias Tool Domains• 
Trial, Random Allocation Blinding Blinding of Outcome Incomplete Outcome Selective Pharmaceuti- Author-Industry Other 
Year, Sequence Concealment of Partici- Assessmentb Datab Outcome cal Industry Financial Ties Sources of 
Country Generation pants and Reporting Funding< and/or Industry Bias 
Personnel Employment< 
Key Question #1 (Treatment) 
Costa, 198533 Unclear risk Unclear risk Low risk Observer-rated: Low Observer-rated: High Unclear risk Unclear risk Unclear risk Low risk 
Self-report: Low Self-report: High 
Dwight-Johnson, 200545 Low risk Low risk High risk Observer-rated: NA Observer-rated: NA Unclear risk Low risk Unclear risk Low risk 
Self-report: High Self-report: High 
Ell, 200834 Low risk Low risk High risk Observer-rated: NA Observer-rated: NA Unclear risk Low risk Low risk Low risk 
Self-report: High Self-report: High 
Evans,199535 Unclear risk Unclear risk High risk Observer-rated: NA Observer-rated: NA Unclear risk Low risk Low risk Low risk 
Self-report: High Self-report: Low 
Fann, 200936 Unclear risk Low risk High risk Observer-rated: NA Observer-rated: NA Unclear risk Low risk Low risk Low risk 
Self-report: High Self-report: Low 
Fisch, 200337 Low risk Low risk Low risk Observer-rated: NA Observer-rated: NA Unclear risk Unclear risk Unclear risk Unclear risk• 
Self-report: Low Self-report: High 
Greer, 199238 Low risk Low risk High risk Observer-rated: NA Observer-rated: NA Unclear risk Low risk Low risk Low risk 
Self-report: High Self-report: Low 
Kroenke, 201039 Low risk Unclear risk High risk Observer-rated: NA Observer-rated: NA Unclear risk Low risk Unclear risk Low risk 
Self-report: High Self-report: Low 
Moorey, 200940 Unclear risk Unclear risk High risk Observer-rated: NA Observer-rated: NA Unclear risk Low risk Low risk Low risk 
Self-report: Unclear Self-report: High 
Nezu, 200341 Low risk High risk High risk Observer-rated: Unclear Observer-rated: Low Unclear risk Low risk Low risk High risk 0 
Self-report: High Self-report: Low �-
Razavi, 199642 Unclear risk Unclear risk Low risk Observer-rated: Unclear Observer-rated: High Unclear risk Unclear risk High risk Low risk � Self-report: Low Self-report: High "' 
Strong, 200843 Low risk Low risk High risk Observer-rated: NA Observer-rated: NA Low risk Low risk Low risk Low risk 
Self-report: High Self-report: Low 
Van Heeringen, 199646 Unclear risk Unclear risk Low risk Observer-rated: Unclear Observer-rated: High Unclear risk High risk Unclear risk Low risk 3· 
Self-report: NA Self-report: NA 
O"Q 
3· 
Wilkinson, 200?4° Low risk Low risk High risk Observer-rated: NA Observer-rated: NA Unclear risk Low risk Low risk Low risk "C 
Self-report: High Self-report: Low !:t. 
Key Question #2 (Screening) 
Maunsell, 199651 Low risk Low risk High risk Observer-rated: NA Observer-rated: NA Low risk Low risk Low risk Low risk 
"' 
� 
Self-report: High Self-report: Low ;:;: 
• Authors of study did not provide data on number of patients who were approached or eligible for the trial, but they did not that the patients enrolled represented a small fraction of eligible 
patients. b Effect sizes reported are much higher than seen in any other psychotherapy trials of this size and larger than normally considered plausible. This trial has been excluded as an ::i m n 
-..J extreme outlier in other reviews ..... 6• � 
Chapter 3 
Review q uestion #2: effect of screening for psychological distress 
For Review Question #2, 4,142 of the original 4,167 citations were excluded after title and 
abstract review and 24 after full text review, leaving 1 RCT 51 of screening for psychological 
distress among newly diagnosed breast cancer patients (Figure 2). 
Figure 2: PRISMA flow diagram of study selection process for review question #2 
4,167 Un ique titles/abstracts 
identified and screened 
for potential eligib i l ity 
4,142 Titles/abstracts excluded: 
� . No original  data or case report (266) � . No cancer (668) . Not an RCT of distress screening (3,208) 
,, 
25 Articles selected for 
fu l l-text review 
24 Articles excl uded: 
� � . No cancer (2 )  . Not an RCT of distress screening (22) 
,, 
1 Study included in 
systematic review of 
Key Question #2 
In this study, the usual care group (N=127) received a brief psychosocial intervention in the 
first 2 weeks post-randomization as part of standard care (mean 2.2 social work contacts). 
The intervention group (N=123) received the same brief intervention (mean 2.4 social 
work visits) plus telephone screening with the General Health Questionnaire, beginning 
21 days post-randomization and continuing monthly for 12 months. Once screening was 
initiated, 80% of screened patients had at least 1 positive screen, which triggered a social 
work telephone contact beyond referrals that occurred as part of usual care (mean = 6.1 
68 
Distress screening in patients with cancer 
social work contacts versus 2.4 for usual care). As shown in Table 3, at 12 months post­
randomization, Psychiatric Symptom Index scores for the intervention and usual care groups 
were equivalent. In addition, women in the intervention group were somewhat more likely 
to have a diagnosis of MDD at 12 months post-randomization (n = 22, 18%) compared to 
women in the control group (n = 15, 12%), although this was not statistically significant. Risk 
of bias in this screening RCT was generally low (Table 2). 
A number of other studies (see Table 4) described by their authors or in other reviews 10-12 as 
related to screening were excluded from the present systematic review. Several studies were 
excluded because decisions about whether patients should receive further assessment, 
referral, or treatment were not based on a pre-specified cut-off score on a measure of 
distress. In those studies, a range of screening tools was often made available for c linical 
consultations, but a positive screen on a distress screening tool was not used to determine 
referral for psychosocial evaluation or treatment. Studies were also excluded because they 
(1) were not RCTs; (2) included multiple screening tools for many practical or logistical issues, 
not allowing the effect of screening for psychological distress to be evaluated separately; or 
(3) did not report distress symptom or diagnosis outcomes. 
Discussion 
Several clinical recommendations 4-6 have been made for screening for psychological distress 
to be part of standard cancer care. Guidelines and recommendations, however, vary in the 
degree to which they are evidence-based 52 and none of these recommendation statements 
have been based on a systematic review that found benefits from screening, defined 
according to standard definitions. 
There are well-established procedures for evaluating screening programs 8•16•17• The 
principal criterion is whether there is evidence from well-conducted RCTs that benefits 
from screening outweigh possible harms (e.g., economic costs, drug side effects). The main 
findings of this systematic review are that (1) treatment of distress with pharmacological 
or behavioral interventions can improve psychological distress in cancer patients with 
psychological distress; and that (2) only 1 RCT of distress screening, with screening defined 
based on standard definitions of medical screening 8•14•15, has been conducted with adult 
cancer patients. In that study 51 of telephone screening for psychological distress among 
newly diagnosed breast cancer patients, monthly telephone screening did not improve 
psychological distress. The authors of that study concluded that a brief psychosocial 
intervention, which was provided as part of standard care, may have reduced distress and 
reduced the potential impact of screening. Additionally, the fact that 80% of patients in that 
study had at least 1 positive screen in a 12-month period suggests that screening may not 
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Table 4: Excluded studies for effect of screening on depression outcomes (review question #2) 
First Author, Cancer site N consented Comparison Distress outcomes Reason(s) for exclusion 
Year, / random-
Country ized• 
Berry, Mixed 660 Intervention: Patients completed a quality of life questionnaire, Only number of PHQ-9 A positive distress screen based on 
2011, ESRA-C. A summary of the results, with symptoms above a symptoms and EORTC a defined cut-off score was not used 
USA72 predetermined threshold flagged, was provided to the clinician prior QLQ-C30 emotional to determine who received further 
to visit. function symptoms assessment or treatment. Distress 
discussed with clinician, symptoms were not an  outcome, only 
Control: Patients completed a quality of life questionnaire, the but not distress outcomes the discussion of symptoms. 
ESRA-C. No summary of the results was provided to the clinician. were assessed. 
Boyes, Mixed 80 Intervention: Results from a computer survey completed prior to No significant difference Screening of multiple problems and 
2006, each visit were provided to the patient's oncologist. The survey after 4 visits between perceived care needs did not allow 
Australia53 included and assessment of 12 physical symptoms associated with groups for change in assessment of the effect of distress 
chemotherapy, symptoms of anxiety and depression {HADS), and HADS-D scores and screening. In addition, a positive distress 
perceived supportive care needs (31 items), along with computer- proportion of patients with screen based on a defined cut-off score 
generated suggested strategies to manage each identified issue. HADS-D � 11. was not used to determine who received 
further assessment or treatment. 
Control: Results from computer survey not made available to 
oncologist. 
Bramsen, Mixed 129 Intervention: Patients were offered the possibility of psychosocial No significant difference Not a randomized controlled trial 
2008, support by head nurse and information leaflet. Those who accepted between groups on EORTC (sequential cohort design). A positive 
The were screened using a semi-structured interview with a checklist. QLQ-C30 emotional distress screen based on a defined 
Netherlands73 Results were discussed in an interview, and patients were asked if they functioning subscale, IES cut-off score was not used to determine 
wanted a follow-up contact .. total score or GHQ-12 total who received further assessment or 
score. treatment, which was based on whether 
Control: Usual care with no screening. patients requested it following an 
interview. 0 
Carlson, Lung and 1,134 Full screening intervention: Results from DT, problem checklist, No difference between full Screening of multiple problems did not � 
2010, breast fatigue and pain thermometers, and PSSCAN, depression and anxiety screening intervention, al low assessment of the effect of distress 
Canada26 sections, along with personalized feedback report placed on patient's triage intervention, or screening. u, 
electronical medical record at initial visit. usual care groups on n, 
PSSCAN depression n, 
Triage intervention: Full screening, as described above, along with an scores 3 months post- ::i" 
offer to speak to a member of the study psychosocial team about any randomization. 
OQ 
::i" 
of the assessed issues. 
d. 
Control: DT completed, but results were not disclosed to patient or n, 
placed on electronic medical record. � 
Detmar, Mixed 273b Intervention: Patients completed a quality of life questionnaire, the No difference between A positive distress screen based on ;:;: 
2002, EORTC QLQ-30, at 3 successive outpatient visits with results made groups in SF-36 Mental a defined cut-off score was not used :::,-n 
Netherlands58 available to patient and physician prior to consultation. Health subscale after 4th to determine who received further 
-..J visit. assessment or treatment. n 
I-' Control: Usual care. � 
--.J  
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Intervention: Patients completed 11-point DIT (score range 0-10), and Only number of positive 
those with a distress score .!: 4 and an impact score .!: 3 were referred screens and number 
by their oncologist for a psycho-oncology service consultation. diagnosed and treated, 
but not depression 
Control: Usual care with referral to psycho-oncology services by outcomes, were assessed. 
physician of patients considered moderately or severely distressed. 
Intervention: At a single clinic visit, patients completed the 
EORTC QLQ-C30, which was provided to clinic staff prior to clinic 
appointment with no specific instructions for use. 
Control: Patients completed the EORTC QLQ-C30 
Intervention: Patients completed the DT, and nursing staff was 
encouraged to assess problems and discuss psychosocial referral for 
patients with DT score .!: S. 
Control: Usual care with no screening. 
Assessment and Feedback Intervention: For a 6 month study period, 
prior to clinic visits, patients completed the EORTC QLQ-C30 and 
HADS with results provided to physicians prior to visit. 
Attention Control: For a 6 month study period, prior to clinic visits, 
patients completed the EORTC QLQ-C30 and HADS with no results 
provided to physicians. 
Usual Care Control: Patients did not complete EORTC QLQ-C30 or 
HADS. 
Only number of quality 
of life issues addressed 
in appointment and 
patients satisfaction, but 
no depression outcomes, 
were assessed. 
Contrary to hypothesis, 
patients in the screened 
group reported 
significantly higher level 
of unmet needs 6 months 
after initial clinic contact. 
Scores on FACT-Emotional 
Subscale were better in 
the intervention group 
than the usual care group, 
but not different from the 
attention control group. 
Reason(s) for exclusion 
Not a randomized controlled trial 
(sequential cohort design). In addition, 
outcomes included number of positive 
screens and number treated, but no 
distress outcomes were assessed. 
Not a randomized controlled trial 
(sequential cohort design). In addition, 
a positive distress screen based on 
a defined cut-off score was not used 
to determine who received further 
assessment or treatment and no distress 
outcomes were assessed. 
Not a randomized controlled trial 
(sequential cohort design). Outcome 
of unmet psychosocial needs, but not 
distress. 
A positive distress screen based on 
a defined cut-off score was not used 
to determine who received further 
assessment or treatment. In addition, 
screening of multiple problems did 
not allow assessment of the effect of 
distress screening. 
Abbreviations: BDI-SF = Beck Depression Inventory - Short Form; CNQ = Cancer Needs Questionnaire; DIT = Distress and Impact Thermometer; DT = Distress Thermometer; EORTC QLQ-C30 
= European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30; ESRA-C = Electronic Self-report Assessment - Cancer; FACT - emotional = Functional 
Assessment of Cancer Therapy - emotional; FACT-G = Functional Assessment of Cancer Therapy - General; FLIC = Functional Living Index - Cancer; GHQ = General Health Questionnaire; HADS 
= Hospital Anxiety and Depression Scale; HADS-D = Depression subscale of Hospital Anxiety and Depression scale; IES = Impact of Event Scale; MDD = Major depressive disorder; PHQ = 
Patient Health Questionnaire; PL = Problem List; POMS = Profile of Mood States; PSI = Psychiatric Symptom Index; PSSCAN = Psychological Screen for Cancer; SDS = Symptom Distress Scale; 
SF-36 = Short Form - 36 Health Survey Questionnaire. 
"Number consented for non-randomized controlled trials and number randomized for randomized controlled trials. bphysicians, rather than patients, were randomized. This number is 
the number of eligible patients who agreed to participate. <The authors reported a post-hoc subgroup analysis that found significantly improved BDI-SF scores for the 44 patients in the 
intervention group with baseline BDI-SF scores .!: 8 compared to the 19 control patients with BDI SF .!: 8. However, patients were not randomized based on BDI-SF scores, and the relevance of 


















Several reviews on screening for distress in cancer patients have been published previously 10-
12, and they similarly concluded that there was no evidence that distress screening improved 
distress outcomes among cancer patients. Two of these reviews included 7 studies 10•12, and 
one included 14 studies 11• The authors of those studies were consistent in arguing that 
evidence for benefits of screening for distress on patient outcomes in cancer patients is 
inconclusive and scarce, and in calling for high-quality trials to determine if distress screening 
would improve patient outcomes. 
Two of the reviews 10•11 concluded that there is evidence that the use of distress 
questionnaires may improve communication about psychosocial issues between patients 
and oncology staff. It is important to keep in mind, however, that using questionnaires to 
facilitate conversations with patients, while potentially helpful, is not screening and does 
not inform the question of whether screening with these tools to determine who receives 
subsequent assessment will benefit patients. Consistent with this, a major shortcoming of 
previous reviews on distress screening 10-12 is that they all included studies that would not 
be considered trials of screening interventions in the context of any standard definition of 
medical screening 8•14•15• Indeed, with the exception of 1 study 50, all of the studies included 
in these reviews were excluded from the current review for a number of reasons (see Table 
4 for excluded distress screening studies). Five studies 25,53-55 screened for multiple problems 
at the same time (i.e., fatigue, pain, perceived support, and psychological distress), which 
made it impossible to assess the specific effects of screening for distress. Six studies 54-59 did 
not use a defined cut-off score to indicate a positive screen for heightened distress or to 
determine which patients would receive further assessment or treatment. In addition, 6 of 
the studies 57,59-53 were not RCTs, but were, for example, sequential cohort designs. Finally, 3 
of the studies 61-63 did not assess distress as an outcome, but investigated other outcomes, 
such as referral rates. 
One large study 26 was excluded from the current review because it screened simultaneously 
for multiple problems with substantially different possible care responses (e.g., psychological 
distress, pain, fatigue, weight change, transportation, parking, drug coverage, finances). In 
that study, 585 patients with breast cancer and 549 patients with lung cancer were randomized 
to 1 of 3 conditions, including (1) a control condition in which screening measures were 
administered without feedback to patients or clinicians; (2) screening, which generated a 
report that was included in the patient's medical file; and (3) screening, followed by phone 
triage with referral to resources. It was not possible, however, to determine in this study 
how many patients screened positive for psychological distress versus other practical or 
logistical issues, such as difficulties with transportation, parking, drug coverage, or finances, 
none of which would be best managed through psychological intervention. 
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Furthermore, interpretation of psychological distress outcomes was difficult, not only due 
to the multiple problems being screened and multiple corresponding response options, 
but also due to the results themselves. In the full study sample, there were no significant 
differences between groups on depression or anxiety symptom scores 3 months post­
randomization. Distress thermometer scores were significantly lower among patients with 
phone triage compared to the control condition, but the magnitude was very small (Hedges' 
g = 0.19). There were no significant differences in distress thermometer scores between the 
2 screening conditions or between screening, which generated a report for the medical file, 
and the control condition. Group differences may have been attenuated by the fact that all 
patients, regardless of group assignment, met with a research assistant who, in addition to 
obtaining consent, provided them with literature and phone numbers of the psychosocial 
resources department, and informed them that they could contact the department and 
speak to someone about their concerns. This suggests that simply providing patients with 
information and the opportunity for even a minimal discussion and encouragement to seek 
services, regardless of results of distress screening, might provide many of the benefits 
sought by implementing screening. Alternatively, given the study design, it is possible that 
identifying and addressing practical or logistical issues that are not best addressed through 
psychological interventions, may have been the most important factor. If this were the case, 
it would support the need for more thorough assessment of these kinds of issues, but would 
not support the idea that screening for psychological distress benefits patients. 
Indeed, distress screening can benefit patients only to the extent that it identifies patients 
with significant psychological distress who are not already recognized as distressed or 
receiving supportive services, successfully engages those patients in treatment, and 
achieves positive treatment results. In cancer care settings, it is not uncommon that high 
numbers of patients are already treated with antidepressants as an attempt to address 
concerns about distress, even though many of these patients do not have current or past 
histories of depression 64• Furthermore, as illustrated by one study from Austria 65, the desire 
for psychosocial support to cope with cancer may not be correlated with distress levels, and 
nearly as many patients with low levels of distress may desire supportive care as patients 
above the cut-off criterion on a screening tool. Thus, better patient psychosocial care may 
be best achieved by providing more information and coordinating care pathways, rather 
than seeking to automate triage processes through mechanized screening and numerical 
algorithms. 
Beyond screening for distress in cancer care settings, a number of other systematic reviews 
have concluded that there are no RCTs that have shown that depression screening improves 
depressive symptoms in cancer 13, cardiovascular disease 66, or perinatal care 67• A 2008 
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meta-analysis of depression screening in primary care 68 reviewed 11 trials and found several 
trials where screening increased identification or treatment of depression, but none where 
screening improved depression outcomes. The U.S. Preventive Services Task Force has 
recommended depression screening in primary care 69, but specifies that screening should 
only occur when integrated depression care systems for evaluation and case management 
are available. No trials, however, have shown that patients screened and referred for such 
collaborative care would have better outcomes than patients who are not screened, but 
who could potentially access collaborative care via other pathways 9• This was an important 
reason why the UK National Institute of Clinical Excellence 70 did not recommend routine 
depression screening in primary care. 
Given the current lack of evidence for benefits of distress screening, potential costs from 
implementing such a program must be carefully considered. An important concern is that 
routine screening would either take time or consume resources that could be devoted 
to other patient needs. Some might assume that screening questionnaires are easily and 
inexpensively implemented. However, this confuses the cost of administering a questionnaire 
and the cost of screening. The cost of screening includes assessments, consultations, 
treatment and follow-up services, which is much larger than the cost of administering a 
questionnaire 7•8• 
Another concern is that attention and potentially limited mental health resources could be 
devoted only to those who screen positive for distress even though many other patients 
might like to discuss their psychosocial needs or might have self-referred or been referred 
by their clinicians. It is important that the psychological needs of cancer patients are 
recognized and addressed, and there are many alternatives to screening to meet this need. 
As long as there is no evidence that screening leads to improvements in distress, focusing 
on the availability and implementation of psychosocial support might better benefit cancer 
patients. 
In conclusion, the present systematic review found that there is currently no evidence from 
any RCTs that distress screening effectively reduces distress among cancer patients. Only 
1 RCT could be identified that investigated the effects of distress screening 51, and that 
study did not find that screening improved distress outcomes. In that study, patients were 
able to access psychosocial services via screening (in the intervention group) or via other 
mechanisms, such as patient self-referral or referral by providers to supportive programs 
offered as part of standard care. 
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Without high-quality evidence from well-designed RCTs that demonstrate sufficient benefit 
to justify costs and potential harms from screening, recommendations for implementation 
of screening programs are premature. Research is needed that compares the benefits and 
harms of screening for psychological distress in additional trials in which patients in the 
screening group may access psychosocial resources via screening or other referral processes 
and patients in the non-screened group can access the same services via self- or other 
referral processes. It is possible that screening programs could include assessment of the 
various complex needs of patients with cancer. Trials to test such interventions should, 
however, clearly differentiate psychosocial needs that are best managed in the context 
of mental health services versus practical or logistical issues that are best addressed via 
other mechanisms. They should also differentiate problems, such as fatigue and pain, which 
may or may not be related to psychological issues and for which first-line interventions are 
usually not psychological, from psychological distress. Furthermore, if multiple psychosocial 
issues are assessed as part of a screening program, clear paradigms for identifying positive 
screens are needed, and a clearly identified primary outcome should be provided for each 
trial to determine whether patients have benefitted from screening. Other issues that 
should be given consideration in future research include the possibility of targeting high-risk 
subgroups whose distress may not be otherwise identified 71 and investigating at what point 
during the course of the disease screening should occur, including the risk of increased false 
positive screens and burden to already strapped existing resources if screening is done at 
multiple time points. 
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Chapter 4 
Abstract 
Objectives: To investigate the proportion of original studies included in systematic reviews 
and meta-analyses on the diagnostic accuracy of screening tools for depression that 
appropriately exclude patients who already have a diagnosis of or are receiving treatment 
for depression and to determine whether these systematic reviews and meta-analyses 
evaluate possible bias from the inclusion of such patients. 
Design: Systematic review. 
Data sources: Medline, PsyclNFO, CINAHL, Embase, ISi, SCOPUS, and Cochrane databases 
were searched from 1 January 2005 to 29 October 2009. 
Eligibility criteria for selecting studies: Systematic reviews and meta-analyses in any 
language that reported on the diagnostic accuracy of screening tools for depression. 
Results: Only eight of 197 (4%) unique publications from 17 systematic reviews and meta­
analyses specifically excluded patients who already had a diagnosis of or were receiving 
treatment for depression. No systematic reviews or meta-analyses commented on possible 
bias from the inclusion of such patients, even though 10 reviews used quality assessment 
tools with items to rate risk of bias from composition of the sample of patients. 
Conclusions: Studies of the accuracy of screening tools for depression rarely exclude patients 
who already have a diagnosis of or are receiving treatment for depression, a potential bias 
that is not evaluated in systematic reviews and meta-analyses. This could result in inflated 
estimates of accuracy on which clinical practice and preventive care guidelines are often 
based, a problem that takes on greater importance as the rate of diagnosed and treated 
depression in the population increases. 
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Introduction 
Depression is a common and disabling condition 1, and improving care has been prioritized. 
Routine screening for depression is one solution that has been proposed. Depression 
screening involves the use of screening tools to identify patients who might have depression 
but who are not seeking treatment for symptoms and whose depression is not otherwise 
recognized by their physicians so that they can be further assessed and, if appropriate, treated 
2•3 • Screening for depression has been recommended in several medical settings, including 
cardiovascular care 4, perinatal care 5-7, oncological care 8, and primary care 9, although no 
clinical trial has found better depression outcomes for screened versus unscreened patients 
when the same treatment and care resources are potentially available to both groups 
10•
11
• Screening for depression can identify patients with depression who might otherwise 
go undetected, but it can also lead to misdiagnosis, the identification of patients as being 
depressed who are not, and overdiagnosis, which occurs when some patients with mild 
conditions are identified as depressed and exposed to the risk of labeling and treatment, 
even when the condition might not cause measurable morbidity or mortality. Recently, a 
report from the National Institute for Health and Clinical Excellence {NICE) 11 noted a lack 
of evidence for benefit from depression screening and, rather than routine screening, 
recommended case identification strategies to identify depression among high risk groups 
of patients or patients otherwise identified by physicians as possibly having depression. 
A great deal of research has been conducted to determine the diagnostic accuracy 
of depression screening tests in different clinical settings. Based on data from such 
studies, expert panels have considered the risks and benefits of screening and issued 
recommendations to screen for depression in various settings 9•11• Diagnostic or screening 
tests, however, are useful only to the extent that they distinguish between disordered and 
non-disordered states that are not otherwise obvious to clinicians 12 and if they are accurate 
across the spectrum of patients who will be assessed in clinical practice 12-18• 
The term "spectrum effect" has been used to describe variations in test performance that 
sometimes occur across subgroups of patients that differ in demographic or clinical features. 
Spectrum effects raise questions about the generalizability of study results to specific 
populations of patients that might differ in important ways from study samples 19• The term 
"spectrum bias" is related and also describes situations in which the accuracy of a test is 
heterogeneous across subgroups of patients. Spectrum bias is said to be present when a 
study samples preferentially from certain portions of the patient spectrum but provides a 
global estimate of accuracy that could misrepresent what would be experienced in actual 
practice 12-19• Estimates of diagnostic accuracy that are based on case-control designs and 
whose samples include only obvious cases and healthy controls, for instance, have been 
shown to substantially overestimate diagnostic accuracy 13•14•18• 
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Self-reported depression questionnaires are used for various purposes (such as screening 
for unidentified cases, tracking severity of symptoms, detecting relapse). For the purpose of 
screening, which involves the identification of cases not previously recognized, if individuals 
who already have a diagnosis of depression are not specifically excluded from studies 
assessing the diagnostic accuracy of depression screening tools, examined cohorts will have 
a greater prevalence and severity of depression than if only individuals without clinically 
recognized depression were screened. Not excluding patients who already have a diagnosis 
would, in turn, lead to determinations of screening accuracy and new case yield that are 
inflated compared with what would be achieved if the instrument were used to screen 
patients in clinical practice 12-18• 
Systematic reviews and meta-analyses are highly cited and are prioritized in grading evidence 
for practice guidelines 20• 21• If studies of the diagnostic accuracy of depression screening 
tools that include patients who already have a diagnosis or are receiving treatment are 
included in systematic reviews and meta-analyses without adjustment for potential bias, 
these reviews could provide misleading accuracy estimates, thereby misleading calculations 
of risk-benefit by expert panels and, thus, clinicians. 
We evaluated the proportion of studies included in systematic reviews and meta-analyses 
of the diagnostic accuracy of depression screening tools that excluded patients who already 
had a diagnosis of or were receiving treatment for depression. We also assessed whether 
authors of systematic reviews and meta-analyses noted the possibility of spectrum bias 
from the inclusion of such patients in the original research studies they reviewed. We 
hypothesized that few studies of depression screening tools would exclude such patients 
and that systematic reviews and meta-analyses would not consider spectrum bias from their 
inclusion. 
Methods 
Selection of systematic reviews and meta-analyses 
We searched Medline, PsyclNFO, CINAHL, Embase, ISi, SCOPUS, and Cochrane databases 
from 1 January 2005 to 29 October 2009 for systematic reviews and meta-analyses of the 
diagnostic accuracy of depression screening tools. We restricted the search to this period to 
obtain recent systematic reviews and meta-analyses that reflect relatively current practice. 
The search terms used were ((systematic review OR meta-analysis) AND (screening OR 
sensitivity OR specificity) AND depression). Eligible articles included systematic reviews 
and meta-analyses in any language published in final form or on the internet before final 
publication that reviewed the accuracy of screening tools for depression compared with 
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a diagnosis of depression. Depression screening tools included any self-report measure 
used to attempt to identify patients with depression. We included systematic reviews and 
meta-analyses that reviewed diagnostic accuracy and other psychometric characteristics 
of depression questionnaires (such as validity and reliability) but extracted data only on 
diagnostic accuracy. We excluded systematic reviews and meta-analyses that compared 
scores only on self-report screening tools with classifications of depression based on cut offs 
from other self-report screening tools but not a diagnosis of depression. Two investigators 
reviewed systematic reviews and meta-analyses for eligibility independently. If either 
reviewer deemed a systematic review or meta-analysis potentially eligible based on a 
review of the title and abstract, we carried out a full text review of the systematic review 
or meta-analysis. Any disagreement between reviewers after full text review was resolved 
by consensus after consultation with an independent third reviewer. Chance corrected 
agreement between reviewers was assessed with Cohen's K. 
Data extraction 
Two investigators independently extracted and entered on a standardized spreadsheet data 
items from the systematic reviews and meta-analyses, as well as from the original studies 
included in the reviews, with discrepancies resolved by consensus. For each systematic 
review or meta-analysis, they recorded whether or not original studies mentioned possible 
bias because of the inclusion of patients who already had a diagnosis of or were receiving 
treatment for depression. Investigators also determined whether or not each systematic 
review or meta-analysis included an assessment of the quality of included diagnostic 
accuracy studies. If so, they recorded the tool that was used to do this and whether or not 
the tool included an evaluation of the risk of spectrum bias. Investigators also recorded 
the impact factor of the journal in which each systematic review or meta-analysis was 
published, using the impact factor for the year of publication 22• In addition, they reviewed 
the introduction and discussion sections and recorded the described purpose for which 
accuracy of the screening tool was being assessed (such as screening or identification of 
new cases, monitoring progress of treatment, detection of relapse). 
Original diagnostic accuracy studies included in the systematic reviews and meta-analyses 
were classified as having excluded patients who already had a diagnosis of or were receiving 
treatment for depression if the authors of the study specifically indicated this in the exclusion 
criteria. If studies did not specifically indicate that such patients were excluded they were 
classified as having included them. 
For each systematic review or meta-analysis, and overall, we determined the number of 
unique publications on the diagnostic accuracy of depression screening tools, as well as 
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the number of unique cohorts of patients. We assessed the number of publications and 
the number of cohorts because, in some cases, there were multiple publications from the 
same cohort. This occurred, for instance, when different publications reported results from 
different screening tools or criterion standards with the same group of patients, when 
one or more publications reported on a subset of the sample from another publication, or 
when the same patients were assessed at different time points (such as during pregnancy 
and after delivery}. Identification of different publications from the same cohort was done 
by cross referencing authors and coauthors, characteristics of patients, and countries in 
which the research was conducted. Verification was done by comparing information in the 
publications. Cohort status was coded conservatively in that publications that seemed to be 
from the same cohort were coded as such, even if this could not be confirmed with 100% 
certainty. 
We did not publish or register a review protocol for this study. All methods were determined 
a priori with the exception of reviewing the introduction and discussion sections to record 
the described purpose for which the accuracy of depression screening tool was being 
assessed. This additional step was added to the study methods after data extraction and 
tabulation of results to clarify whether the intention of the included systematic reviews and 
meta-analyses was to assess diagnostic accuracy for identification of new cases versus other 
possible uses of depression symptom questionnaires. 
Results 
Search results 
The electronic database search yielded 1216 unique titles and abstracts for review. Of these, 
1160 were excluded after review of titles and abstracts because they did not report results 
from a systematic review or meta-analysis or because they reported data from a systematic 
review or meta-analysis that was not related to the diagnostic accuracy of a depression 
screening tool. Of the 56 articles that underwent full text review, we excluded 39, leaving 17 
eligible systematic reviews and meta-analyses (Figure 1}. Chance corrected agreement on 
inclusion and exclusion decisions between reviewers, as assessed with the Cohen's K, was 
0.95. 
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Figure 1: Selection of systematic reviews and meta-analyses of diagnostic accuracy of screening 
tools for depression 
1216 Unique titles and abstracts 
identified and screened for 
potential eligibility 
1160 Titles and abstracts excluded: 
• Not a systematic review or meta-analysis (377) 
• Not a systematic review or meta-analysis of 
diagnostic accuracy of depression screening 
,, tools (783) 
56 Articles selected for full-text 
review for eligibility 
39 Articles excluded: 
• Not a systematic review or meta-analysis (14) 
� • Not a systematic review or meta-analysis of 
(24) 
• Subset of another included systematic review 
or meta-analysis (1) 
,, 
17 Systematic reviews or meta-
analyses included in review 
Table 1 shows the characteristics of selected systematic reviews and meta-analyses. Of 
the 17 systematic reviews and meta-analyses included, 10 were systematic reviews 23•32, 
and seven were meta-analyses 33·39 _ The systematic reviews and meta-analyses included 
between two and 63 original studies and were published in a wide range of journals in terms 
of impact factor. Two meta-analyses assessed the nine item depression scale of the patient 
health questionnaire (PHQ-9) 33•39; one systematic review 23 and two meta-analyses 37•38 
evaluated the geriatric depression scale; seven systematic reviews 24•26•27•29·32 and one meta­
analysis 36 assessed depression screening tools, generally, in defined medical populations; 
two systematic reviews assessed specific screening tools, other than the patient health 
questionnaire or geriatric depression scale, in defined patient populations 25•28; and two 
meta-analyses assessed brief screening tools {for example, fewer than five items) in primary 
care 34 and palliative care 35• All 17 systematic reviews and meta-analyses described the 
purpose of the review as related to determining diagnostic accuracy for new case detection 
by screening, and none discussed how their results might apply to other uses of depression 
screening tools {such as monitoring progress of treatment, detection of relapse). 
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Table 1 (continued) 
Study Journal Screening tool, Review Publications Cohorts Cohorts that Method Quality Inclusion or 
impact patients/setting type reviewed reviewed excluded of quality assessment exclusion of 
factor* diagnosed or assessment included diagnosed or treated 
treated patients spectrum biast patients noted 
Allen, 200923 1.2 GOS in older SR 4 4 0 (0%) Ad hoc§ No No 
adults or veterans 
in outpatient 
settings 
Gibson, 200925 3.7 EPDS in perinatal SR 37 35 2 (5.7%) Based on York Yes No 




Hewitt, 200936 6.9 Depression MA 63 56 4 (7.1%) QUADAS Yes No 
screen ing tools i n  
perinatal care 
Kalpakjian, 1.4 Depression SR 4 4 0 (0%) No NA No 
200926 screening tools in  
spinal cord injury 
patients 
Mirkhil, 200927 3.0 Depression SR  4 4 0 (0%) Diagnostic Yes No 
screening tools in test studies ::0 
patients with pain evaluation tool .;;· 
episode 8, 
Williams, 200932 4.7 Depression SR 9 9 0 (0%) USPSTF Yes No er 
screening tools s· 
in children and � adolescents 
� 
Mitchell, 2010,J37 3.8 GOS in older MA 13 12 0 (0%) No NA No s· 
primary care (1Q a. 
patients (1) \J 
MN = American Academy of Neurology; EPDS = Edinburgh Postnatal Depression Scale; GOS = Geriatric Depression Scale; HADS = Hospital Anxiety and Depression Scale; � 
NA = not applicable; PHQ-9 = Patient Health Questionnaire-9; QUADAS = Quality Assessment for Diagnostic Accuracy Studies; USPSTF: US Preventive Services Task Force. a· 
* Impact factor from year systematic review or meta-analysis was published 
t Includes quality items related to "representativeness" of samples. nl 
:j: In methods author wrote "We excluded studies that i ncluded patients with a k nown current depressive illness (for whom a screen would not provide new 
information)." Of 23 studies included in systematic review, however, 22 did not exclude patients who were already recognized as depressed or treated for s· 
depression. Authors of review did not comment on incl usion or exclusion of such patients in results or discussion. .... 
§ Reported extraction of one or two items related to study quality (for example, blinding) 
0 
lO 0 
I-' ,i Article was e-publication ahead of print at the time of our search and was subsequently published in 2010. V, 
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Inclusion or exclusion of patients who already had a diagnosis or were receiving treatment 
The 17 systematic reviews and meta-analyses included a total of 197 unique publications on 
the diagnostic accuracy of screening tools for depression in 170 unique cohorts of patients. 
The diagnostic accuracy studies examined more than 25 different screening tools in a wide 
range of patients. Only eight of 197 unique publications (4%) and eight of 170 cohorts (5%) 
specifically excluded patients who already had a diagnosis of or were receiving treatment 
for depression. As shown in table 1, 11 23•26•27•30-3 3,35,37-39 of the 17 systematic reviews or meta­
analyses did not examine a single cohort of patients that specifically excluded those who 
already had a diagnosis of or were receiving treatment for depression. 
Table 2 shows that only four 40-43 of the eight studies that excluded such patients reported 
the number of patients who were excluded because of pre-existing mental health treatment. 
The proportion of patients excluded for this reason was 22% in a Veteran's Affairs primary 
care setting in the United States (published in 2004) 43; 10% in a 2003 study of patients in 
general practice from New Zealand 42; 2% in a 2004 study of postpartum women from Turkey 
40; and 0.2% in a 1996 study of postpartum women from Sweden 41• 
Treatment of spectrum bias in systematic reviews and meta-analyses 
As shown in table 1, 13 23-25,27,30-36•38•39 of the 17 systematic reviews and meta-analyses 
conducted some form of quality assessment of included studies, including two meta­
analyses 36•39 that used the quality assessment for diagnostic accuracy studies (QUADAS) 
tool 49; one systematic review 27 that used the diagnostic test studies evaluation tool 50; 
one meta-analysis 34 that used the Newcastle-Ottawa scale 51; two systematic reviews 30•32 
that used methods developed by the US Preventive Services Task Force (USPSTF) 52•53; one 
systematic review 31 that based quality review on guidelines from the American Academy 
of Neurology 54; one systematic review 25 that evaluated quality items based on a system 
from the York Centre for Reviews and Dissemination 55; one systematic review 24 that used 
a study specific tool based on criteria identified by the Cochrane Methods Working Group 
on Systematic Review of Screening and Diagnostic Tests 56; one meta-analysis 35 that based 
quality ratings on a published article by Pai et al. 57; and one systematic review 23 and two 
meta-analyses 33•38 that used ad hoc procedures, such as extracting data on one to two items 
related to study quality. 
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Table 2: Cohorts of diagnostic accuracy studies that excluded patients who already had diagnosis of 
or were receiving treatment for depression 
Study (review/s 
included in) 
Arroll, 2003 42 
( Mitchell 34) 
Arroll, 2005 44 
( Mitchell 34) 
Aydin, 2004 40 
(Gibson 25, Hewitt 36) 
Beck, 2005 45 
( Hewitt 36) 
Corson, 2004 43 
( Mitchell 34) 
Lloyd-Williams, 2000 46, 
2001 47 (Morse 28, 
Thekkumpurath 29) 
Vittayanont, 2006 48 
( Hewitt 36) 
Wickberg, 1996 41 
(Gaynes 24, Gibson 25, 
Hewitt 36) 
NR = not reported 
Country of Population 
original study 
New Zealand General 
practice 
patients 











UK  Cancer 








Year(s) data No (%) Exclusion criterion 
collected excluded 
NR  47/476 (10%} Taking psychotropic drugs 
NR  NR Receiving psychotropic 
drugs 
2001 6/347 (2%) Psychiatric treatment 
history 
NR NR Diagnosis of depression 
during current pregnancy 
2002-2003 762/3466 Mental health 
(22%} appointment in chart 
within past 6 months 
NR NR  Currently prescribed 
antidepressant 
medication 
2003-2004 NR Current diagnosis of  and 
receiving treatment for 
psychiatric disorder 
NR 4/1655 Already in contact with 
(0.2%) general practitioner or 
psychiatrist 
Of these, 10 systematic reviews or meta-analyses 24•25•27•30•32,34•36•39 used quality assessment 
methods that included an assessment of spectrum bias. The authors of one of these 
systematic reviews 24 noted study limitations from the lack of non-white patients, and the 
authors of another 32 reported that younger children were poorly represented in studies of 
children and adolescents. The authors of one meta-analysis reported that half of studies 
reviewed did not include representative samples but did not provide a rationale for this 
conclusion.36 The authors of another noted the possibility of a "disease progression 
bias" in one study of patients after stroke and indicated that none of the other 11 studies 
reviewed had limitations related to composition of patients 39• In one systematic review, 
one of four included studies was downgraded because of the description of the sample, 
but an explanation was not provided 27• The authors of the five other systematic reviews 
or meta-analyses that used quality assessment methods that included an assessment of 
spectrum bias did not comment specifically on quality ratings related to possible spectrum 
bias 21,26,21 ,30,31 . 
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Overall, none of the 17 systematic reviews or meta-analyses commented on possible 
spectrum bias from the inclusion in studies of patients who already had a diagnosis of or 
were receiving treatment for depression. 
Discussion 
We found that less than 5% of studies on the diagnostic accuracy of depression screening 
tools appropriately excluded patients who already had a diagnosis of or were receiving 
treatment for depression. The importance of this finding relates to the potential effect on 
assessments of the accuracy of depression screening instruments and the number of new 
cases they will uncover and, therefore, on their utility in clinical practice. The diagnostic 
accuracy of a screening test is often considered a fixed characteristic of a test, but it can vary 
substantially in populations with different clinical features 16• Studies that have examined 
accuracy of diagnostic tests consistently show that increased prevalence or severity of 
disease in the cohort of patients being examined inflates the reported sensitivity of the 
test being assessed 14• If the accuracy of screening tools for depression was studied in a 
group of patients, some of whom had already received a diagnosis for the condition, the 
assessments would be biased by the inclusion of individuals with a greater prevalence 
and severity of depression than if the instruments were used in clinical practice to screen 
patients without clinically recognized depression. This would, in turn, lead to inflated, and 
potentially misleading, estimates of accuracy on which clinical practice and preventive care 
guidelines are generally based. 
Potential magnitude of problem 
The potential magnitude of this problem grows as the prevalence of already diagnosed and 
treated depression in the population increases 55,59_ Estimates of the prevalence of depression 
in primary care range from 5% to 13%, including 6% to 9% among adults aged 55 or older 
60• Rates are somewhat higher in patients with chronic physical illness 1• Among adults aged 
35 and older in the US, rates of antidepressant use increased from 8% to 14% from 1996 
to 2005, with a third to a half of prescriptions specifically for psychiatric problems 58• Rates 
of prescriptions for antidepressants might be even higher among patients with chronic 
physical disease. Based on provincial data from Ontario, Canada, for instance, the rate of 
antidepressant prescriptions within six months of an acute myocardial infarction doubled 
from 8% in 1993 to 16% in 2002 among patients aged 65 and older 61• In a more recent 
cohort of more than 1200 outpatients with stable cardiovascular disease, just under 20% 
were treated with an antidepressant at the time of enrolment in the study 62,63• In addition 
to patients who receive treatment with antidepressants, a relatively small percentage of 
people receive psychotherapy for depression without drug treatment 64, and some people 
are recognized by their physicians as depressed but choose not to undergo treatment. 
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A recent meta-analysis found that general practitioners correctly identify about 50% 
of patients with depression without the assistance of a screening tool 65• Dichotomizing 
a doctor's identification or non-identification of depressive disorders, however, could 
underestimate the degree to which they recognize depression. A study of over 700 patients 
in primary care from the US and the Netherlands, for instance, found that complete 
disagreement between physicians' assessments and a diagnostic interview for depression 
was much less common than is often thought 66• In that study, only 27% of false negative 
cases based on physician assessments were true false negatives. In most cases of false 
negatives, physicians recognized symptoms of depression but underestimated severity 
compared with the diagnostic interview {40%} or gave another psychiatric diagnosis {33%). 
Thus, in many settings, a substantial proportion of depressed patients are recognized as 
depressed without screening, either because they seek treatment for their depression or 
because a healthcare professional otherwise recognizes their symptoms. Based on reported 
rates of prescriptions for antidepressants and estimates of physicians' ability to recognize 
depression, it could be that as many as half or more of patients who are detected as cases 
in studies assessing the diagnostic accuracy of screening tools would not even be screened 
in clinical practice. 
Data are not available that would allow a precise calculation of the degree by which studies 
that fail to exclude patients who already have a diagnosis of or are receiving treatment 
for depression might overestimate diagnostic accuracy and the number of new patients 
who would be identified through depression screening. Two reviews, however, have 
reported that studies of other types of diagnostic tests that have used case-control designs 
13 or case-control designs that compared severely affected patients and healthy controls 18 
substantially overestimate diagnostic accuracy (relative diagnostic odds ratios 3.0 13 and 4.9 
18
, respectively). 
Even a relatively small increase in reported diagnostic accuracy resulting from the inclusion 
of patients who already have a diagnosis or are receiving treatment would result in a 
substantial overestimate of the positive predictive value and new case yield from depression 
screening compared with what would be expected in clinical practice. A systematic review 
of the diagnostic accuracy of depression screening tools in primary care found a median 
sensitivity of 85% and median specificity of 74% 67• Based on this, in a primary care setting 
with a prevalence rate of 10% 60, 32% of all patients would screen positive for depression, of 
whom 27% would be true positive cases, equivalent to 9% of all patients screened. If existing 
studies overestimated the sensitivity by even 10% because of the inclusion of patients with 
a diagnosis or being treated (relative diagnostic odds ratio 1.9), and it is conservatively 
assumed that physicians recognize 50% of depressed patients without screening, the rate 
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of screening with positive results would decrease only slightly, from 32% to 27%. Only 14% 
of these, however, would be true positives, and, overall, less than 4% of patients screened 
would be newly identified cases of depression. 
We know of only one study, which was not included in any of the systematic reviews or 
meta-analyses that we reviewed, that assessed the yield of screening for depression with 
and without excluding patients with psychiatric disorders already treated with psychotropic 
drugs 68• In that study of 113 women with breast cancer, the true positive rate of screening 
for depression fell from 21% to 7% after exclusion of patients who were already receiving 
treatment for depression before screening. Our results should be considered in the context 
of studies that have assessed whether screening for depression benefits patients. There are 
at least 11 trials in primary care 10, as well as trials in perinatal care 69•70, and cancer care 71, that 
have tested whether screening and referral for depression treatment improves depression 
outcomes, and all have had negative results. Reflecting this, the US Preventive Services 
Task Force recommends screening for depression only when it is supported by integrated 
staff assisted depression management programs 9• To our knowledge, only one published 
research study has documented an attempt to screen and provide collaborative care, as 
recommended by the task force, in a clinical setting 72• In that study, from the Netherlands, 
1687 high risk patients were invited to enroll in a screening trial, 780 participated, and 71 
cases of major depression were detected. Of the 71 patients identified, 36 were already 
receiving treatment for depression and 18 additional patients refused treatment or did not 
attend their scheduled appointment. Thus, only 17 people of 1687 potentially screened 
started treatment for depression. 
Strengths and limitations of review 
One possible limitation of the current study is that we searched for systematic reviews 
and meta-analyses, rather than for original studies, and there are probably many original 
studies on the diagnostic accuracy of depression screening tools that were not included. Our 
purpose, however, was to assess whether original studies appropriately excluded patients 
who already had a diagnosis or were receiving treatment and to determine whether 
systematic reviews and meta-analyses reflected potential bias from the failure to do this, 
which required a review of reviews. It is unlikely that including additional studies that were 
not listed in recent systematic reviews or meta-analyses would have substantively altered 
the results. 
Another potential limitation is that the proportion of patients who already had a diagnosis 
of or were receiving treatment for depression who were inappropriately included in the 
diagnostic accuracy studies reviewed is unknown. Only four of the studies that excluded 
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such patients reported the proportion excluded for this reason, and this varied widely 
depending on the setting and the time period of the study. It was less than 2% in studies that 
collected data from 10 years ago in Turkey 40 and more than 15 years ago in Sweden 41, but 
about 10% in a 2003 study of patients in general practice from New Zealand 42 and just over 
20% in a 2004 study of primary care patients treated in a US Veteran's Affairs setting 43• In 
addition, the small number and substantial heterogeneity of studies that excluded patients 
who already had a diagnosis or were receiving treatment did not allow for an assessment 
of the effect of inclusion and exclusion decisions on diagnostic accuracy estimates. On the 
other hand, numerous studies have found that the inclusion of established cases among 
examined cohorts consistently inflates assessments of the accuracy of a diagnostic test 14, 
and it is likely that this would also be the case in studies of depression screening tools. 
Conclusions and policy implications 
The importance of our findings relates to the use of depression questionnaires for 
screening, a procedure conducted to identify previously unrecognized cases 2•3 • In clinical 
practice, depression questionnaires are sometimes used for purposes other than screening, 
including monitoring the severity of symptoms in patients who already have a diagnosis of 
depression and assessing patients for recurrence of symptoms while they are being treated. 
The introduction and discussion sections of the 17 systematic reviews and meta-analyses 
we reviewed indicate that all were intended to assess the diagnostic accuracy and utility of 
depression questionnaires for the purpose of screening-that is, for identification of new 
cases. None discussed how findings might apply to other possible uses for the questionnaires 
(such as monitoring progress of treatment or detection of relapse). In addition, the 
recommendations that have been issued by expert panels regarding depression screening 
in various settings discuss the use of screening instruments as a means of identifying new 
cases. 
Screening for depression is somewhat different from many other types of screening in that a 
history or interview might not necessarily be part of the evaluation before a screening tool is 
administered. To illustrate, the US Preventive Services Task Force recommends screening for 
cervical cancer in women who have been sexually active and have a cervix 73• On the other 
hand, such screening is not recommended for women older than 65 or for women who 
have recently had a normal result on a smear test. This approach to screening is predicated 
on some "filtering" to determine the appropriate individuals or groups to be screened. On 
the other hand, the task force's recommendations regarding depression screening 9 focus 
on issues in healthcare systems, such as the availability of staff assisted depression care, 
rather than on any upstream evaluation of patients before screening. In clinical settings, 
screening tools for depression might be routinely administered to all patients in the waiting 
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room of a hospital, physician's office, or clinic, as has been recommended by expert panels 
4• Regardless of whether these screening tools are used with or without upstream "filtering" 
in clinical practice, accurate determinations of test characteristics that reflect the ability to 
detect previously unrecognized cases can be obtained only if this upstream "filtering" is 
done in studies to exclude patients who already have a diagnosis of depression. Our findings 
show that this is rarely done, and, as a result, existing evidence on the accuracy and case 
yield of depression screening tools could substantially overestimate their utility in clinical 
practice. Well-designed studies that exclude patients who already have a diagnosis of or are 
receiving treatment for depression are needed to generate realistic determinations of the 
accuracy of depression screening tools in clinical settings to inform decisions about risks and 
benefits with screening. 
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Chapter 5 
Abstract 
Meta-analyses may contribute to more reliable knowledge about the existence of certain 
relations in the area of psychosomatic research. Surprisingly, the increasing popularity of 
meta-analysis is not reflected in the number of meta-analyses on observational studies 
published in Psychosomatic Medicine. This may be due to the specific difficulties that apply 
to meta-analyses of observational research. The aim of this paper is to provide a non­
technical overview of the principles of meta-analysis applied to observational research. We 
will highlight general principles of meta-analysis and discuss the major threats to its validity, 
with an emphasis on its specific merits and pitfalls for psychosomatic research, using several 
examples. We conclude that meta-analysis is a relatively simple technique, leaving little 
reason for not routinely applying it when performing a systematic review. An adequately 
conducted meta-analysis may not only provide a summary estimate of a certain association, 
but has additional value in discovering relevant confounders, mediators, and moderators as 
well as identifying areas of research that require more attention. 
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Introduction 
Meta-analysis is a statistical procedure that integrates several studies concerning a certain 
research question to reach a more secure conclusion. State-of-the-art meta-analyses have 
the potential to provide a more objective appraisal of the evidence than traditional narrative 
reviews. They can reveal that repeated results in the same direction across several studies, 
even if not one is significant, can be much more powerful evidence than a single significant 
result from an individual study 1 • In addition, meta-analyses can provide insight into why 
different studies have found different results. Furthermore, whereas adequately powered 
randomized controlled trials have a relatively high positive predictive value of reflecting the 
true relationship, this value drops for research findings of observational studies 2• Meta­
analysis of reported associations in observational studies may raise the positive predictive 
value of the true relationship. Finally, meta-analysis may identify areas of research that need 
more investigation, for example based on results of subgroup or sensitivity analyses 3.4 _ 
Meta-analysis is a particularly useful procedure in psychosomatic research. Many studies in 
this field meet characteristics that contribute to the risk of non-replication, such as having 
small sample sizes, retrieving small effect sizes, testing a large number of relationships 
without clear rationale, and having large flexibility in designs, definitions, outcomes, and 
analytical methods 2,s. in spiteofthis, the sharply increased number of published meta-analyses in 
general medicine 6•7 is not reflected in Psychosomatic Medicine, where the average number 
of meta-analyses published is stable at around two per year (Table 1). Since 2000, 15 out of 
16 meta-analyses published in Psychosomatic Medicine were purely based on observational 
research (and the other one was a combination of observational and intervention research) 
8, whereas this was the case for only one fourth of the 127 meta-analyses published in this 
time period in the Journal of the American Medical Association, as an example of a general 
medical journal. In the light of certain difficulties that are associated with meta-analyses 
of observational studies, most importantly the risk to produce very precise but equally 
spurious results 9, the relative low number of meta-analyses in Psychosomatic Medicine 
may not be surprising. 
Since the last review on meta-analysis in Psychosomatic Medicine almost two decades ago 
10, new techniques, procedures, and recommendations have become available 6• The current 
paper provides an update in the form of a non-technical overview of the general principles 
of meta-analysis to readers with a basic knowledge of statistics. We will highlight the general 
principles of meta-analysis and discuss the major threats to its validity, with an emphasis 
on its specific merits and pitfalls for observational, psychosomatic research. Our aim is that 
after reading our paper, researchers should be able to critically interpret meta-analyses 
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Inclusion of studies 
Literature search 
In searching literature for a meta-analysis, the goal is to include as many of the existing 
relevant studies as possible in a reproducible manner. Meta-analyses on psychosomatic 
research should use at least the literature databases Medline and Embase. In addition, 
other, more subject-specific databases can be searched, depending on the research question 
(e.g. PsyclNFO, CENTRAL, CINAHL, ISi Science and Social Science Citation Index, Cochrane 
Library). Each database has specific search possibilities and most databases provide 
tutorials. Databases often use key-words, but free text should also be searched 26•27• The 
search should be conducted without language restrictions to reduce the risk of language 
bias 28•29• Because searching the literature is almost a specialty in itself and errors in search 
strategies are common 30, additional consultation of a librarian may be worth considering. 
The probability that research findings are published is influenced by the nature and the 
direction of the results. Significant research findings are overrepresented, whereas results 
conflicting with the prevailing beliefs about the association are underrepresented 31• 
Searching for unpublished studies is thus important in order to achieve a representative 
sample of the work available in the research area under study, but it requires considerable 
effort. Unpublished findings may, for example, be revealed by asking relevant research 
groups for any unpublished results or checking dissertation databases (e.g. Dissertation 
Abstracts Online, ProQuest Dissertations and Theses). 
Selection of relevant studies 
Articles are selected for inclusion based on a predesigned protocol containing inclusion 
criteria specifying the type of subjects, exposure, outcomes, and type of study 26•27•3 2• This 
is preferably done by two independent reviewers, since they select on average 9% more 
studies than one 33 • One particular problem in the selection process is the fact that several 
articles with different first authors may report on the same study, or on partly overlapping 
data. This problem may especially occur in observational studies that gather information on 
a large number of variables over a relatively long period of time, resulting in more than one 
publication on a single study. Just like the search strategy, the selection process should be 
reported in detail. 
Methodological quality 
Critical appraisal of the methodological quality of primary studies is an essential feature of 
meta-analysis. Good methodological quality can be defined as having a design that minimizes 
bias in the estimation of the association under study. Critical appraisal checklists or scales 
('tools') can be used as a threshold for inclusion of studies, or preferably, the meta-analysis 
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can be repeated excluding low quality studies to assess whether results would change (see: 
sensitivity analysis). Although there is a plethora of tools for assessing quality of intervention 
trials, consensus on the ideal tool for assessing methodological quality of observational 
studies is currently not available 34• Major domains that should be incorporated in every 
observational studies quality tool are selection of participants, measurement of dependent 
variables, and control for confounding. 
The type of tool used to assess quality can dramatically influence the interpretation of meta­
analyses 35• To develop a valid tool, experts in the field could be consulted and development 
of the tool should be clearly stated. Reliability of the tool can be assessed by using at least 
two independent raters to score the individual papers, and interrater agreement statistics 
should be reported. Researchers should be aware that using a quality tool inevitably 
introduces subjectivity, such as the decisions on which items to include and on the scoring 
rules for each quality item. When developing a quality tool, general items for quality of 
reporting can be used, such as consensus guidelines on reporting of randomized trials, 
CONSORT 36; diagnostic tests, STARD 37; or observational studies in epidemiology, STROBE 
38• Recommendations for adequate reporting of case-control studies in the psychiatric 
setting have also been made 39, which are largely applicable to observational psychosomatic 
research. Additionally, researchers can include specific items that are pivotal for good quality 
studies in their field. Assessing sources of bias is a crucial but equally complex function of 
a quality tool, because distinguishing quality of reporting and quality of the actual study 
design is often not possible. Notwithstanding some degree of uncertainty about the validity 
of comparing study quality, quality tools specifically designed for a meta-analysis of a certain 
topic under study may additionally serve as a guideline for conducting high quality future 
research. 
An example of a quality tool for meta-analysis of observational studies in the psychosomatic 
area is one developed for studies on cardiac vagal activity in functional somatic syndromes. 
Experts in the field were asked to review this quality tool that includes items such as whether 
the functional somatic syndrome has been reliably assessed, whether the measurement 
of cardiac vagal activity has been reported in appropriate units, and whether specific 
covariates such as age, gender, body mass index, depression, and medication use have been 
assessed or adjusted for 40• In this meta-analysis, it could not be proven that study quality 
accounted for the mixed findings. It was advised, however, that future research adhering to 
the proposed quality criteria may provide a more definite answer on the question whether 
lower cardiac vagal activity is involved in the etiology of functional somatic syndromes. The 




Effect size per study 
Meta-analysis in psychosomatic medicine 
The basic information needed for a meta-analysis is the effect size per study, which is the 
measure of the magnitude (strength) of the association between two variables. Information 
needed to calculate this effect size consists of a summary measure and a measure of its 
precision (standard error or 95% confidence interval). Widely used summary measures 
are the correlation coefficient, odds ratio (OR), and standardized mean difference (SMD), 
but mean difference, risk ratio, rate ratio, hazard ratio, proportion, etc. are also possible 
summary measures. In case of variability in reported effects, several formulas for converting 
test statistics (such as t-, x2-, Z- or F-values, or their associated p-levels) to effect size 
estimates (such as Cohen's d, OR, and correlation coefficients) and formulas for converting 
effect size estimators from one type to another are available 41A2• 
In the area of psychosomatic research, however, there may be specific problems concerning 
retrieving effect sizes, as different measures for the same construct are often applied in 
the original studies. For example, in a meta-analysis on depression and pain perception 
thresholds, effect sizes had to be calculated from studies using different methods to 
measure depression (Beck Depression Inventory, Hamilton Depression Scale, or diagnostic 
criteria according to Diagnostic and Statistical Manual, Fourth Edition) and pain perception 
(cold-, heat-, pressor-, ischemic-, and electrical stimuli) 18• Effect sizes based on the standard 
deviation (SD), such as the SMD, provide a solution to this problem. The SMD is calculated 
as the difference between the means of the cases and controls divided by the pooled SD. 
Although the SMD is the predominantly used effect size in social sciences 1, it has been 
disputed by others 43• The use of SMDs is criticized because of the underlying assumption 
that the different scales from which the SMD is calculated are linearly related. Although this 
is a limitation of the SMD, calculating SMDs is sometimes the only feasible option (e.g., in 
cross-sectional case-control studies). 
Correlation coefficients and SMDs 
When an effect size is applied to continuous variables, commonly used effect size indices 
are the r family and the d family 1• The r effect size family includes all types of correlation 
coefficients (i.e., r, phi, rho) and is preferably used when the studies composing the meta­
analysis primarily report the correlation between variables (e.g., continuously measured 
psychological factors, such as anger or hostility, and development of hypertension in 
population cohorts) 23• The d effect size family provides SMDs and is preferably used when 
the studies composing the meta-analysis primarily report ANOVAs and t-tests comparisons 
between groups on continuous variables (e.g., cardiovascular activity in post-traumatic stress 
disorder (PTSD) patients versus healthy controls) 25• Cohen's d and Hedges' g are two widely 
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used examples of an SMD. When sample sizes are small, Cohen's d may produce estimates 
of the population effect size that are slightly too large 44• Therefore, Cohen's d is sometimes 
adjusted by the following formula (v [(N cases + N controls - 2) / (N cases + N controls)] * 
d), which results in Hedges' g 45• For example, a study compared cardiac vagal activity in 11 
patients with chronic fatigue syndrome (2.75 SD 1.39 In ms2) with 11 healthy controls (3.09 
SD 0.56 In ms2) 46• It can be calculated that Cohen's d = -0.34 (95% Cl = 0.00 to -1.14). In this 
small sample, correction leads to a small attenuation of the effect size, namely Hedges g = v 
[(11+11-2) / (11+11)] * -0.34 = -0.32. The r of this association is 0.17 based on Cohen's d (r = v 
[d2 / [d2 + 4], indicating that the explained variance (r2) of chronic fatigue syndrome by lower 
cardiac vagal activity in this study is 0.172 = 2.8% (and 2.5% when using Hedges g). 
Occasionally, descriptive or inferential statistics needed to compute an effect size are not 
reported. Conservative approaches to impute an effect size for missing values exist. For 
example, when a significant association was reported in the primary study, a conservative 
effect size assuming that the p-value was equivalent to 0.05 can be computed. In case there 
was no significant association, an effect size of 0.00 can be imputed. Several methods to 
impute m issing data in meta-analyses have been discussed elsewhere 47• 
The magnitude of effect sizes is often interpreted by using Cohen's conventions, in which 
an SMD of 0.0 means no difference, 0.2 represents a small difference, 0.5 a moderate 
difference, and 0.8 a large difference 48• Inherent to the multifactorially caused conditions 
typically under investigation in psychosomatic research, effect sizes are usually small. For 
example, the median Cohen's d in the studies listed in Table 1 is 0.34 (interquartile range 
0.27 - 0.55). The final evaluation of the meaning of the effect size, nevertheless, requires 
individual judgment regarding the specific topic under study, in which the consequence of 
the outcome or the possibility of prevention and treatment are also taken into account. 
ORs and other probability effect sizes 
Probability effect sizes are usually given in studies with a binary outcome, such as in studies 
with disease versus no disease or mortality versus no mortality as endpoint. The selection 
of the appropriate summary statistic is a subject of debate due to conflicts in the relative 
importance of mathematical properties and the ability to interpret results intuitively 6• 
Recommendations on how to choose between ORs, risk differences, risk ratios, and other 
relative measures have been given elsewhere 49• Frequently, ORs are reported, such as in 
a meta-analysis on the association between depression and cardiovascular disease and 
mortality 16•17•20• The odds are the number of patients who fulfill the criteria for a given 
endpoint divided by the number of patients who do not. The OR relatively easily allows 
combining data and testing for statistical significance. 
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Although relative effect measures are generally used for summarizing the evidence, absolute 
measures, such as the absolute risk reduction or the number of patients needed to treat 
to prevent one event are more useful when applying the results in a concrete clinical or 
public health situation, and should be recalculated from the relative summary estimates 
4,so. Also, effect sizes should be compared to the effects of well-established risk factors in 
the field in order to determine their (clinical} importance. For example, the influence of 
depression as a risk factor for the development of coronary disease in community samples 
without clinically apparent heart disease was considered similar to published effect sizes of 
the widely accepted risk factor smoking 20• 
Pooling of effect sizes 
Methods for calculating the summary estimate by combining the effect sizes of the individual 
studies use a weighted average of the results, in which larger studies have more influence 
than smaller ones. This study weight is computed from the variance or squared standard 
error of the mean (SEM}: weight factor (w} = 1 / SEM 2 • The summary estimate in a meta­
analysis is the mean weighted effect size, calculated by the sum of the products of effect 
size and weight per study, divided by the sum of all study weights (� effect size * w I Iw}. 
The accompanying 95% confidence interval can be calculated with the following formula: ± 
1.96 v 1 / (SEM of summary estimate} 2 • It is assumed that each value contributing to the 
summary estimate is statistically independent of the others. An extensive overview of the 
statistical basis of formal meta-analysis has been provided by others si_ The meta-analysis 
can be repeated using different methods to assess whether the same results are achieved 
and the summary estimate is robust to the decisions made to obtain it. 
Software 
Programs designed for the statistical pooling of data in meta-analysis are available, and 
most general statistical packages include meta-analysis options. Most of these programs are 
relatively easy to master and offer tutorials and a help function. Moreover, many programs 
and add-ons to statistical packages are freely available on the Internet. In general, programs 
offer at least basic statistical methods and graphical presentations and commercial software 
is not necessarily better than free software 52• Differences may exist in statistical methods, 
usability, graphics, and whether or not the software is being maintained. The basic results 
obtained from the different software packages are essentially the same 53• The studies of 




Fixed effect versus random effects models 
When pooling the effects of all studies included in the meta-analysis, the fixed effect model 
or the random effects model can be used. The fixed effect model assumes that the samples 
of all studies are based on the same population and that the same underlying effect is thus 
measured in all studies (i.e., there is one true effect size). In this method, between-study 
variation is assumed to be due to sampling error. A disadvantage of the fixed effect model 
is that it is highly unlikely that studies do measure the same underlying effect, especially in 
epidemiologic research 54• The random effects model, in contrast, assumes that each sample 
comes from a somewhat different population and that the effects in these populations may 
also differ. Between-study variation is assumed to be due to differences in the underlying 
effects in the samples. The random effects model gives the average effect of all studies 27• 
A disadvantage of the random effects model is that it assumes the studies are a random 
sample of effect sizes and that between-study variation is distributed normally 31• This is 
often not the case, for example as a result of publication bias 54• An advantage of the random 
effects model is that it permits to generalize to studies that might be done in the future. 
In the fixed effect model, the inverse variance method is used to pool effect sizes based on 
continuous data, such as mean differences or SMDs. To pool effect sizes based on binary 
data, such as ORs and RR's, the Mantel-Haenszel method can be used 55, or the Peto method 
in case of pooling ORs of studies with balanced arm sizes, small intervention effects, or rare 
events 56• When the effect sizes are pooled using a random effects model, DerSimonian and 
Laird's method is used both for effect sizes based binary and continuous data 57 • 
The random effects model is more conservative than the fixed effect model and is used when 
heterogeneity is suspected 4• Although tests for heterogeneity are often used to determine 
whether a fixed or random effects model must be used, these tests are often underpowered 
and deciding on the model should therefore be primarily based on characteristics of included 
studies 27•31• In general, the random effects model is more plausible and using the fixed effect 
model should only be done when this can be firmly justified on theoretical grounds. An 
example of how using random effects versus fixed effect analysis can change the summary 
estimate and conclusion is found in a meta-analysis on cortisol levels in patients with 
functional somatic syndromes 58• The fixed effect model shows significantly lower cortisol 
in patients with functional somatic syndromes compared to healthy controls (SMD -0.12, 
95% Cl -0.18 to -0.05, p<0.01), whereas the more appropriate random effects model shows 
a wider Cl and no statistical significant difference (SMD -0.07, 95% Cl -0.17 to 0.04, p = 0.24). 
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Forest plot 
The main results of a meta-analysis are usually represented in a forest plot. Forest plots 
graphically display information on the individual studies included in the meta-analysis, the 
amount of variation between studies, and an overall estimate of the results of all studies 
combined (Fig. 1) 59• ORs are best plotted on logarithmic scales, as this enables ORs of the 
same magnitude but opposite directions - for example, 0.1 and 10.0 - to be equidistant from 
1.0 4. 
Figure 1: Example of a forest plot on the prognostic value of depression on cardiovascular mortality. 
ORs are plotted on the logarithmic scale 17• Reprinted with permission. 
Comparison: 01 Depression versus no depression 
Outcome: 01 All-cause mortality 
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Next to the forest plot, the basic details of each study supplying data should be presented, 
such as primary author, year of study, design, crude data, derived summary estimate and 
measure of its precision, allowing readers to evaluate the summaries against what was 
presented in original reports, or to repeat the meta-analysis while making other decisions 
or using other techniques. 
Heterogeneity 
Heterogeneity in meta-analysis means that included studies differ considerably on one or 
several important aspects, which may affect comparability of their results and which may 
have caused differences in results. Studies can be different in (a) biological, psychological, 
or clinical variables including gender, age, characteristics of study participants, severity of 
exposure, and condition or disease, (b) methodological variables including study design, 
measurement procedures, extent of control for confounding, and response measures, and 




The presence of heterogeneity can be calculated statistically 60• The most used measures are 
the Q statistic, /2, and tau-squared (r2). To begin with, the Q statistic (also called Cochran's x2 
statistic) is a chi-squared test calculating whether variation in study results is due to chance 
or due to systematic underlying differences and the null hypothesis should be rejected. A 
value of Q similar to the degrees of freedom in the analysis indicates little heterogeneity. 
When it is considerably higher, and the p < 0.10, this indicates heterogeneity 61• The Q 
statistic, however, has a number of limitations. The Q statistic has low power when a single 
study largely contributes to the mean weighted effect size 31• It also has low power when 
included studies are small or when there are few studies, whereas this test may detect 
heterogeneity even when it is not substantial when many studies are included 27• In the 
studies presented in Table 1, meta-analyses in which the Q test was not significant were 
usually based on a small number of primary studies (< 10), whereas the Q test was significant 
in all meta-analyses with a relatively large number of included primary studies (> 30). This 
implies that heterogeneity can be considered the rule, rather than the exception, in meta­
analyses published in Psychosomatic Medicine. A second measure of heterogeneity is the /2 
statistic, which is a derivative of Q. This statistic gives the percentage of variability in results 
that is caused by heterogeneity rather than coincidence 27• Generally, an /2 > 50% indicates 
considerable heterogeneity. A third statistic that is often used to report heterogeneity is r2 • 
This is the variance of the true effect size; thus, there is no heterogeneity when this statistic 
is 0 54• There are several more statistics that assess heterogeneity, some specific to the type 
of effect measure 31• 
However, because of problems with power and accuracy, when statistical tests of 
heterogeneity indicate that the null hypothesis of no heterogeneity holds, this does not 
indisputably prove that studies are completely homogeneous 31• It should still always be 
investigated whether studies have important clinical and methodological differences. 
When heterogeneity is suspected, this must be accounted for in the statistical analysis and 
mentioned in the discussion. Usually the presence of heterogeneity is considered to be a 
negative aspect of meta-analysis, because it makes the results of the meta-analysis difficult 
to interpret 31 and suggests that samples may be too different to be combined. However, 
as no widely accepted quantitative measure exists to grade heterogeneity, it may be better 
to examine it in a meta-analysis rather than use it as a reason for not conducting one 62• 
Heterogeneity can also have advantages. If studies that are clinically and methodologically 
heterogeneous lead to comparable results, this means that the results are generalizable to 
a wider population. In addition, investigating sources of heterogeneity can lead to a better 
understanding of associations, new hypotheses 26•31, and improvement of future research 63• 
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Moderator analysis 
Performing meta-analysis on subgroups based on characteristics that potentially are 
responsible for differences in effect sizes between studies can demonstrate whether the 
strength of the summary estimate is influenced by these characteristics. This procedure is 
referred to as moderator analysis. For example, in a meta-analysis a significant difference 
was found in interleukin-6 { IL-6) serum levels between depressed patients and controls, 
with an SMD of 0.25, 95% Cl 0.18-0.31. However, the magnitude of the summary estimate of 
the association between IL-6 and depression was largely attenuated in studies that adjusted 
for BMI (N = 22, SMD = 0.08, 95% Cl 0.02 to 0.13, p = 0.007) as compared to studies without 
BMI adjustments (N = 39, SMD = 0.50, 95% Cl 0.37 to 0.63, p<0.001) 11• 
Ideally, such subgroup analyses are planned in advance, since investigating heterogeneity 
post hoc based on the data from the meta-analysis itself can lead to overinclusion 31• 
Providing a rationale for each moderator and giving due consideration to the role that 
each moderator is intended to play is essential 5• In case of post hoc subgroup analyses, 
results should be reported as exploratory and the need for replication should be mentioned 
54• Particularly in observational studies, possible moderator analyses on confounders, 
moderators, and mediators are an important part of the meta-analysis. The extent to which 
putative confounders, moderators, and mediators have been taken into account in original 
studies is often highly variable and extracting useful data is not always possible. 
Some difficulties may arise when using terminology regarding confounders, moderators, 
and mediators. A variable may be considered as a confounding or mediating factor in the 
original study, but this variable is tested as a moderator in the meta-analysis. For example, 
authors in the previously mentioned meta-analysis on IL-6 and depression propose that 
depressive symptoms may facilitate weight gain over time as a result of physical inactivity. 
In this pathway, BMI may be a mediator in reality (in case depression leads to weight gain 
and weight gain to inflammation), but is referred to as a moderator of the effect size in the 
meta-analysis. 
The difficulties faced in moderator analyses are many. First, there is the risk of spurious 
findings due to multiple testing. When the number of original studies in the meta-analysis 
is small (i.e., N = 10 - 15), there are insufficient degrees of freedom to test more than one 
moderator variable 64• Nevertheless, many more subgroup analyses are often performed, as 
illustrated by some of the studies listed in Table 1. Second, when moderating variables are 
continuous they have to be categorized in order to be able to perform a moderator analysis. 
It is, however, often unknown how to define subgroups. Artificially grouping data into 
categories introduces measurement error with an inevitable loss of power 5 • Furthermore, 
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the arbitrariness of the choice of cut point may lead to the undesirable temptation of trying 
more than one value and choosing the one that gives the most satisfactory result 50• Third, 
moderator analysis does not provide a statistical test of the existence of a moderator effect. 
Fourth, one cannot look at effect moderation while keeping other covariates constant. 
When two moderators are highly correlated and the first causes changes in the effect size, 
a moderator test for the second will likely also be significant, even though this second 
moderator does not truly influence the strength of the effect. 
An example of difficulties in interpreting the results of moderator analysis is a meta-analysis 
across 37 studies on cortisol levels in patients with PTSD 65• Overall, cortisol levels were not 
significantly different in PTSD patients compared with controls (SMD -0.12, 95% Cl -0.32 to 
0.08, p = 0.24) 65 • Figure 2 presents subgroup analyses (SMD and 95% Cl are shown) based 
on several moderators. Although there is no significant difference in cortisol between PTSD 
patients and controls in the primary summary estimates, significantly lower levels of cortisol 
are found in females with PTSD compared to female controls (gender is a moderator), in 
patients with PTSD with physical or sexual abuse compared to controls (trauma type is a 
moderator), and in PTSD patients when they are compared to controls without trauma 
exposure, as opposed to controls with trauma exposure but without PTSD (exposure status 
of control group is a moderator). However, as the authors mention, it is not possible to 
disentangle whether those moderators act separately from each other. For example, the 
association between female gender and lower cortisol could be explained by a larger 
prevalence of sexual abuse in women. In this case, meta-regression could be a possible 
solution to further elucidate the independent contribution of those factors. 
Meta-regression 
Meta-regression is a regression-based analysis that aims to test for study heterogeneity 
by associating study characteristics to study outcome. Typically, the independent variables 
(predictors) are characteristics of each study, such as participants' mean age, proportion 
of women, or follow-up duration. The dependent (outcome) variable is the study effect 
size such as the SMD or log OR. The procedure for multivariable meta-regression closely 
follows conventional regression analysis, the only difference being that a variable equal 
to the inverse variance (i.e., the study weight) has to be used as case weight in order to 
perform a weighted regression. Meta-regression can be used to explain heterogeneity and 
provides the possibility to simultaneously assess multiple characteristics. Again, the fixed 
effect or random effects model can be used for meta-regression. The full range of regression 
models and methods (i.e., linear or logistic regression, testing interactions, model fitting 
statistics, etc.) can be employed 43 • For example, in a meta-analysis on placebo response in 
chronic fatigue patients, it was found that the placebo response was higher in interventions 
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based on immunological assumptions compared to interventions based on psychological 
assumptions. The authors hypothesized that this difference could be explained by higher 
expectations of patients on interventions assuming physical causation as opposed to 
interventions assuming psychological causation. Alternatively, they also considered the 
possibility that systematic differences between immunological and psychological trials, such 
as illness duration, placebo type, and duration of follow-up, could explain the larger placebo 
effect in immunological trials. In a meta-regression, however, only intervention type (i.e., 
psychological or immunological) turned out to be significantly associated with a stronger 
placebo response (p = 0.03), independent from all other factors 8• 
Figure 2: Examples of moderator analyses in a meta-analysis on cortisol and PTSD (Meewisse et al. 
2007). Reprinted with permission. 
Tune of measurement 




Male (n= I 0) 
Trauma type 
War veterans (n= 12) 
Sexual/physical abuse (n=5) 
Refugees (n=2) 
Various (n=3) 
Years since trauma 
0--10 (n=8) 
1 1-20 (n=2) 
>20 (n=9) 
Comorbid depression 
Depression absent (n=9) 
Depression present (n=◄) 
Exposure controls 
Not exposed (n= 1 1 ) 
Trauma exposed (n=9) 
Publication year (n=23) 
1994 
2004 
-3 0 -2.0 





0.4 18  
0.0 1 5  
0.983 
- 1 .0 0.0 1 .0 2 0  3.0 
Standardised mean difference in cortisol level 
Control higher PTSD higher 
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Some problems affect the validity and reliability of meta-regression. Primarily, meta­
regression is prone to inflate false-positive rates when heterogeneity is present, when there 
are few studies, and when there are many covariates. Consider the case of two studies 
producing effect estimates with non-overlapping confidence intervals: any covariate whose 
value differs between these studies will be significantly related to the heterogeneity among 
the studies, and hence a potential explanation of it, while this explanation could be entirely 
spurious 66• Furthermore, it is unclear how many covariates can reliably be investigated 
without the risk of overfitting, and how this depends on the number of studies, the extent 
of the heterogeneity, and the relative weights of the different studies. Rules of thumb for 
conventional regression analyses (10-15 observations per covariate assessed, for instance) 
64 are not directly relevant to meta-regression, as this type of regression deals with the 
complexities of heterogeneity and differential study weights. To be on the safe side, 
meta-analysts who aim to explore heterogeneity using meta-regression should minimize 
the number of covariates investigated, select those justified through scientific rationale, 
and specify them in advance 66• Second, regarding translation of the results of the meta­
regression to individuals, the problem of aggregation bias ('ecological fallacy') may arise. 
This bias refers to the assumption that individuals have the average characteristics of the 
group to which they belong, and thus that relationships observed for groups necessarily hold 
for individuals. The meta-regression analysis is conducted at the study-level and does not 
include the underlying patient-level variation. The relationship between group means may 
not reflect the relationship between values of exposure and outcome in an individual, and 
average quantities instead of person-specific quantities can lead to erroneous conclusions 
67
• For example, suppose that countries with a high per capita income have high suicide 
rates. Inferring that increasing personal income at the individual level is also associated 
with suicide related mortality can lead to erroneous conclusions, as within countries, suicide 
related mortality may be lower in high income than in low income persons. Thus, when 
interesting findings are discovered using meta-regression, person-level data from large 
cohort studies or trials may be required for confirmation.  
Alternatively, meta-analysis of individual patient data (IPD) (also referred to as 'mega­
analysis') could be considered, in which raw data from every primary study are obtained 
and transformed to a common format. The strengths of IPD meta-analysis, in general, 
are that the power is greatly enhanced by the larger number of subjects and that more 
subgroup analyses can be done. More importantly, however, in observational research, 
individual patient data can be used to consistently adjust for confounders. Adjustment for 
confounders is usually impossible in common meta-analysis, as not all studies perform the 
same adjustments in their analyses and they report adjusted analyses in different ways. An 
example is the meta-analysis on the impact of depression on mortality. In this research, 
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several moderator analyses, such as on measurement instrument to assess depression or 
duration of follow-up, did not explain heterogeneity 16• Also, the relative risk of mortality 
was nearly the same in unadjusted and adjusted results, and the amount of heterogeneity 
was not reduced. Authors argue that one possible explanation for the heterogeneity 
of the adjusted analyses may be the selection of risk factors, which varied greatly from 
study to study. One possible solution to this problem would be to pool and reanalyze the 
original data of all included studies. This can only be done when different studies include 
comparable measures of the variables to be adjusted for. A major obstacle of IPD meta­
analysis is that it is time-consuming and requires cooperation between several research 
groups, which may not always be attainable. In addition, variables that must be compared 
will generally be measured using different instruments in the individual studies and must 
therefore be harmonized before analysis is possible. Information may be lost during this 
process of harmonization. A good overview of the methodology of IPD meta-analysis is 
given by Stewart et al. 68• 
Interpretation of meta-analysis findings 
Sensitivity analysis 
The process of undertaking a meta-analysis inevitably involves many more or less subjective 
decisions and sensitivity analyses can be carried out to determine whether the assumptions 
or decisions made have a major effect on the result of the meta-analysis. Thus, sensitivity 
analysis addresses the question of whether the findings of the meta-analysis are robust 
to the methods used to obtain them. Examples of sensitivity analyses include assessing 
the influence of including studies that were doubted to meet eligibility criteria, comparing 
fixed effect with random effects models, comparing cohort and case-control studies, 
adding conservative effect size estimations for studies that did not provide adequate data 
to calculate an effect size, or excluding outlying studies. Two other commonly performed 
sensitivity analyses are assessing the influence of methodological study quality of primary 
studies and the influence of publication bias. 
Methodological quality used in interpreting meta-analysis results 
It remains a matter of debate how the results of quality assessment should be incorporated 
in the analysis and interpretation of results of meta-analyses. Exploring the effects of quality 
on the quantitative results by using quality as a weighting factor has been discouraged 
69
• We recommend using quality scores in a sensitivity analysis, which can demonstrate 
whether the findings of the meta-analysis are different for low and high quality studies. 
For example, sensitivity analysis in a meta-analysis on the association between positive 
wellbeing and mortality in healthy populations indicated a stronger association between 
positive psychological well-being and reduced mortality in high quality studies compared 
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to low quality studies 12• This sensitivity analysis, thus, supports the validity of the overall 
finding that there is an association. 
Publication bias 
Publication bias in observational meta-analyses may lead to inflated effect estimates that 
tend to be in the hypothesized direction. Several approaches have been developed to 
assess publication bias. The most well-known approach is the funnel plot - a scatter graph 
with for each primary study the effect estimate is plotted against a measure of precision 
(such as sample size, or preferably, the standard error of the effect size) 70• It is expected 
that more precise studies report effect estimates close to the true effect, whereas effects 
estimates from less precise studies will scatter more widely. In the absence of publication 
bias, the plot is expected to resemble a funnel-like shape, which is symmetrical around 
the summary estimate. In a meta-analysis on decreased cardiac vagal activity in functional 
somatic syndromes, the funnel plot was not symmetric, as there is gap where small studies 
with null findings are expected (Figure 3a). 
Figure 3a: Funnel plot (N = 14) showing the correlation between the standardized mean difference 
(SMD) and its standard error (SEM) with pseudo 95% confidence l imits. The summary estimate reveals 
that card iac  vagal activity is significantly lower in patients with functional somatic d isorders compared 










SEM of SMD 
Funnel plots can be visually interpreted, but this is  subjective and the agreement between 
raters and the association between graph ratings and publication bias is found to be poor 
71• A test for funnel plot asymmetry formally examines whether the association between 
estimated effects and a measure of study precision is larger than might be expected to occur 
by chance. The principle is to relate the effect estimates to their SEM, and to test the null 
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hypothesis that the association is absent. There are many tests for funnel plot asymmetry, 
which are compared by Rucker et al. 72• Two of the most well-known are the Begg and 
Mazumdar 73 adjusted rank correlation test, and the regression asymmetry test of Egger et 
al. 74• The Begg and Mazumdar test 73 is based on a Kendall's r rank correlation between the 
standardized effect size and its SEM. The test of Egger et al. 74 is based on a linear regression 
of the effect estimate against its standard error, weighted by the inverse of the variance of 
the effect estimates. However, the tests have low power to detect funnel plot asymmetry, 
and do thus not exclude the presence of publication bias. Publication bias is not the only 
reason for funnel plot asymmetry. Asymmetry also arises because of small-study effects - a 




• Small study effects occur because of differences in methodological quality between 
larger and smaller studies, heterogeneity between studies with different sample sizes (small 
studies may more likely include selected groups of patients), an effect modifier associated 
with study precision, or merely chance 74•75 • In addition, some effect estimates (e.g., ORs 
and SMDs) are naturally correlated with their standard errors, and can produce spurious 
asymmetry in a funnel plot 27• Another mathematical estimation of publication bias is 
provided by the fail safe N, which indicates the number of new, unpublished, or unretrieved 
non-significant studies that would be required to lower the significance of a meta-analysis to 
non-significant. A fail safe N that is small, particularly compared with the number of studies 
included in the meta-analysis, indicates that the degree of confidence that can be placed in 
the main conclusions of the meta-analysis is low. The fail safe N has been criticized for two 
reasons. First, it overemphasizes statistical significance. Second, it is based on the addition 
of studies that have an average null effect, whereas unpublished studies may also have an 
effect in the opposite direction as the observed meta-analysis result 76• 
An important question is how to proceed when publication bias is suspected. A relatively 
simple approach to correct for publication bias is the 'trim and fill' method 77•78, available in 
most statistical meta-analysis programs. The principle behind this method is to impute new 
studies to an asymmetric funnel plot, followed by a meta-analysis that includes the imputed 
studies. The method works by estimating the number of studies on the right-hand side of the 
funnel plot that have no counterpart on the left-hand side. Studies causing the asymmetry 
are then 'trimmed' from the right-hand side of the funnel plot, possibly leading to a shift 
of the re-estimated summary estimate that may again create asymmetry. The process is 
repeated until there is no residual asymmetry, after which the trimmed studies are put back 
and their missing counterparts are imputed or 'filled' by replicating the opposite side of the 
funnel plot with the mirror axis placed along the adjusted summary estimate. The difference 
between the original summary estimate and the summary estimate based on the extended 
dataset including the imputed studies is assumed to indicate the degree of publication bias. 
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Assumptions underlying the trim and fill method include that the magnitude of the effect 
size, and not the p-value, determines the chance of publication. Moreover, this technique 
assumes that publication bias leads to this simple form of funnel plot asymmetry, and 
that missing effect size estimates are of the same size as those observed in the opposite 
direction. Nevertheless, it has been shown that the use of the trim and fill method can help 
to reduce the influence of publication bias on the summary estimates, even though the 
performance of this method decreases when heterogeneity increases 79• With regard to the 
studies on cardiac vagal activity in functional somatic syndromes, Egger's test rejected the 
null hypothesis that there was no funnel plot asymmetry (p = 0.01). The trim and fill method 
resulted in a fill of five studies and a shift from an initially significant summary estimate 
to a re-estimated summary estimate that was non-significant (Figure 3b) 40• This analysis 
points to the possibility that studies contradicting prevailing beliefs of lower cardiac vagal 
activity in functional somatic syndromes have not been published. The trim and fill method 
is recommended to be used as a form of sensitivity analysis of the summary estimate. 
Figure 3B: Trimmed and fi l led funnel plot (N = 19) showing the corre lation between the standardized 
mean difference (SM D) and its standard error (SEM ) with pseudo 95% confidence l imits. Squares 
represent the studies that have been fi l led. The adjusted summary estimate reveals that cardiac vaga l 
activity is not significantly different in patients with functiona l  somatic d isorders compared to hea lthy 
controls (SMD = 0.01, 95% Cl -0.34 to 0.36, p = 0.95). Reprinted with minor modifications from Biol 
Psychol 2009;82:101-110, Tak LM, Riese H, De Bock GH, Manoharan  A, Kok IC, Rosmalen JG. As good 
as it gets? A meta-ana lysis and systematic review of methodologica l qual ity of heart rate variabi l ity 
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Controversy around meta-analysis 
There are a number of outspoken critics of meta-analysis. Most points of criticism do not only 
apply to meta-analysis, but to the entire field of observational research, such as the risk of 
reporting bias, publication bias, confounding, and lack of comparability between studies. Some 
even argue that meta-analysis of observational studies should not be done at all, because 
it would only reinforce the biases inherent to epidemiologic research by creating significant 
but incorrect results 80• In a properly performed meta-analysis, however, these limitations 
can be dealt with in a sound way, as has been discussed in this article. Some critics argue 
that the statistical pooling of data in observational data is highly prone to bias and spurious 
findings. Instead, it is suggested that it is more important to thoroughly investigate causes of 
heterogeneity 9• We agree that statistical combination of studies should not generally be the 
main aim of systematic reviews of observational studies, especially as heterogeneity seems 
the rule rather than the exception (Table 1). The thorough consideration of possible sources of 
heterogeneity between studies, by using moderator analysis, meta-regression, and sensitivity 
analysis should be considered as more important features of meta-analysis in this field. When 
there are still serious limitations to the results of the meta-analysis, these can be discussed and 
interpretation can be adjusted accordingly. Thus, instead of disputing the technique of meta­
analysis itself, we feel its undue reputation of providing the final answer should be rectified. 
Concluding remarks 
Many papers in Psychosomatic Medicine primarily are observational studies aiming to 
answer etiological questions. Apart from providing a summary estimate, the importance 
of meta-analyses based on those studies also lies in the identification of sources of bias, 
heterogeneity, generation of new hypotheses, and the construct of guidelines to conduct 
better research in the future. Rather than pretending to provide the final, not debatable 
answer, meta-analysis relies on shared subjectivity. Every analysis inevitably requires certain 
subjective decisions, but these have to be transparent and explicit. The discussion of a 
meta-analysis should not simply state the results of the statistical pooling, but it should also 
discuss the level of certainty of the conclusions and any limitations to the interpretation of 
the findings. Specific guidelines on adequate reporting of meta-analyses based on clinical 
trials (i.e., PRISMA) or on observational studies (i.e., MOOSE) are available 81•82• 
This review aimed to demonstrate that performing a meta-analysis is a good way to gain 
more knowledge concerning a specific research topic. We agree with Rosenthal and 
Dimatteo 1 when they stated that anyone who is considering a review of the literature 
has little justification for not doing it quantitatively, as the skills and training required for 
performing a high quality meta-analysis are modest. We hope that the number of meta­
analyses in Psychosomatic Medicine will increase, as they have the ability to produce more 
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Depression and inflammation in patients with 
acute and stable coronary heart disease: a meta­
analysis 
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Objective: Around 20% of all CHD patients are suffering from major depression, representing 
a threefold increased risk compared to the general population. Inflammation has been 
suggested as a possible physiological link between depression and CHD. Several studies 
have investigated the association between depression and inflammation, with conflicting 
results. We therefore conducted a meta-analysis on the association between depression 
and inflammation in patients with acute and stable coronary heart disease. 
Methods: A literature search was performed in Medline, Embase and PsyclNFO for studies 
reporting on the association between depression and inflammatory markers in patients 
with stable and acute coronary heart disease. 
Results: Only with respect to CRP and IL-6, we found sufficient numbers of studies to 
perform a meta-analysis. The pooled effect size combining data from 12 articles showed 
that the association between depression and CRP was d=0.30, p<0.001. For IL-6 the pooled 
effect size was d=0.005, p=0.92, based on 9 articles. 
Conclusions: We conclude that depression in patients with stable or acute coronary heart 
disease is associated with elevated levels of CRP, but not IL-6. For CRP, the effect size was 
small to moderate. CRP could therefore be a more general and stable reflection of different 
pro- and anti-inflammatory processes. This could explain why depression was associated 
with CRP, but not with IL-6. 
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Introduction 
Patients with coronary heart disease (CHD), and in particular myocardial infarction (Ml) 
frequently suffer from depression. Around 20% of all patients with CHD are found to be 
clinically depressed during the months following Ml 1-3, while another 20% present with 
elevated depressive symptoms that do not fulfil diagnostic criteria 4• These rates are around 
three times higher than those in the general population 5• Depression in cardiac patients 
seems to neg�tively affect cardiac prognosis 6• Meijer and colleagues concluded in a meta­
analysis that post-Ml depression is associated with a 2.7 time increased risk of cardiac 
mortality and a 1.6 times increased risk of new cardiac events 7• 
Several physiological mechanisms have been proposed to explain the association between 
depression and CHD outcomes, e.g., heart rate variability 8, hypothalamus pituitary adrenal 
(HPA) axis hyperactivity 9, and inflammation 10• Several markers of inflammation, such as 
C-reactive protein (CRP), interleukin (IL)-6 or tumor necrosis factor (TNF)-a have indeed 
been found to be higher in depressed people compared to people without depression 11,12• 
Various researchers have proposed hypotheses in which the association between depression 
and inflammation is explained, i.e. the macrophage theory 13•14, the cytokine hypothesis of 
depression 15•16, the immune response system (IRS) model of depression 17, and cytokine­
induced sickness behaviour 18• All hypotheses have in common that pro-inflammatory 
cytokines are able to induce depression or depressive symptoms. In addition, inflammation 
is proposed as a causal mechanism in the formation of atherosclerosis 19•20, which in turn 
plays a role in the aetiology and progression of CHD 21-24• Pai and colleagues reported that 
in initially cardiovascular disease free participants, CRP was associated with non-fatal Ml or 
fatal cardiovascular events over six to eight years of follow up 25• 
Several studies have investigated the association between depression and inflammation in 
cardiac patients. Hekler and colleagues showed a positive association between depression 
and IL-6 in Ml patients, but only at 7 months after the Ml had occurred. At two weeks 
post-Ml there was no association 26• A Chinese study among Ml patients reported a positive 
association between depression and CRP. However, the drawback of that study is the 
small sample size (n=35) 27• In the largest study to date, Whooley and colleagues found 
no evidence for an association between depression and elevated levels of CRP, fibrinogen 
and IL-6 in stable CHD patients. Instead, they reported an association between lower levels 
of inflammation and depression 28• Results of other individual studies on the association 
between depression and inflammation have been conflicting. 
A large-scale meta-analysis was undertaken by Howren and colleagues 29, in which the 
association between depression and inflammatory markers was evaluated in several 
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populations, including patients with heart disease. They concluded that in heart disease 
patients, depression is associated with increased levels of CRP (d=0.18, p=0.02) and IL-6 
(d=0. 10, p=0.05). However, there were some limitations to this specific subgroup analysis, 
namely that non-English studies were not included, patients with congestive heart failure 30-
32 (in which arguably inflammation plays a different role than in ACS patients) were included, 
as well as a study without a clinically overt patient sample consisting of subjects with 
atherosclerosis 33• 
We therefore set out to conduct a meta-analysis of the association between depression 
and inflammatory markers in patients with CHD, to combine and summarize the results 
of individual studies and decrease the effects of their limitations. We hypothesized there 
would be a positive association between depression and inflammatory markers, most 
notably CRP and IL-6. 
Methods 
literature search 
An exhaustive literature search was conducted in Medline, Embase and PsyclNFO between 
1987 and November 2010 using pre-specified search terms and inclusion criteria. In addition, 
a search of the reference sections of eligible studies was performed. 
Study selection 
Three independent raters (H.D., A.M. and J.R) identified studies that met the inclusion 
criteria. Disagreements were resolved through group discussion. Studies were reviewed 
using the following criteria: 
- Studies should be observational or intervention trials containing a control group. 
Patients should have either stable or acute coronary ischemia, specified as myocardial 
infarction (Ml), severe angina, atypical chest pain or stenosis in coronary vessels at some 
point in their adult lives. 
- Animal studies were excluded. 
- Depression had to be measured with a validated self-rating instrument or a structured 
interview designed to assess depression, or a psychiatric diagnosis had to be made by a 
psychiatrist based on established diagnostic criteria. 
- Patients had to be rated on a continuous scale of depression severity or divided into 
groups with different levels of depression. 
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markers: IL-lra, TNF-a, soluble receptors 1 and 2 of TNF- a (sTNFRl, sTNFR2), IL-6 or CRP. 
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- A statistical measure of the association between depression and inflammation had to be 
given, including the significance of the effect or a 95% confidence interval. 
Inflammatory markers and depression had to be measured within two weeks of each 
other. 
- Case studies, reviews, meta-analyses, editorials and commentaries were excluded. 
The authors of six studies were contacted for additional information (mean + SD) of CRP and 
IL-6 values for depressive symptoms group and no depressive symptoms group, number of 
participants per subgroup and the amount of time between blood collection and depressive 
symptoms assessment 26•34-38• They provided us kindly with sufficient information to include 
their studies in our meta-analyses. For two papers 27•39, information on percentage of male 
patients or depressed participants was not reported and could not be obtained from the 
authors. 
Quantitative data synthesis 
Data from all studies concerning the association between depression and inflammation 
were first converted into Cohen's d effect sizes, and thereafter pooled using MIX version 1.7 
40•41 • Assuming that the included studies consisted of different samples, pooled effect sizes 
were calculated using a random effects model 42 • Because not all the included studies adjust 




Figure 1 shows the flow diagram of the literature search. A total of 13 studies were selected 
for the analyses. Because only one study reported on IL-lra 39, sTNFRl, and sTNFR2, and 
TNF-a was reported on in only two articles 34•36•43, the association between depression and 
these markers were not evaluated any further and final analyses were restricted to CRP and 
IL-6. 
CRP and depressive symptoms 
We included 12 articles on the association between CRP and depression in cardiac patients 
27•28•34·39.43-45 (Table 1). These articles together comprised a total of 2,429 patients. All 
participants were diagnosed with either Ml, unstable angina, stenosis, exercise-induced 
ischemia, or had undergone coronary revascularization, bypass surgery or coronary 
angioplasty. Time of the measurements after the cardiac event differed per study, varying 
from 1 week up to any point in their adult lives. 
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Figure 1: Flow chart of literature search 
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• time depr.-infl. 
Depressive symptoms were measured with the BDI in nine studies, but were analyzed in 
different ways. When studies used multiple questionnaires including the BDI, we chose to 
include data using the BDI, in order to increase comparability across the studies. Two studies 
did not use a cut-off score 39•46, three studies used a cut-off score of 10 35•36.43, and two studies 
used a cut-off score of 14 27•45• Shimbo and colleagues reported on associations at two 
different timelines, baseline and after three months follow up 35• Because all studies were 
cross-sectional, we used the baseline depression measurement for analyses. Kronish and 
colleagues applied a cut-off score of S4 for no depressive symptoms and �10 for depressive 
symptoms 37• Miller and colleagues divided the patients into three evenly sized groups 
having either no depression, mildly severe depression or moderately severe depression 
34• We merged the latter two groups for our analyses. Whooley and colleagues evaluated 
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depression with the CDIS-IV and PHQ-9 28• Bankier and colleagues used the SCID to assess 
major depressive disorder 44 (Table 1). Von Kanel and colleagues assessed depressive 
symptoms using the validated German version of the depression scale from the HADS 38• 
They divided participants into 'no depression' (score range 0-7), 'mild depression' (score 
range 8-10), 'moderate depression' (score range 11-14), and 'severe depression' (score range 
15-21). Data from these participants with a score of �8 were merged in order to obtain two 
groups consisting participants with and participants without depressive symptoms. Out of 12 
articles, five 27,34,35A4A5 reported significant associations between CRP and depression. Three 
studies did not find an association 39A3.46, while one study 28 reported a non-significant trend 
towards a negative association. Three additional studies did not report on the association 
between depression and CRP, but provided us with the data upon request, so we were able 
to calculate Cohen's d for these studies 36-38• A forest plot is provided in Figure 2, including 
Cohen's d for each individual study. 
Table 1: Overview of studies investigating the association between CRP and depression in patients 
with stable and acute coronary ischemia. 
Study Patients n Mean age (yr.) Male Instrument Depression assessment Depression Cohen's 
(%) post event (%) d 
Cui et al.27 Ml 31 56 BDI 2-11 months post Ml 32 0.95 
Whooley et al.28 CHD 984 Depressed: 62 81 CDIS-IV > 6 months post cardiac 22 -0.03 
Non-depressed: 68 PHQ event, no limitation 
Miller et al.34 ACS 65 61 62 BDI � 3 months 67 0.56 
HRSD 
Shimbo et al.35 ACS 100 - 51 BDI 1 week 45 0.70 
Carney et al.36 CHD 44 Depressed: 56 59 BDI 3 months post Ml 55 0.28 
Non-depressed: 62 
Kronish et al.37 ACS 105 Depressed: 59 55 BDI 1 week 45 -0.049 
Non-depressed: 60 
Von Kanel et al.38 Ml 44 Depressed: 59 80 HADS 4.5 months 23 0.02 
Non-depressed: 57 
Janszky et al.39 CHD 156 0 BDI 17 months 0.16 
Sch ins et al.43 Ml 103 Depressed: 57 87 BDI 3-12 months post Ml 55 0.13 
Non-depressed: 56 
Ban kier et al.44 CHD 72 Depressed: 67 78 SCID 0.49 
Non-depressed: 68 
Frasure-Smith ACS 682 Depressed:58 81 BDI 2 months 28 0.19 
et al.45 Non-depressed:60 
McGlory,G.46 ACS 43 57 0 BDI At admission 49 -0.41 
Pooled Cohen's d 0.30 
CHD = Coronary Heart Disease; ACS = Acute Coronary Syndrome; Ml = Myocardial Infarction; CDIS-IV = Computerized 
Diagnostic Interview Schedule; PHQ = Patient Health Questionnaire; BDI = Beck Depression Inventory; HRSD = 
Hamilton Rating Scale for Depression; SCID = Structured Clinical Interview for DSM. 
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Figure 2: Forest plot on CRP included papers 
I 
Study Year Cohen's d SE 
--
McGlory46 2009 -0.41 3.17 I 
Kronish et al.37 2010 -0.05 4.25 
Von Kane! et al.38 2010 0.02 0.29 
Whooley et al.28 2007 0.03 0.27 
Schins et al.43 2005 0.13 0.76 
--
Janszky et al.39 2005 0.16 0.15 -f-a-
Frasure-Smith et al .45 2009 0.19 0.21 -i----
Carney et al.36 2007 0.28 0.79 --
Bankier et al .45 2009 0.49 1.66 
Miller et al.34 2005 0.56 0.27 = 
Shimbo et al.35 2006 0.72 0.23 -
Cui et al.27 2006 0.82 0.36 -
Pooled : 0.30 
---; 
-2 -1 0 1 ? 
Cohen's d 
Data-analyses were conducted using a random effects model and showed a pooled Cohen's 
d of 0.30 {95%Cl=0.13-0.46, p<0.00l){ Figure 2). In order to evaluate potential publication 
bias, the dissemination bias was calculated. The fail safe N was relatively high1 and a 
trim-and-fill plot revealed a fill of 1 study2. The Egger regression test was non-significant 
{p=0.79). All these results suggest that there is no publication bias. A fixed effect model 
showed similar results; Cohen's d=0.30 {95%Cl=0.13-0.46, p<0.001). Heterogeneity tests 
revealed no heterogeneity3 • Because the depression and inflammation measurements in 
the studies by Whooley and colleagues 28 and Janszky and colleagues 39 were administered 
a considerable amount of time after the cardiac event took place, we performed sensitivity 
analyses without their data. A random effects model showed that Cohen's d increased to 
0.42 {95%Cl=0.20-0.64, p<0.001). Fixed effect model analyses showed comparable results 
{Cohen's d=0.41; 95%Cl=0.19-0.64, p<0.001). 
1 16 unpublished studies would be needed to lower the p-value to a non-significant level. This is relatively high as 
it equals the number of studies included in the present analyses, suggesting that the effect size presented in this 
meta-analysis is a good reflection of the true effect size. 
2 This did not decrease the effect size (Cohen's d=0.30, 95%Cl=0.13-0.46). 
3 (Q=9.54, p =0.57 and 12=0%) 
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/L-6 and depressive symptoms 
A total of nine articles were included for analyses on depression and IL-6 26-28,34,36,38,39.43,45• 
These studies described data on 2,080 participants with either Ml or stable or acute CHD. 
Two articles did not report on number of depressed participants 26•39, and one article 27 did 
not explain the characteristics of the participants excluded from analysis. As the authors 
could not provide this information upon request, so for those we were not able to report 
on total numbers of depressed participants and sex. Depression and inflammation level 
measurements took place varying from 2 weeks after the cardiac event up until anywhere 
in the participants' adult life after a cardiac event (Table 2). One study assessed depression 
at baseline and seven months post discharge of the hospital 26• In order to increase 
comparability with the remaining studies we used baseline data for the analyses. 
Table 2: Overview of studies investigating the association between IL-6 and depression in patients 
with stable and acute coronary ischemia 
Study Patients n Mean age (yr.) Male Instrument Depression assessment depression Cohen's 
(%) post event (%) d 
Hekler et al.26 Ml so 56.8 78 CES-D � 9 days -0.25 
Cui et al.27 Ml 31 56 BDI 2-11 months post Ml 32 0.03 
Whooley et al.28 CHD 984 Depressed: 62 81 CDIS-IV > 6 months post cardiac 22 -0.03 
Non-depressed :68 PHQ event, no limitation 
Miller et al.34 ACS 65 61 62 BDI � 3 months 67 0.10 
HRSD 
Carney et al.36 CHD 44 Depressed: 56 59 BDI 3 months post Ml 55 0.06 
Non-depressed: 62 
Von Kanel et al.38 Ml 44 Depressed: 59 80 HADS 4.5 months 23 0.11 
Non-depressed: 57 
Janszky et al.39 CHD 157 - 0 BDI 17 months 0.18 
Schins et al.43 Ml 103 Depressed: 57 87 BDI 3-12 months post Ml 55 0.11 
Non-depressed: 56 
Frasure-Smith ACS 682 Depressed:58 81 BDI 2 months 28 0.15 
et al.45 Non-depressed:60 
Pooled Cohen's d 0.004 
CHD = Coronary Heart Disease; ACS = Acute Coronary Syndrome; Ml = Myocardial Infarction; CDIS-IV = Computerized 
D iagnostic Interview Schedule; PHQ = Patient Health Questionnaire; BD I  = Beck Depression Inventory; HRSD = 
Hamilton Rating Scale for Depression; SCID = Structured Clinical Interview for DSM; CES-D = The Center for 
Epidemiologic Studies - Depression. 
Six studies used the BDI to evaluate depressive symptoms 27•34•36•39•44.45, two of them applying 
a cut-off score of 14 27•45, and one using a cut-off score of 10 43• One study used the continuous 
total BDI score. One study provided us with additional data on BDI and IL-6 using a cut-off 
of 10 36• Another study used a combination of the BDI and the 17-HRSD to divide patients 
into three groups 34• One study used the validated German version of the HADS, and divided 
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participants into 'no depression' (score range 0-7), 'mild depression' (score range 8-10), 
'moderate depression' (score range 11-14), and 'severe depression' (score range 15-21) 38• 
For more information on how we used the data from Miller and colleagues, and Von Kanel 
and colleagues for analyses, see the section on CRP. Furthermore, two studies used either 
the CES-D or the CDIS-IV 28 to assess depression (Table 2). A forest plot is provided in Figure 3. 
Figure 3: Forest plot for IL-6 included papers 
Study Year Cohen's d SE 
Hekler et a l .26 
--
2007 -0.25 0.29 
Whooley et a l .28 2007 -0.15 0.16 
Von Kanel et a l .38 2010 -0. 1 1  0.24 
Cui et a l .27 2006 -0.03 14.77 
Carney et a l .36 2007 0.06 3.18 
Mil ler et a l .34 2005 0.11 0.25 
Schins et al .43 2005 0.11 0.42 
Frasure-Smith et a l .45 2009 0.15 0.14 
J anszky et al .  39 2005 0.18 0 .15 
Pooled : 0.04 -
-2 -1 0 1 2 
Cohen's d 
None of the studies reported a significantly positive association between depression and 
IL-6. One study reported a significantly negative association between IL-6 and depression 
28
, and another study found a non-significant negative association 26• Five studies found 
no association at all 27,34,39.43.45_ Two studies 36•38 did not report on the association between 
depressive symptoms and IL-6, but the authors provided us with additional data upon 
request, so we were able to calculate Cohen's d for these studies. Cohen's d was calculated 
for each study separately (Figure 3) and then merged into a pooled effect size. A random 
effects model revealed an overall effect size of 0.04 (95%Cl=-0.11-0.18, p=0.59). To analyze 
a potential publication bias, a trim-and-fill plot was used. This did not lead to a major 
difference in effect size, and the association remained non-significant (Cohen's d=0.06, 
95%Cl=-0.08-0.19). The fail-safe N test was low, but the effect size for depressive symptoms 
and IL-6 already was non-significant4 • Similar results were obtained using a fixed effect 
model (Cohen's d=0.04; 95%Cl=-0.11-0.18, p=0.59). 
4 The fail-safe-N test indicates how many unpubl ished non-sign ificant studies are needed to lower the pooled 
effect size to non-significant {37). 
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With respect to IL-6, we performed sensitivity analyses without the data from studies in 
which depression and inflammation status was assessed a relatively long time after a cardiac 
event 28•39• The effect size did not change and remained non-significant (Cohen's d=0.05; 
95%Cl=-0.14-0.24, p=0.61}. 
Discussion 
This meta-analysis revealed that depression and CRP are significantly associated in patients 
with stable or acute coronary heart disease, with a moderate effect size of 0.30. IL-6 was 
not associated with depression. Sensitivity analyses showed that the association between 
depression and CRP were stronger when CRP and depression were measured more closely 
after the cardiac event (Cohen's d=0.42 vs. Cohen's d=0.30}. 
The finding that CRP was associated with depressive symptoms, whereas IL-6 was not could 
be explained by the differences in their physiological nature. Levels of CRP are upregulated 
in the presence of IL-6, but also TNF-a and white blood cells. It could therefore be that CRP 
is a more stable marker of inflammation than IL-6. 
Our results are partly in contrast with those found in a recent meta-analysis on depression 
and inflammation conducted by Howren and colleagues 29• In their meta-analysis, the 
association between depression and inflammation, i.e. CRP, IL-1 and IL-6 was evaluated 
in different samples i.e. clinical samples (amongst others coronary artery disease [CAD]­
related diseases} and community samples. Their reported overall effect sizes for the link 
between depression with CRP and IL-6 among patients with CHO-related diseases were 
rather small but statistically significant, 0.18 (p = 0.02} and 0.10 (p = 0.05} respectively. We 
did not find a significant association between depression and IL-6. In concordance with our 
present findings, Howren and colleagues found stronger associations between depression 
and CRP than with IL-6. Still, their results differ from our current results, for which multiple 
explanations are suitable. First, Howren and colleagues included CAD related papers, also 
encompassing heart failure 30-32A7A5 and atherosclerosis 33• We excluded these studies 
because heart failure is a more advanced stage than CHO, often a consequence of Ml, with a 
different underlying pathophysiology. Similarly, adding patients with atherosclerosis makes 
the overall results for persons with clinically overt CHO debatable. Atherosclerosis is an 
inflammatory process and mainly involved in the aetiology of CHO. However, it does not 
always lead to CHD and is less severe than CHD. We identified 6 corresponding studies for 
both CRP and IL-6 26•28•34•35•39•43 and we additionally included five papers that were published 
after January 2008 (when Howren and colleagues finished their search} 37•38•44•46 of which one 
was duplicate data 45 of a study 49 included by Howren and colleagues. Finally, we included 
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one non-English paper27 and one paper of which the authors for additional information upon 
our request 36• Both studies were not identified by Howren and colleagues 29• By excluding 
papers on heart failure and atherosclerosis, and including 6 more papers concerning CHD, we 
believe that the results found in the present study are more representative of CHD patients 
in specific. The fact that Howren and colleagues found less pronounced associations for 
hsCRP may be due to the fact that they included a wider range of both less severe and more 
severe cardiovascular pathology in which the role of inflammation may also be different. 
There is a variety of evidence and hypotheses explaining the association between pro­
inflammatory markers and depression in heart disease. First, there may be a common genetic 
factor affecting both inflammation and depression, as was found for depressive symptoms 
and IL-6, suggesting that depressive symptoms and inflammation may be markers of the 
expression of a common, genetically modulated pathway 50• 
A second explanation could be that inflammation induces sickness behaviour, which is 
closely related to or may induce symptoms of depression. It has previously been found that 
pro-inflammatory cytokines are able to cause depressive disorder 18• A possible biological 
explanation for th is is immune-to-brain communication, in which pro-inflammatory cytokines 
affect the brain causing feelings of depression 18• Other sources of evidence for this theory 
come from immunotherapy in cancer patients whom IFN-a therapy was associated with the 
development of neurovegetative symptoms of depression such as fatigue, abnormal sleep, 
abnormal appetite and psychomotor retardation. In a subgroup of patients, immunotherapy 
induced emotional/affective symptoms or cognitive symptoms of depression 51•52• Treating 
these cancer patients with an anti-depressant (paroxetine) relieved cognitive symptoms, 
pain and disturbed mood, while neurovegetative symptoms remained present 51• In patients 
with heart disease, such a distinction is rarely made. Elovainio and colleagues found in a large 
representative cohort that somatic and affective symptoms of the BDI were both associated 
with CRP in men and women. In men, somatic symptoms of depression and CRP remained 
associated after adjustment for demographics, health behaviors and cardiac risk factors but, 
in women, the association was not robust for full adjustment. Moreover, previous studies 
reported that somatic symptoms were more predictive than cognitive symptoms of new 
cardiac events 53•54, and associated with disease severity and all-cause mortality 55 in patients 
with cardiac disease. This could first of all explain the inconclusive results found in this area 
of research, but also how somatic symptoms can contribute to worse cardiac prognosis. 
Therefore, we emphasize that in future research on the association between depression 
and inflammation a distinction should be made between the different types of symptoms 
of depression. 
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In contrast to the sickness behaviour theory, there is some preliminary evidence suggesting 
that it is not inflammation causing depressive symptoms, but depressive symptoms 
causing inflammation 56•57• Stewart and colleagues found that in an otherwise healthy 
sample, depression was prospectively associated with IL-6, but not vice versa 57• Another 
prospective cohort study found that significant depressive symptoms were associated with 
subsequent levels of CRP and IL-6 after 5 years of follow-up, whereas again, CRP and IL-6 
were not prospectively associated with significant depressive symptoms. In addition to this, 
it appeared that subsequent levels of inflammation were highest in the participants who 
reported depressive symptoms at two or more time points, suggesting that particularly 
recurrent chronic depressive symptoms are associated with inflammation 56• Furthermore, 
the prospective association between depressive symptoms and inflammation was mainly 
explained by health behaviors, e.g., smoking, physical inactivity, and obesity. Taken together, 
this suggests that future research should not only be prospective, but should also evaluate 
whether a depression is chronic, recurrent or experienced during a single episode. Finally, 
it would be informative to adjust the association between inflammation and depression for 
the confounding or mediating effects of health behaviors. 
Study limitations 
In this meta-analysis we only reviewed articles using cross-sectional data. There is hardly any 
longitudinal data on the association between depression and pro-inflammatory cytokines, 
though this is necessary to be able to investigate causality in this association. 
Conclusion 
We conclude that in patients with CHD, CRP appears to be moderately associated with 
depression, whereas IL-6 does not. CRP is an end product of an inflammatory sequence, 
produced in the presence of IL-6, but also in the presence of for instance TNF-a. CRP could 
therefore be a more general and stable reflection of different pro- and anti-inflammatory 
processes. This could explain why depression was associated with CRP, but not with IL-6. We 
emphasize that in future research more attention needs to be given to the relation between 
individual symptoms of depression and inflammation. In addition, prospective research 
needs to be conducted to investigate causality in the association between depression and 
inflammation. 
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Abstract 
Objective: Meta-analysis of over 25 years of research into the relationship between post 
myocardial infarction (Ml) depression and cardiac prognosis, to investigate changes in this 
association over time, and to investigate subgroup effects. 
Method: A systematic literature search was performed (Medline, Embase and PsyclNFO; 
1975-2011) without language restrictions. Studies investigating the impact of post-Ml 
depression on cardiovascular outcome, defined as all-cause mortality, cardiac mortality, and 
cardiac events within 24 months after the index Ml were identified. Depression had to be 
assessed within 3 months after Ml using established instruments. Pooled odds ratios were 
calculated using a random effects model. 
Results: A total of 29 studies were identified, resulting in 41 comparisons. Follow-up (on 
average 16 months) was described for 16,889 Ml patients. Post-Ml depression was associated 
with an increased risk of all-cause mortality (OR 2.25; 95% Cl 1.73-2.93, p<0.001), cardiac 
mortality (OR 2.71; 95% Cl 1.68-4.36, p<0.001), and cardiac events (OR 1.59; 95% Cl 1.37-
1.85, p<0.001). Odds ratios proved robust in subgroup analyses but declined over the years 
for cardiac events. 
Conclusions: Post-Ml depression is associated with a 1.6 to 2. 7-fold increased risk of 
impaired outcomes within 24 months. This association has been relatively stable over the 
past 25 years. 
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Introduction 
Beginning in the 1980's, reports accumulated that psychosocial stress and depression 
following myocardial infarction were linked to prognosis i-s . The increasing number of 
studies showing links between post-Ml depression and prognosis suggested that identifying 
and treating depression in Ml patients could contribute to improving survival rates and 
overall prognosis. 
In the 25 years since these first investigations, much research has been done in this field, 
which has been summarized in several meta-analyses 6-8• This research showed depressed 
cardiac patients have an increased risk of both fatal and non-fatal events (including patients 
with depressive disorder and patients with elevated symptoms of depression based on self­
report questionnaires) compared to those without depression. Barth et al. performed a 
meta-analysis on 29 papers concerning patients with coronary heart disease, most of which 
were Ml patients. They found that depression in Ml patients was associated with a 2.0 to 
2.6 times higher risk of mortality 6• Similarly, in a meta-analysis of 22 papers, Van Melle 
et al. found an increased risk of 2.0 to 2.5 of poor cardiac or mortality outcomes within 2 
years after an Ml in patients with depression compared to non-depressed patients 8• The 
most recent meta-analysis by Nicholson et al., reviewed studies published up to 2004 and 
reported that depressed post-Ml patients had a 2.1 times higher risk of mortality than non­
depressed patients 7• So in summary, previous meta-analyses demonstrated depressed post­
Ml patients have a 2.0 to 2.6 times increased risk of adverse outcomes compared to non­
depressed post-Ml patients. 
A fair number of important studies on post-Ml depression and (cardiac) prognosis have 
been published in the 7 years since previous literature searches. In addition, none of the 
existing meta-analyses have statistically investigated whether the association of depression 
with mortality or cardiac events changes over time, as has been suggested earlier 8• 9• This is 
an important question, as new insights in study design and statistical methodology as well 
as advances in the treatment and prevention of Ml in recent years can affect the nature and 
strength of the association between post-Ml depression and prognosis. 
Therefore the main objective of this study was to perform a new meta-analysis to 
summarize the association between post-Ml depression and prognosis, defined as all-cause 
mortality, cardiac mortality, and cardiac events that occurred within 24 months after the 
index Ml . A secondary goal was to investigate whether the strength of the relationship 
between depression and cardiac outcomes has changed over the years, and whether or 
not methodological factors influence this relationship the degree to which depression is 





A literature search was performed on January 5th, 2011 to identify prognostic studies that 
investigated the association between post-Ml depression and cardiac prognosis published 
since our previous literature search in January 2004 8• The combined search results included 
literature published since 1975. Relevant articles were selected from the electronic databases 
Medline (Pubmed), Embase and PsyclNFO without language restrictions. For this purpose, 
search terms related to depression and myocardial infarction were used and customized to 
the search strategies of each database. In addition to the database searches, major reviews 
and relevant articles were cross-referenced. When necessary additional information was 
requested from authors by e-mail. 
Study selection 
Inclusion and exclusion criteria 
Studies that met the following criteria were eligible for inclusion: patients were hospitalized 
for Ml; a validated depression rating scale or structured diagnostic interview was used; 
depression was measured within three months after the Ml; studies were prospective, 
reporting on (cardiovascular) prognosis in depressed vs. non-depressed patients; study 
outcome was all-cause mortality, cardiac mortality or cardiac events; and the end point was 
within 24 months after the index Ml. For the end point cardiac events, studies were included 
that reported on cardiac death, cardiac arrest, recurrent Ml, cardiac rehospitalization, or a 
combination of the above. Depression was defined as either depressive disorder or elevated 
symptoms of depression. 
Selection of studies identified by the literature search was done by three independent raters 
(J.v.M., P.d.J., and A.M.) in two phases. First, a title abstract review was performed, in which 
studies were excluded that clearly did not meet inclusion criteria. Second, full texts were 
retrieved and reviewed for the articles that were selected as potentially eligible for inclusion 
in the title-abstract review. In the review process, reviews, meta-analyses, comments, letters, 
editorials, case reports, and design reports of studies as well as studies that did not include 
depression as a mood state (but for example ST-segment depression) were excluded. 
Only studies on data of Ml patients were included to create a relatively homogeneous group 
of subjects. Furthermore, the endpoint was chosen to be within two years after Ml, as we 
were interested in relatively short-term effects of post-Ml depression on prognosis. Most 
mortality and new events after Ml occur within the first few months, so it was expected 
that any association with post-Ml depression would be evident by 2 years. By using a 2-year 
follow-up period, relevant studies with varying follow-up durations could best be compared. 
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If studies reported outcomes later than two years after the index Ml, authors were contacted 
to request data on 2-year outcomes. 
When multiple articles were based on the same dataset, those with the best methodological 
quality or those that were most informative were selected (i.e. more subjects, longer follow­
up, etc.). However, when multiple articles were based on the same subjects, but reported 
on different, not overlapping outcomes, they were all included. 
When studies included Ml patients as a subgroup of acute coronary syndrome (ACS) and 
it was recorded whether patients had unstable angina or Ml, the authors were asked for 
depression and outcome data for Ml patients only. 
Quality assessment 
Reporting the quality of studies included in meta-analyses is recommended by experts 10, 
as the quality of the results of a meta-analysis largely depends on the quality of included 
studies. In addition, quality assessment may be helpful in deciding which variables measured 
in the studies of the meta-analysis could be used in subgroup or sensitivity analyses. 
Therefore included articles were assessed according to the following six methodological 
quality criteria: (1) sample size of each group (preferably at least 25 patients per group); 
(2) representativeness of the population (i.e. whether the sample had any specific inclusion 
or exclusion criteria such as those based on age or gender); (3) whether there was more 
than 25% loss to follow-up; (4) whether studies controlled for at least 3 of the following: 
hypertension, smoking, hypercholesterolemia, diabetes mellitus, LVEF, or previous Ml; (5) 
whether clinical endpoints were scored adequately, i.e. by means of central death registry, 
chart review or independent blinded endpoint committee; and (6) whether depression was 
measured using a structured diagnostic interview or a self-report instrument. 
Data analysis 
Data analyses for the summary estimate of the odds ratios were performed separately for 
three outcomes: all-cause mortality, cardiac mortality, and cardiac events. First, data from the 
included studies were pooled. Reported results were converted into raw data (2 x 2 tables) 
and dichotomized outcomes. Then, pooled odds ratios and 95% confidence intervals were 
calculated using MIX 1.7, a statistical package designed for performing meta-analyses 11, 
using a random effects model 12 • When studies reported both clinically diagnosed major 
depressive disorder and depressive symptoms, data on major depressive disorder were 
included. To test between-study variance, heterogeneity tests were performed using the Q 
and 12 statistics. Possible publication bias was investigated using funnel plots and Egger tests. 
Second, to investigate whether the association between post-Ml depression and cardiac 
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prognosis changed over time, individual, unadjusted odds ratios were used and changes over 
time were investigated using STATA 11 (Statacorp LP, TX, USA). Different meta-regression 
models were applied to investigate whether there was any trend in the odds ratios over time. 
Null, linear, quadratic, and cubic models were applied and best-fitting models were selected 
using the Schwarz Bayesian Information Criterion. The year of start of data collection (study 
start) was used as independent variable instead of year of publication, as there may be a 
considerable time lag between the period a study is performed and the time it is published. 
Analyses were weighted for the number of subjects in each study, in such a way that larger 
studies contributed more to the pooled odds ratio than smaller studies. 
Third, subgroup analyses were performed in MIX 1.7 for two methodological differences 
between studies: type of depression instrument (structured diagnostic interview vs self­
rating) and number of subjects per study (dichotomized smaller N vs. larger N). For each 
outcome, studies were divided into subgroups and separate odds ratios were calculated. 
Odds ratios were then compared with a chi-square-test. 
Results 
literature search and selection 
The literature search resulted in 6,095 unique titles/abstracts. Cross-referencing and 
personal contacts resulted in an additional 48 potentially eligible articles. After the review 
and selection process, 31 articles reporting on 29 studies were selected and included, 
reporting on 16,889 patients (5,353 depressed and 11,536 non-depressed) and representing 
41 different analyses. Most of the ineligible articles were excluded because they were not 
based on original data, such as reviews, case-reports, an editorials; because they did not 
select subjects based on the presence of Ml; or because they did not include depression as 
an emotional state or as a risk factor for poor prognosis. lnterrater reliability between the 
two sets of reviewers (J.v.M.-P.d.J. and P.d.J.-A.M.) was calculated for the full text review 
(Cohen's Kappa = 0.80 and 0.86 respectively). Figure 1 is a flow-chart of the search results. 
Ten authors were contacted to request additional information. Requests were made for 
outcome data at 24 months post-Ml, data for depressed patients only, instead of patients 
with depression or anxiety, duration of follow-up, exact number of events in depressed vs. 
no-depressed groups, data on Ml patients only instead of ACS patients, timing of depression 
measurement after the Ml, year in which the study started, loss to follow-up, and which 
depression rating instrument was used. Seven authors provided the requested information. 
Three authors could not answer, or did not respond to the request, which in these cases 
meant their studies could not be included in the meta-analysis. 
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Figure 1: Flow-chart of literature search 
Literature search Pubmed, Cross-referencing 
Embase, PsyclNFO 48 unique titles 
6095 unique titles 
I 
'' 




No original data or case report, no myocardial infarction 
at baseline, no depression as an emotional state or no 
non-depressed control group, reported outcome is not 
all-cause mortality, cardiovascular mortality or 
, cardiovascular events, depression not assessed within 
Full text review: three months after index Ml 
306 -




Duplicates, no original data or case report, no myocardial 
Inclusion: infarction at baseline, no depression as an emotional 
31 state or no non-depressed control group, depression not 
assessed within three months after index Ml, no validated 
depression measurement instrument 
, l l 
Analyses on all-cause Analyses on cardiac Analyses on cardiac 
mortality: mortality: events: 
17 6 18 
Main study characteristics 
In Table 1, the main study characteristics of included articles are summarized. Collectively, 
the combined samples included 16,889 patients. Mean patient age at the time of the index 
Ml was 61 years (range 54 to 65 years). Twenty-six percent of patients were women and 
mean follow-up time was 16 months, ranging from 1 week to 24 months. The proportion of 
patients with major depression or patients scoring above the cut-off of self-rating instruments 
ranged from 5 to 69% (average 28%). This proportion was relatively high in some studies, as 
they purposefully included more depressed patients. The average percentage of all-cause 
mortality was 9% (range 2 to 21%), of cardiac mortality 5% (0.5 to 10%), and of cardiac 
events 21% (range 5 to 47%). 
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Table 1 (continued) 
1st author Vear of N Mean age % female Instrument Cut-off Time post % depr. Outcome FU time Lost to Start data publication Ml (days) (months) FU (%) collection 
Rafanelli31 2003 61 61 17 modified na 30 11 CE 24 0 1995 
SCI / DCPR / 
Psychosocial 
Index 
Rumsfeld32 2005 634 65 28 MOS-D MOS-D � 3-14 23 ACM/CE 24 na 1999 
0.06 
Shiotani33 2002 1042 63 20 Zung SOS Zung SOS 63 42 CM/CE 12 1 1998 
� 40 
Silverstone3 1987 108 63 25 MADRS MADRS 1 44 ACM/CE 0,25 na 1984 
� 14 
Smolderen34 2009 2347 61 32 PHQ-9 PHQ � 10 1-3 22 ACM/CE 24 2 2003 
S0rensen35 2006 761 59 24 MDI MDI na ±7 10 ACM/CE 12 na 1999 
Steeds36 2004 131 60 33 BDl- 1 1  BD l- 1 1  � 12 ±7 47 ACM 24 na 1999 
Strik37 2003 206 59 24 SCIO na 30 31 ACM/CE 6 0 1997 




Thombs39 2008 416 61 25 BDI  BD I  � 10 2-5 29 ACM 12 0 1997 
ro 




ACM = all-cause mortality; BDI = Beck Depression Inventory; B01-FS = Beck Depression Inventory Fast Scale; CE = cardiac events; CIDI = Composite International 
:J 
OJ 
Diagnostic I nterview; CM = cardiac mortality; DIS = Diagnostic I nterview Schedule; DISH = Depression Interview and Structured Hamilton; HADS-D = Hospital Anxiety 
:J 
and Depression Scale - Depression; KSb-S = Klinische Selbstbeurteilungsskalen aus dem Munchner psychiatrische Informations-System; MADRS = Montgomery-
Asberg Depression Rating Scale; MDI = Major Depression Inventory; MOS-D = Medical Outcomes Study - Depression; na = not available; PHQ = Patient Health cm I-' :J 




Figure 2a: Forest plot al l-cause mortality 
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Doyle (16) 2003 8175 9/358 
Parashar(30) 2003 14/499 28/1382 
Smolderen (34) 2003 861524 17911823 
L'�-"" 38413053 48717309 0,01 0,1 OR (log scale) 
























with 95% Cl 
1 1 ,80 (1,42 lo 98,03) 
1,97 (0,94 to4,14) 
3,96 (1,50 to 10,45) 
2,22 (0, 70 to 6,99) 
0,97 (0,50 to 1,87) 
2,13 (1,02 to4,48) 
1,67 (0,77 to 3,59) 
0,56 (0,06 to 5, 1 1 )  
5,52 (3,02 to  10 ,  10) 
2,05 (0,90 to 4,67) 
1,84 (1 ,1 9 to 2,82) 
3, 15 (1,21 to 8, 16) 
7,28 (0,85 to 62,31) 
6,83 (0,87 to 53, 15) 
4,63 (1,72 to 12,43) 
1,39 (0,72 to 2,67) 
1,80 (1,36 to 2,38) 
2,25 (1, 73 to 2,92) 
_J 
Seventeen studies, consisting of 10,362 patients, reported on all-cause mortality. A total 
of 892 patients died within two years after the index Ml. The pooled odds ratio of all­
cause mortality after Ml in 3,053 depressed patients compared to 7,309 non-depressed 
patients was 2.25 (95% Cl = 1.73-2.93, p<0.001} (Figure 2a}. The studies were statistically 
heterogeneous (Q=30.15, p=0.02; 1 2= 46.93% (95% Cl=6.62-69.84}}. 
Figure 2b: Forest plot cardiac mortality 
Depressed Non-depressed 
First author Year n event/n total n evant/n total 
Ladwig (2) 1983 6/80 61473 
Wolin (40) 1985 9/98 5/169 
Irvine (21) 1990 12198 121203 
Frasure-Smith (19) 1991 221290 151606 
Lane (23) 1997 9/87 18/197 
Shlotanl (33) 1998 4/438 1/604 







OR (log scale) 
100 
Weight Association measure 
(%) wlth 95% CI 
13,16% 6,31 (1,98 lo 20,08) 
13,79% 3,31 (1,07 lo 10,19) 
20,83% 2,22 (0,95 lo 5, 14) 
27,14% 3,23 (1,65 to 6,33) 
20,72% 1 ,14 (0,49 to 2,66) 
4,37% 5,55 (0,61 to 49,89) 
100% 2,70 (1,68 to 4,36) 
Cardiac mortality was reported in six studies, consisting of 3,343 patients. A total of 119 
patients died of cardiac causes within two years after the index Ml. The pooled odds ratio 
of cardiac mortality after Ml in 1,091 depressed patients compared to 2,252 non-depressed 
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patients was 2.71 {95% Cl=l.68-4.36, p<0.001) {Figure 2b). The six studies were relatively 
homogeneous {Q=7.06, p=0.22; 12=29.14 {95% Cl=0.00-70.97)). 
Cardiac events {fatal and non-fatal) were reported in eighteen studies, consisting of 10,119 
patients. A total of 2,247 patients had another cardiac event within two years after the index 
Ml. The pooled odds ratio of cardiac mortality after Ml in 2,946 depressed patients compared 
to 7,173 non-depressed patients was 1.59 {95% Cl=l.37-1.85, p<0.001) {Figure 2c). The 
eighteen studies were statistically homogeneous {Q=24.S, p=0.11; 12= 30.64 {95% Cl=0-60.8)). 
Figure 2c: Forest plot cardiac events 
Depressed Non-depressed Waight Association measure 
First author Year n evanUn total n ovenUn total (%) wlth 95¾CI 
Ahem (1)  1983 16/139 1 1/212 I� 3,1 1 %  2,37 (1,06 to 5,28) 
Ladwig (2) 1983 1 1/80 18/473 
�-
3,17% 4,02 (1,82 to 8,89) 
SIiverstone (3) 1984 14/48 2/60 0,93% 1 1 ,94 (2,55 to 55,75) 
Frasure-Smith (20) 1991 13/34 35/184 
--
3,22% 2,63 (1,20 to 5,76) 
Rafanelli (31) 1995 1(7 6/54 0,43% 1,33 (0,13 to 13,04) 
Sydeman (38) 1996 2/4 18/97 0,55% 4,38 (0,57 to 33,27) 
Lauzon (25) 1996 106/191 153/359 --+- 10,23% 1,67 ( 1 , 1 7 102,39) 
Strik (37) 1997 1/63 9/143 0,52% 0,24 (0,02 to 1,93) 
De Jonge (14) 1997 34/119 75/349 ! f+- 7,12% 1.46 (0,91 to 2,34) 
Lane (24) 1997 24/81 58/191 _.,_ 5,45% 0,96 (0,54 to 1,70) 
Shlotanl (33) 1998 138/438 145/604 -- 13,12% 1,45 (1,10 to 1 ,9 1 )  
Rumsfeld (32) 1999 60/143 162/491 ,..... 9,37% 1,46 (1,00 10 2,15) 
Sorensen (35) 1999 12/73 75/688 r-*- 4,26% 1,60 (0,82 to 3, 12) 
Drago (18) 1999 2/14 12/84 0,85% 1 ,00 (0, 1 9  to 5,03) 
Nakatanl (28) 1999 320/860 274/943 . 16,58% 1,44 ( 1 , 1 8  to 1,76) 
Denollet (15) 2003 131100 20/31 6  �- 3,57% 2,21 (1,05 l04,62) 
Smolderen (34) 2003 102/474 267/1718 
f 
13,96% 1.49 (1 , 1 5 to 1,92) 
Doyle (17) 2006 12/78 26/207 3,56% 1,26 (0,60 to 2,65) 
META-ANALYSIS: 881/2946 1366(7173 100% 1,59 (1,36 to 1,85) 
I 
0,01 0,1 1 1 0  100 
OR (log scale) 
For the three meta-analyses, funnel plots and Egger tests showed no evidence of publication 
bias. Table 2 summarizes the three meta-analyses, including the heterogeneity and 
publication bias tests. Funnel plots are shown in Figures 3a-3c. 
Table 2: Results meta-analyses and heterogeneity 
Outcome Pooled OR 95 % CI 12 (95 % Cl) 
All-cause mortality 2.25* 1.73-2.93 46.93 {6.62-69.84) 
Cardiac mortality 2.71* 1.68-4.36 29.14 (0-70.97) 
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Eight studies reported associations adjusted for baseline demographic and cardiac disease 
severity variables. These adjusted and unadjusted odds ratios were compared to gain 
insight into the role of cardiac disease severity and other confounding variables in the 
association between post-Ml depression and prognosis. The studies reporting adjusted 
associations were too few and heterogeneous to pool by meta-analysis. Therefore, adjusted 
and unadjusted associations as they were reported in the original articles are simply listed 
in Table 2. Note that associations are not necessarily reported as odds ratios, but also as 
hazard ratios. However, when the frequency of events among subjects is low, which is the 
case with mortality or cardiac events, these numbers are roughly comparable 41•42• In seven 
of the eight studies, adjusted odds ratios were smaller than unadjusted odds ratios. The 
attenuation ranged from 4% to 65%, and was on average 21%. 
Secondary analyses 
Changes in odds ratios over time 
There was no association between the year of study start and the odds ratio for the outcome 
all-cause mortality. Figure 4a shows the odd ratios against time. For the outcome cardiac 
mortality, the number of studies (6) was too small to perform a meta-regression. 
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There was a significant linear association between year of study start and the odds ratio 
for the outcome cardiac events (linear model F{l, 16), p=0.01, R2=0.29, BIC=58.12). This 
means that later studies generally reported lower odds ratios than earlier studies. The linear 
model, however, was only slightly better than the quadratic model {quadratic model F{2, 
15), p=0.02, R2=0.40, BIC=59.17). When the analysis was rerun without an outlier, again to 
assess the robustness of the association, there was a superior model fit for the quadratic 
association {quadratic model { F{2, 14), R2=0.55, p<0.01, BIC=31.49 vs linear model (F{l, 15), 
R2=0.46, p<0.01, BIC=32.37). This means that the decline was somewhat stronger in the 
earlier years and weakened in the later years. Overall, there was a decline in the odds ratio 
of about 0.1 each year {Figure 4b). 
Figure 4a : association between year of study start and odds ratio for all-cause mortality 







1 984 1989 1 994 1 999 2004 
year of study start 
Figure 4b: association between year of study start and odds ratio for cardiac events 
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Differences between structured diagnostic interviews and self-rating instruments 
For the outcome all-cause mortality, six studies {n=2,280) used interview-based instruments 
to assess depression and eleven studies {n=8,082) used self-report instruments. The odds 
ratio for interview-based instruments was 3.69 {95%CI 2.05-6.63; p<0.001), and for self­
report instruments 1.83 {95%CI 1.51-2.23; p<0.001), which was significantly different {chi­
square=2.22, p=0.03). 
All studies reporting on cardiac mortality used self-rating instruments, so no subgroup 
analysis could be performed. 
For the outcome cardiac events, seven studies {n=l,260) used interview-based instruments 
to assess depression and eleven studies {n=8,859) used self-report instruments. The odds 
ratio for interview-based instruments was 1.96 {95%CI 0.99-3.89; p<0.05) and for self-report 
instruments 1.53 {95%CI 1.35-1.73; p<0.001), which was not significantly different {chi­
square=0.70, p=0.48). 
There were no changes in the frequency of use of self-report instruments and interviews 
over time. 
Differences between smaller studies and larger studies 
Studies reporting on all-cause mortality were divided into two subgroups. The subgroup of 
nine studies with each less than 400 subjects contained 2012 patients and the subgroup 
of eight studies with each more than 400 subjects contained 8350 patients. The odds ratio 
for the smaller studies was 2.25 {95% Cl 1.38-3.66) and for the larger studies 2.30 {95% Cl 
1.65-3.20). There was no significant difference between the odds ratios {chi-square=0.07, 
p=0.94). 
For the outcome cardiac mortality, the studies were again divided into two subgroups. The 
subgroup of three studies with each less than 330 subjects contained 852 patients and the 
subgroup of three studies with each more than 330 subjects contained 2,491 patients. The 
odds ratio for the smaller studies was lower than that for the larger studies {1.90 {95%CI 1.06-
3.48, p=0.03) vs 3.92 {95%CI 2.24-6.88, p<0.001)), and this difference was not significant, 
but showed a trend {chi-square=l.76, p=0.08). 
Finally, studies reporting on cardiac events were divided into two equal subgroups with 
nine studies. The subgroup of nine studies with each less than 400 subjects contained 1,700 
patients and the subgroup of nine studies with each more than 400 subjects contained 8,419 
patients. The odds ratio for the smaller studies was higher than that for the larger studies 
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(1.74 (95%CI 1.01-2.98, p=0.04) vs 1.53 (95%CI 1.37-1.71, p<0.001)). The difference was not 
significant (chi-square=0.45, p=0.65). Finally, for all three outcome types, there were no 
changes of study size over time. 
Quality assessment 
Studies were evaluated on six quality aspects. First, the preferred sample size was at least 
25 patients in the depressed and in the non-depressed groups. In all studies, the number 
of non-depressed patients was over 25 (average n=400, range 54-1823). The number of 
depressed patients was lower than 25 in three studies (average n=175, range 4-920). Second, 
studies were assessed on representativeness of the population. The majority of studies (22) 
did not have any unusual inclusion or exclusion criteria. Exclusion criteria such as those 
based on the presence of dementia, the presence of other major psychiatric disorders, and 
being unable to speak the researchers' language were not considered unusual. Third it was 
assessed whether there was more than 25% loss to follow-up. Thirteen studies did not have 
any loss to follow-up. In the remaining studies, loss to follow-up was on average 5% (range 
0.2-17%), and none reported loss to follow-up over 25%. Six studies did not report the 
number of patients lost to follow-up. Fourth, it was assessed whether studies adjusted for 
at least three of the following cardiac risk factors in their adjusted analyses: hypertension, 
smoking, hypercholesterolemia, diabetes mellitus, LVEF, or previous Ml. Twelve analyses 
were adjusted for at least three of these risk factors, sixteen analyses were not adjusted for 
at least three of these factors, and four analyses were not adjusted or did not report the 
variables they adjusted for. Fifth, it was assessed whether clinical endpoints were scored 
adequately, i.e. by means of central death registry, chart review or independent blinded 
endpoint committee. Three studies did not report how they scored the clinical endpoint, 
and three other studies did not use an adequate method (but patient or family self­
reports only). Finally, it was assessed whether depression was measured using a structured 
diagnostic interview or a self-report instrument. The majority of the studies (20) used self­
rating instruments, six studies used a standardized structured clinical interview, and four 
studies used both. An overview of the quality assessment of the included articles is listed 
in Table 3. 
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Table 3: Quality assessment included studies 
first author sample size representative- percentage factors controlled for clinical endpoints type of depression 
ness of population lost to scored adequately measurement 
follow-up instrument 
Ahern1 351 subjects > 75 years and 1% LVEF, previous Ml, beta-blockers, digitalis, na self-rating 
women with child- anxiety, anger, social desirabil ity, social 
bearing potential support, mood states, type A-B 
excluded 
Carney13 1328 No unusual na ENRICHD all-cause mortality risk score; standardized, group-masked interview 
subjects inclusion or initial BDI score; SSRI use classification of major 
exclusion criteria endpoints, death certificates 
De Jonge14 468 subjects No unusual 0% age, gender, education level, LVEF, patient interviews, hospital interview 
inclusion or revascularization records, data from treating 
exclusion criteria specialist, data from primary 
care physician 
Denollet15 416 subjects age < 30 years 0% age, gender, cardiac h istory, LVEF, invasive medical records self-rating 
excluded treatment, statins, aspirin, diuretics, SSRls, 
BMI 
Doyle16 433 subjects No unusual 0% age, sex primary care physicians self-rating 
inclusion or for vital status, date of 
exclusion criteria death from national births, 
marriages and deaths registry 
Doyle17 285 subjects No unusual 5% age, sex, smok ing, diabetes, history of medical records self-rating 
-u 
inclusion or CHD, history of revascularization, length of 5l 
exclusion criteria hospital stay, LVEF  � 
Drago18 98 subjects No unusual 2% age, gender, diabetes mellitus, dyslipi- medical examination, phone both 
inclusion or daemia, previous AMI, anterior AMI, interview or ambulatory � 
exclusion criteria non-preserved LVEF, acute treatment examination, death 
with thrombolysis or primary coronary certificates diagnosis for fatal a· 
angioplasty and H RV value events 
Frasure- 896 subjects No unusual 0% age, smoking, LVEF, non-Q-wave Ml, Kil l ip patient or family contacts, self-rating "C 
Smith19 inclusion or class Quebec Medicare data, 2 
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F r a s u r e - 2 2 2  s u b j e c t s  N o  u n u s u a l  0 %  a n x i e t y ,  h i s t o r y  o f  m a j o r  d e p r e s s i o n ,  c o n t a c ti n g  p a t i e n t s ,  f a m i l y  b o t h  
S m i t h
2 0  
i n c l u s i o n  o r  
p r e v i o u s  M l ,  L V E F ,  K i l l i p  c l a s s ,  A C E  i n h i b i t o r s  m e m b e r s ,  c o m m i t t e e  o f  
e x c l u s i o n  c r i t e r i a  a t  d i s c h a r g e  c a r d i o l o g i s t s  r e v i e w e d  d e a t h  
c e r t i f i c a t e s ,  a m b u l a n c e  a n d  
h o s p i t a l  r e c o r d s  
l r v i n e
2 1  
3 0 1  s u b j e c t s  N o  u n u s u a l  5 %  p r e v i o u s  M l ,  p r e v i o u s  C H F ,  s o c i a l  b l i n d e d  e x t e r n a l  v a l i d a t i o n  
s e l f - r a t i n g  
i n c l u s i o n  o r  p a r ti c i p a t i o n ,  s o c i a l  n e t w o r k  c o n t a c t s ,  c o m m i t t e e  
e x c l u s i o n  c r i t e r i a  d y s p n e a / f a t i g u e  
K a u f m a n n
2 2  
3 3 1  s u b j e c t s  N o  u n u s u a l  0 %  
e j e c t i o n  f r a c t i o n ,  p r e v i o u s  M l ,  C H F ,  r e c o n t a c t i n g  p a t i e n t s  a t  h o m e  
i n t e r v i e w  
i n c l u s i o n  o r  
C A B G ,  p r e v i o u s  s t r o k e ,  d i a b e t e s ,  a g e ,  
e x c l u s i o n  c r i t e r i a  h y p e r t e n s i o n ,  f a m i l y  h i s t o r y  o f  C A D  
L a d w i g
2  
5 5 3  s u b j e c t s  f e m a l e  p a ti e n t s  0 %  
r e c u r r e n t  M l ,  l a t e  p o t e n t i a l s ,  d y s p n e a ,  
h o m e  p h y s i c i a n ,  h o s p i t a l  s e l f - r a ti n g  
a n d  >  6 6  y e a r s  o c c u r r e n c e  o f  t r i p l e t s  o r  m o r e  c o m p l e x  p h y s i c i a n ,  r e l a t i v e s ,  
e x c l u d e d  a r r h y t h m i a s  i n  2 4  h a l t e r  E C G  b y s t a n d e r s  
L a n e
2 3  
2 8 8  s u b j e c t s  N o  u n u s u a l  6 %  
a g e ,  p a r t n e r  s t a t u s ,  l i v i n g  a l o n e ,  e d u c a t i o n ,  
h o s p i t a l  p a t i e n t  i n f o r m a t i o n  
s e l f - r a t i n g  
i n c l u s i o n  o r  P e e l  i n d e x  s c o r e ,  K i l l i p  c l a s s ,  l e n g t h  o f  s y s t e m  
e x c l u s i o n  c r i t e r i a  h o s p i t a l  s t a y  
L a n e
2 4  
2 8 8  s u b j e c t s  N o  u n u s u a l  1 %  n o t  s t a t e d  h o s p i t a l  a n d  g e n e r a l  p r a c t i c i a n  s e l f - r a t i n g  
i n c l u s i o n  o r  r e c o r d s ,  d e a t h  c e r t i f i c a t e s  
e x c l u s i o n  c r i t e r i a  
L a u z o n
2 5  
5 5 0  s u b j e c t s  N o  u n u s u a l  0 %  a g e ,  s e x ,  p r i o r  M l ,  h i s t o r y  o f  p r e v i o u s  c e n t r a l  d e a t h  r e g i s t r y  
s e l f - r a t i n g  
i n c l u s i o n  o r  a n g i n a ,  a n t e r i o r  l o c a t i o n  o f  i n f a r c t ,  d i a b e t e s  
e x c l u s i o n  c r i t e r i a  m e l l i t u s ,  h y p e r t e n s i o n ,  s m o k i n g  
L e s p e r a n c e
2 6  
2 2 2  s u b j e c t s  N o  u n u s u a l  0 %  h i s t o r y  o f  m a j o r  d e p r e s s i o n ,  B D l > l O ,  a g e  c o n t a c t i n g  p a t i e n t s  o r  f a m i l y  
i n t e r v i e w  
i n c l u s i o n  o r  > 6 5  y e a r s  
m e m b e r s  
e x c l u s i o n  c r i t e r i a  
M a y o u
2
7  
3 4 4  s u b j e c t s  
N o  u n u s u a l  0 %  n a  d e a t h  c e r t i f i c a t e s ,  a u t o p s y  s e l f - r a ti n g  
i n c l u s i o n  o r  r e c o r d s  a n d  O f f i c e  o f  N a t i o n a l  
e x c l u s i o n  c r i t e r i a  S t a t i s t i c s  d a t a  
Table 3 (continued) 
first author sample size representative- percentage factors controlled for clinical endpoints type of depression 
ness of population lost to scored adequately measurement 
follow-up instrument 
Nakatani28 1803 No unusual 0% age, sex, diabetes mellitus, hypertension, research outpatient clinic, self-rating 
subjects inclusion or hyperlipidemia, smoking, history of Kl, verbal or written contact 
exclusion criteria Killip class > or =  I I, anterior infarction, with patients or their family 
reperfusion antiplatelet agents, ace members 
inhibitors, beta-blockers 
Parakh29 284 subjects No unusual 0% age, diabetes, previous Ml, Killip class, Social Security Death Index both 
inclusion or treatment of Ml, LVEF, Q-wave Ml, creatine 
exclusion criteria k inase, renal i nsufficiency, lung disease, 
length of stay, aspirin use, physical function 
(SF-36) 
Parashar30 1881 No unusual 10,60% age, race, sex, medical history (diabetes, contacts with family self-rating 
subjects inclusion or hypertension, COPD, smoking, prior Ml), members, Social Security 
exclusion criteria severity of Ml (ST-segment elevation), LVEF Death Master File, patient 
contacts 
Rafanelli31 61 subjects No unusual 0% age, sex, absolute CV risk (Ml complications, not reported interview 
inclusion or LVEF, residual ischemia, ventricular 
exclusion criteria arrhythmias, smoking, diabetes, 
hypertension, cholesterol, triglycerides, 
fibrinogen, leukocytes, intermittent 
claudication, heart rate 
Rumsfeld32 634 subjects only patients na age, gender, race, BMI, systolic blood all-cause mortality and self-rating 
with heart failure pressure, LVEF, prior heart failure and cardiovascular death or 
included Ml, atrial fibrillation, reperfusion or hospitalization adjudicated "'IJ 
revascularization during hospitalization, by a blinded critical events g 
smoking, hypertension, diabetes mellitus, committee t 
dyslipidemia, COPD, stroke or TIA, renal 
rD 
failure, moderate to heavy alcohol use, ACE/ � 
ARB, beta-blockers, diuretics, aspirin, statins rD 
Shiotani33 1042 No unusual 1% age, diabetes mellitus, hypertension hospital records, telephone self-rating a" 
subjects inclusion or interviews with patients or tll ::::, 
exclusion criteria family Cl. 
'U 
Silverstone3 108 subjects No unusual na none not reported interview 
inclusion or ::::, I-' � 0) exclusion criteria V, vi' 
I-'  
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N a t i o n a l  R e g i s t e r  o f  P a t i e n t s ,  s e l f - r a t i n g  
e x c l u d e d  
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T I A =  t r a n s i e n t  i s c h e m i c  a t t a c k .  
Post-Ml  depression and prognosis 
The effects of the quality criteria on the association between post-Ml depression and 
prognosis for sample size, type of depression measurement instrument, and adjustment for 
confounders were assessed in the secondary analyses. These analyses revealed that sample 
size did not affect the strength of the association reported, that studies using structured 
diagnostic interviews had higher ORs for all-cause mortality than did studies using self­
rating instruments, and that the association between post-Ml depression and prognosis 
was attenuated when adjusted for confounders. The other quality criteria were assessed 
in sensitivity analyses. These analyses revealed no differences in results with regards to 
specific in- or exclusion criteria, loss to follow-up, or end-point scoring method. 
Discussion 
Association between post-Ml depression and prognosis 
Unadjusted odds ratios show that patients with a post-Ml depression have a 2.25 times 
increased risk of all-cause mortality, a 2.71 times increased risk of cardiac mortality, and a 
1.59 times increased risk of new cardiac events . These odds ratios are similar to those found 
in earlier meta-analyses 6•7• 
Individual adjusted associations were lower (on average 21%) than unadjusted associations 
in all but one of the eight studies reporting associations adjusted for baseline demographic 
and medical variables. This attenuation was found in previous similar meta-analyses of the 
association between depression in cardiac patients and prognosis. A meta-analysis of Ml 
patients, for example, found a reduction in association of 41% after adjustment for possible 
confounders 7• Others also found a reduction, though less pronounced 6•8• One possible 
explanation may be reverse causality: depression does not cause cardiac events or death, 
but the severity of the cardiac disease causes both a poorer prognosis and more depressive 
symptoms 7• The fact, however, that after adjustment for disease severity, depression is still 
associated with poorer prognosis suggests that it is an independent risk factor. Most likely, 
the association is bi-directional. In addition, other variables, such as smoking and age, may 
affect the association, not just as confounders, but also as mediators of the association. 
When there is reverse causality or confounding, the pooled odds ratios adjusted for disease 
severity and other confounders will probably turn out lower than unadjusted pooled odds 
ratios 44• 
Unfortunately we could not provide a pooled association that is consistently adjusted for 
the same variables across studies, as each study adjusts for a different set of variables. The 
only way to solve this problem is to perform a meta-analysis of individual patient data of the 
original studies and adjust for the same variables. 
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Changes in odds ratios over time 
Odds ratios were expected to decline over time and such a decline was found for the outcome 
cardiac events, showing a small but significant decline of about 0. 1 for each progressing 
year. This means that the apparent effect of depression on new cardiac events has become 
smaller. Too little is known so far about the mechanisms of this association to be able to 
explain this decline. For the outcomes all-cause mortality, and cardiac mortality, there were 
no significant changes in odds ratios over time. No mentionable changes were found in the 
frequencies of mortality, cardiac events, or depression that could help explain the fact that 
the association did decline for cardiac events, but not for mortality. 
Subgroup analyses: depression measurement and sample size 
The two subgroup analyses, based on type of depression measurement instrument and 
number of subjects per study, revealed interesting results. The odds ratios for diagnostic 
interviews were significantly higher than those for self-rating instruments for all-cause 
mortality. This makes sense, as the fact that studies using (semi-)structured diagnostic 
interviews categorize patients with more severe depressive symptoms as depressed, whereas 
studies using self-rating instruments may include more patients, as they often include 
patients with mild and moderate depressive symptoms as well. Major depression is likely to 
have a stronger association with adverse outcomes than less severe depressive symptoms 
when there is a dose-response relationship. In addition, it has been suggested that standard 
cut-off scores for self-rating instruments lead to an overestimation of depression severity. 
More non-depressed patients may be rated as depressed than when structured diagnostic 
interviews are used. This can explain why the strength of the association between post-Ml 
depression and prognosis is weaker for depression assessed with self-rating instruments 
than for structured interview-based instruments. 
Contrasting results were found in other meta-analyses on depression in CHO patients. 
Nicholson et al. found that studies using clinical measures of depression reported 
weaker associations between depression and prognosis than did studies using symptom 
assessments 7• Barth et al. found no difference in the association between post-Ml 
depression and prognosis as measured with (semi-)structured diagnostic interviews or self­
report instruments and prognosis 6• In the current meta-analysis, smaller studies did not 
report significantly higher odds ratios than did larger studies and sample size did not change 
over time. This indicates that publication bias did not affect the results. 
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Conclusions 
This meta-analysis shows that depression has been consistently associated with a worse 
prognosis after myocardial infarction over the past 25 years. The association between post­
Ml  depression and impaired prognosis is stable over time for mortality, but shows a slight 
decline for new cardiac events. These results once again emphasize that depression in post­
Ml  patients not only deserves attention as a debilitating condition in itself, but also remains 
a signal of an increased risk of cardiovascular events and mortality. 
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Abstract 
Background: The association between depression after myocardial infarction (post-Ml) and 
increased risk of mortality and cardiac morbidity may be due to cardiac disease severity. 
Aims: To combine original data from studies on the association between post-Ml depression 
and prognosis into one database. To investigate to what extent post-Ml depression predicts 
prognosis independently of disease severity. 
Method: Individual patient data meta-analysis of studies, using multilevel, multivariable Cox 
regression analyses. 
Results: Sixteen studies participated, creating a database of 10,175 post-Ml patients. HRs 
for post-Ml depression were 1.32 (95%CI 1.26-1.38, p<0.001) for all-cause mortality, and 
1.19 (95%CI 1.14-1.24, p<0.001) for cardiovascular events. HRs adjusted for disease severity 
were attenuated by 28% and 25% respectively. 
Conclusions: The association between post-Ml depression and prognosis is attenuated after 
adjustment for cardiac disease severity. Still, depression remains independently associated 
with prognosis, with a 22% increased risk of all-cause mortality and a 13% increased risk of 
cardiovascular events per standard deviation in depression z-score. 
Declaration of interest: None. 
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Introduction 
In patients after myocardial infarction (Ml), the prevalence of major depression (MDD) or 
elevated depressive symptoms is relatively high at approximately 20% 1, compared to around 
5% in otherwise healthy people of comparable age 2• Elevated symptoms of depression, 
as measured with symptom questionnaires like the Beck Depression Inventory (BD I), are 
present in around 30% of Ml patients 1• Post-Ml depression has been associated with a worse 
prognosis, and investigations into the strength of this association have been summarized in 
a number of meta-analyses, which showed depressed Ml patients are 1.59 to 2.71 times 
more likely to die early or have new cardiovascular events than are non-depressed patients 
3-s . Such meta-analyses based on summary data, however, have serious limitations. By 
conducting an individual patient data meta-analysis (IPD), a new statistical approach in this 
field, the main limitations can be overcome. 
A major point of discussion in this field is whether depression is an independent risk factor 
for worsened cardiac outcomes, or whether its association with outcome is the result of 
non-causal mechanisms 6• Most importantly, cardiac disease severity may confound the 
association between post-Ml depression and prognosis. Depression and disease severity, 
as measured by, for example, LVEF or Killip class, are associated, and evidence suggests that 
patients with more severe cardiac disease have a higher risk of depression 7-9_ This may be 
the result of a psychological response to the disease and its consequences, as well as of 
physiological mechanisms involved in cardiac disease leading to symptoms of depression, 
such as elevated inflammation 10 and changes in functioning of the autonomic nervous 
system (ANS) or the hypothalamic-pituitary-adrenal (HPA) axis 11•12• Evidently, patients with 
more severe disease are also at higher r isk of adverse cardiac outcomes, such as new cardiac 
events, rehospitalization and cardiac mortality. Similarly, other medical risk factors, such as 
smoking, and diabetes, are likely to be associated with both disease severity and depression 
13•14• Therefore more severe disease and exposure to other risk factors could result in both 
a higher prevalence of depression as well as worsened cardiac prognosis, and thereby 
confound the association between depression and CAD outcomes. 
I ndividual studies find conflicting results when the association between post-Ml depression 
and prognosis is adjusted for disease severity, some finding it to be attenuated, while 
others conclude the association remains unchanged. Previous systematic reviews and meta­
analyses were only able to provide estimates of unadjusted associations, or very limited 
estimates of adjusted associations. This is due to the wide variability of adjustments in 
individual studies, making comparisons across studies impossible. Investigating the effects 
of adjustment is important, however, as variables related to cardiac disease severity 15-17 and 
other health-related variables 13•14•18-20 are prognostic factors for all-cause mortality (ACM) 
and cardiovascular events (CVE), and are associated with depression. 
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The only way to adequately investigate the effects of cardiac disease severity and other 
medical risk factors on the association between post-Ml depression and prognosis is to 
combine data from individual studies into a single database and perform adjusted analyses 
on all data at once. This increases statistical power, generalizability, and reliability of the 
results 21-24, providing more conclusive evidence. Most importantly, time-to-event analyses 
can be performed, to not only utilize information on whether or not an event occurred, 
but also when it occurred 24, which is one of the main advantages of IPD meta-analysis 25• 
The objective of this study, therefore, is to conduct an IPD meta-analysis that allows for 
adjustment for a number of important disease severity variables and other health factors 
that are routinely collected in studies of post-Ml depression. 
Methods 
Literature search and selection of studies 
Search strategy 
Studies included in this individual patient data (IPD) meta-analysis were previously selected 
for two regular, summary data (SD) meta-analyses on post-Ml depression and cardiac 
prognosis 5•26• A literature search was performed on January 5th, 2011 to identify prognostic 
studies that investigated the association between post-Ml depression and cardiac prognosis 
since 1975. Depression treatment studies in which baseline depression scores and all-cause 
mortality or cardiovascular events outcomes were reported were also eligible. Relevant 
articles were selected from the electronic databases Medline (PubMed), Embase, and 
PsyclNFO without language restrictions. Search terms related to depression and myocardial 
infarction were used and customized to each database. In addition to the database searches, 
major reviews and relevant articles were cross-referenced. Search alerts for the three 
databases mentioned above were activated, to identify relevant studies that were published 
after January 5, 2011. All studies included in the summary data meta-analyses were eligible 
for inclusion in the current IPD meta-analysis. 
Selection process 
The selection process has been described in detail elsewhere 5•26• In summary, studies were 
selected by two independent raters according to the following criteria: (1) patients had to 
be hospitalized for Ml; (2) depression had to be determined within three months after Ml 
using methods originally designed to assess depression (standard self-report questionnaires 
or standardized psychiatric interviews) and validated elsewhere; (3) studies had to be 
prospective and assess cardiovascular prognosis in a depressed patient group compared to 
a non-depressed control group; (4) outcome had to be all-cause mortality or cardiovascular 
events (the latter defined as either non-fatal cardiac events or a composite of fatal and non­
fatal cardiac events); and (5) the study had to be based on original data. 
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Authors of all the studies included in the summary data meta-analysis were contacted and 
invited to participate in the project. Considerable effort was put into finding and contacting 
authors and in obtaining all available databases. When corresponding authors could not be 
contacted at the address specified in the original articles, we searched most recent articles and 
the internet for updated information on the authors' location, and we tried to contact other 
members of the research groups. Authors were asked to share original data they had on post­
Ml patients regarding demographics, depression, disease severity, comorbidities, medication 
use, and outcomes. Data were checked for potential errors, and authors were contacted 
regarding questions related to the design of their study or the datasets they provided. 
Depression 
Depression had to be measured using established self-report questionnaires or standardized 
structured diagnostic interviews. For the main analyses, continuous scores on the self­
report questionnaires were used. Dichotomous scores were used for descriptive purposes 
only, and were based on structured diagnostic interviews where available, and on standard 
cut-off scores {literature-based) on the self-report questionnaires where no interviews were 
available. When multiple depression measurement instruments were used, standardized 
structured diagnostic interviews were preferred over self-report questionnaires in 
constructing dichotomous scores. When multiple self-report questionnaires were used in 
the same study, the one most frequently used by the other studies was selected. Across 
the studies, a number of different self-report depression questionnaires were used, so total 
depression scores on these questionnaires were standardized to z-scores for analyses. This 
was done within each study. For some patients, depression questionnaire total scores and 
dichotomous scores were not available due to missing item scores on the questionnaire. 
When no more than 25% of the depression items were missing, item scores were imputed 
with the mean of the available items from that patient, to calculate total scores and 
dichotomized scores. 
Disease severity: LVEF, Killip class, and history of Ml 
To investigate the role of cardiac factors in the association between post-Ml depression and 
prognosis, LVEF, Killip class, and history of Ml were used to quantify disease severity. These 
variables were selected because they are known predictors of outcome in post-Ml patients 
18•19•21-30, and they were available in a sufficient number of patients. They may result in both 
more symptoms of depression 7 and more adverse outcomes 12• 
LVEF  was dichotomized into low {<40%) and normal (2::40%), as not all studies included 
continuous values. Killip class was dichotomized into no heart failure {class I) and heart 
failure {classes II, Ill, and IV), as the 4-category scores were not available in all studies. 
History of M l  was dichotomized into "yes" or "no". 
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Other risk factors: diabetes, smoking, and BMI 
Several other health-related risk factors were expected to affect the association between 
post-Ml depression and prognosis. Of these, diabetes 13•18•19•31, smoking 14, and BMI were 
included in the adjusted analyses, as data on these variables were collected in a large 
number of the patients. 
Age and sex 
Age and sex were included in the analyses for the minimally adjusted comparison model. 
They may explain part of the association, as they are both related to the risk of depression 
and to physical health prognosis. 
Outcome: all-cause mortality and cardiovascular events 
The outcomes of all-cause mortality and new cardiovascular events were considered in 
the analyses. All-cause mortality includes cardiac mortality, and it was included because 
outcome data on all-cause mortality is generally more readily available than specific data 
on (cardiac} causes of mortality or morbidity. Cardiovascular events as defined most 
commonly by the original study authors were accepted, and could be either fatal events, 
non-fatal events, or a combination of both. Cardiovascular events included, for example, 
new Ml, unstable angina (UA}, and coronary artery bypass graft surgery (CABG} . All-cause 
mortality and cardiovascular events may overlap when studies included cardiac death in 
both definitions. 
Study characteristics 
For each study the following characteristics were summarized: year that the study was 
initiated, percentage of males in the sample, inclusion and exclusion criteria, mean age, 
depression measure, percentage of depressed patients, mean depression scores, duration 
of follow-up, and number of outcome events. 
Statistical analysis 
The main analyses were performed in Stata 11 (Statacorp LP, TX, USA}. All studies except 
one included continuous depression scores, and a number of studies in addition contained 
a binary measure of clinical diagnosis of depression. The one study 32 that did not contain 
continuous depression scores was excluded from the current analyses. First, hazard ratios 
(HRs} were calculated using multilevel Cox proportional hazards regression analysis for the 
studies with time-to-event data. Second, odds ratios (ORs) were calculated using logistic 
regression analysis for all studies, including those with dichotomous outcome information 
only (event versus no event without time-to-event data}. 
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Multilevel model 
The individual studies were included as a separate level, resulting in a multilevel model, in 
which the variable "study" was included as a random intercept. Patients across studies were 
likely to differ in systematic ways, for example because of differences in selection criteria, 
study methods, or cardiac care 33• Observations of subjects within studies were therefore 
unlikely to be fully independent. By incorporating a random effect for "study" in IPD meta­
analysis, we accounted for the fact that outcome rates may vary across studies. 
The possibility of a random slope was also investigated, as the strength of the association 
between post-Ml depression and prognosis may vary significantly across studies. As this did 
not appear to be the case, random slopes were not included in the final models. 
In the Cox regression analyses, contrast coding of -0.5/0.5 was used for dichotomous 
variables, to insure between-trial variances were equal between groups (e.g. male vs. 
female) 34•35• 
Bootstrapping 
A bootstrapping procedure with 1000 replications was used for the analyses, to increase 
the robustness of the confidence intervals 36, and to account for the fact that some of the 
depression z-scores were not distributed normally. 
Model construction 
The models were built as follows: First, a base model to which subsequent adjusted models 
could be compared was created by including age, sex, and the depression z-scores as 
predictors of prognosis. As our primary interest was in the influence of individual variables on 
the association between post-Ml depression and prognosis, we then added each preselected 
variable separately to this base model in minimally adjusted analyses. Not all studies had 
data on each of these variables, and to be able to compare differences between the base 
and adjusted models, patients who did not have data on the relevant variable were excluded 
from the relevant analyses in both models. Cardiac disease severity was represented by 
h istory of Ml, Killip class, and LVEF. Diabetes, smoking and BMI were added as risk factors for 
poor prognosis. A variable was considered to explain a substantial portion of the variance 
if it changed the effect size (log HR) by 5% or more 37• Variables that were also significant 
predictors (pS0.05) of outcome were considered to substantially add to the variance. As not 
all studies had time-to-event data, additional logistic regression analyses were performed 
and these models were built in the same way as for Cox regression analyses. 
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Second, we investigated the extent to which the association between post-Ml depression 
and prognosis was attenuated by adjusting for all of the risk factors. As not all studies had 
data on all variables, these multivariable analyses could only be performed with data from 
a limited number of studies. Nevertheless, this provides the best estimate of the extent to 
which post-Ml depression independently predicts cardiac outcomes. 
Model assumptions 
The proportional hazards assumption for Cox regression was tested, as well as the 
assumption of linearity in the association between post-Ml depression and prognosis. The 
model assumptions were met in most cases. In the few cases that they were not, the effects 
of violation of the assumption were further investigated and determined to be minimal. 
Analyses were therefore run for these models in the same way as the other models, for the 
sake of clarity and interpretability of the results. 
Patient characteristics 
Patient characteristics were presented separately for depressed and non-depressed patients. 
Differences in these characteristics between depressed and non-depressed patients were 
assessed with independent samples t-tests for normally distributed continuous variables, 
and Mann-Whitney U-tests for non-normally distributed continuous variables. Dichotomous 
and categorical variables were compared using Pearson's Chi-square test. 
Effects of non-participation of eligible studies 
To investigate whether there were any systematic differences (acquisition bias) between 
participating and non-participating studies that may affect the results of the meta-analysis 
38, we compared results of included and excluded studies concerning strength of the 
association and study characteristics. 
Results 
Study participation 
A total of 6,145 articles were identified through the literature search, cross-referencing, and 
personal communication. Of those, 28 studies were ultimately included in the meta-analysis. 
Two additional studies were identified through search alerts 39 and personal communication 
40
, resulting in a total number of 30 eligible studies. The authors of 16 studies provided 
data for the IPD meta-analysis, resulting in a combined database of 10,175 patients1 • 
Figure 1 is a flow-chart of the literature search and data acquisition. Fourteen studies were 
1 The data of one study were not used for the current analyses, as there were no continuous depression scores 
(Rafanelli). However, these data will be available for future substudies. 
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not included, seven because authors could not be contacted, five because data were not 
available, and two because the authors were not interested in participating. An overview of 
participating studies is given in Table 1. Complete reports of study design and methodology 
of the individual studies are published elsewhere 3o,3o,39-s6• Appendix 1 is an overview of non­
participating studies. 
Figure 1: study selection and data acquisition 
6145 citations identified 
308 citations retrieved 
·-----. 
,, 
30 studies contacted 
16 studies included in analysis 
5837 excluded 
no original data; no Ml at baseline; no 
depression, or no non-depressed control group; 
outcome not all-cause mortality or cardiovascular 
events; depression not assessed within 3 months 
after Ml 
278 excluded 
duplicate data; no original data; no Ml at 
baseline; no depression, or no non-depressed 
control group; depression not assessed within 3 
months after Ml; no validated depression 
measurement instrument 
14 excluded 




T a b l e  1 :  o v e r v i e w  o f  p a r ti c i p a ti n g  s t u d i e s  
P l ,  s t u d y  S t a r t  N
3  
/ %  m a l e  
n a m e ,  
o f  
c o u n t r y  s t u d y  
R .  C a r n e y ,  J .  A .  1 9 9 6  /  2 8 4 8  /  5 8 %  
B l u m e n t h a l  1 9 9 7  
E N R I C H D  a n d  
a n c i l l a r y  H R V  
s t u d y
2  
U S A 4
1
-4 3  
J .  O r m e l ,  P. d e  1 9 9 9  
J o n g e ,  
M I N D - I T  
T h e  
N e t h e r l a n d s  
4 0  
J .  O r m e l ,  P. d e  1 9 9 7  
J o n g e  
D e p r e M I  
T h e  
N e t h e r l a n d s  
44  
J .  D e n o l l e t  
T h e  
N e t h e r l a n d s  
2
0  
2 0 0 3  
F .  D o y l e ,  H .  M .  2 0 0 3  
M c G e e  
I r e l a n d  
5 5  
F .  D o y l e ,  H . M .  2 0 0 6  
M c G e e  
I r e l a n d  
5 6  
5
.  B e r g e r o n e  1 9 9 9  
I t a l y  
4 5  
S . H .  H o s s e i n i  
2 0 0 4  
I r a n  
3 9  
1 8 1 4 / 7 7 %  
5 2 8  /  8 1 %  
5 0 1  /  7 8 %  
4 3 3  /  7 5 %  
2 8 5  /  8 0 %  
9 8 / 7 8 %  
5 4 0 /  6 9 %  
I n c l u s i o n  c r i t e r i a  E x c l u s i o n  c r i t e r i a  
s t a n d a r d i z e d  c r i t e r i a  f o r  M l ;  o t h e r  l i f e - t h r e a t .  m e d .  
l o w  s o c i a l  s u p p o r t  o r  i l l n . ;  c o g n .  i m p a i r m . ;  
d e p r e s s i o n  t o o  i l l ;  o t h e r  m a j o r  
a n c i l l a r y  s t u d y :  n o  
p s y c h .  d i s o r d . ;  u n a b l e /  
d e p r e s s i o n  o r  s o c i a l  r e f u s e d  t o  p a r ti c i p a t e  
i s o l a t i o n ,  o t h e r w i s e  e l i g i b l e  
f o r  E N R I C H D  
s t a n d a r d i z e d  c r i t e r i a  f o r  M l  
o t h e r  l i f e - t h r e a t .  m e d .  
a g e �  1 8  
i l l n . ;  M l  d u r i n g  h o s p .  f o r  
o t h e r  r e a s o n ;  p s y c h .  
d e p r .  t r e a t m ;  p a r t .  i n  
c o n fl i c t i n g  c l i n .  t r i a l  
s t a n d a r d i z e d  c r i t e r i a  f o r  M l  
o t h e r  l i f e - t h r e a t .  m e d .  
i l l n . ;  c o g n .  i m p a i r m . ;  
t o o  i l l ;  u n a b l e  t o  
c o m m u n i c a t e ;  M l  d u r i n g  
h o s p .  f o r  o t h e r  r e a s o n  
S t a n d a r d i z e d  c r i t e r i a  f o r  M l ;  o t h e r  l i f e - t h r e a t .  m e d .  
A g e >  3 0  
i l l n . ;  c o g n .  l m p a i r m .  
s t a n d a r d i z e d  c r i t e r i a  f o r  n r  
A C S  ( o n l y  M l  p a t i e n t s  w e r e  
i n c l u d e d  i n  t h e  I P D  m e t a -
a n a l y s i s )  
s t a n d a r d i z e d  c r i t e r i a  f o r  p a t i e n t  t o o  d i s t r e s s e d  
A C S  ( o n l y  M l  p a t i e n t s  w e r e  
i n c l u d e d  i n  t h e  I P D  m e t a -
a n a l y s i s )  
s t a n d a r d i z e d  c r i t e r i a  f o r  M l  i n - h o s p .  m o r t . ;  o t h e r  
m a j o r  p s y c h .  d i s o r d . ;  
a l c o h o l i s m ;  a n ti d e p r.  
t h e r a p y  
s t a n d a r d i z e d  c r i t e r i a  f o r  M l  o t h e r  l i f e - t h r e a t .  m e d .  
i l l n . ;  M l  r e s u l t  o f  C A B G  
o r  a n g i o g r . ;  t o o  i l l  
M e a n  D e p r e s s i o n  N / %  
M e a n  M e a n  N o .  o f  
�  
a g e  m e a s u r e m e n t  d e p r e s s e d  
d e p r e s s i o n  
f o l l o w - e v e n t s  
00  
i n s t r u m e n t
1  
a n d  
s c o r e  ( S D )  u p ti m e  
A C M /  
c u t - o ff  s c o r e  
( d a y s )  C V E  
6 1  B D l - l A �  1 0  
1 9 5 1  /  6 9 %  
1 4 . 1 3  
A C M :  8 3 4  A C M :  3 5 0  
( 8 . 8 7
)  
C V E : 6 0 9  
C V E :  1 1 5 1  
6 1  B D I  1 - A  �  1 0  
B D I :  4 7 4  /  6 . 7 7  ( 6 . 1 8 )  A C M :  2 1 6 7  
A C M :  2 7 8  
2 6 %  
C V E : 1 5 1 7  C V E : 7 8 4  
6 1  m o d i fi e d  D u t c h  C I D I :  7 3  /  1 5 %  
6 . 8 0  ( 6 . 1 2 )  
A C M :  2 6 6 3  A C M :  1 1 6  
v e r s i o n  o f  C I D I  2 . 1  
C V E : 1 8 5 1  C V E : 2 3 7  
B D I :  1 1 7  /  2 3 %  
B D I  l A �  1 0  
6 0  B D l - l A  �  1 0  
1 3 2  /  2 6 %  7 . 0 3  ( 6 . 1 8 )  A C M :  1 3 7 4  A C M :  3 8  
C V E : 1 2 8 4  
C V E :  8 2  
6 3  
H A D S - D  >  7  H A D S - D  o r  
H A D S - D :  A C M :  3 5 6  
A C M :  1 7  
B D I - F S  >  3  
B D I - F S :  7 5  /  
4 , 1 4  ( 3 , 2 6 )  
C V E : n a  C V E : n a  
1 7 %  B D I - F S :  
1 . 8 8  ( 2 . 6 9 )  
6 1  H A D S - D  >  7  
e i t h e r  H A D S - D  
H A D S - D :  A C M : 4 2 7  A C M :  1 9  
B D I - F S  ( 6 - i t e m )  
o r  B D I - F S :  7 8  
3 , 5 2  ( 3 , 0 7 )  C V E :  4 2 7  
C V E : 6 7  
> 3  / 2 7 %  B D I - F S :  
H A D S - D :  3 3  /  
2 . 1 5  ( 2 . 8 4 )  
1 2 % ;  B D I - F S  
6 9  /  2 4 %  
6 2  s t r u c t .  i n t .  b a s e d  
M D D :  1 4 /  B D I :  8 . 3 4  A C M :  1 4 8 5  
A C M : 6  
o n  D S M - I V  
1 4 %  ( 8 . 4 8 )  
C V E : 1 4 8 5  
C V E : 2 9  
c r i t e r i a  
B D I :  3 5  /  3 4 %  
B D I  l A  �  1 0  
5 8  B D I  l A �  1 0  
3 5 5  /  6 6 %  1 4 . 2 0  
n a ( 2 4  A C M :  n a  
( 9 . 8 0 )  
m o n t h s )  
C V E : 5 5  
Table 1 (continued) 
Pl, study Start N3 / % male Inclusion criteria Exclusion criteria Mean Depression N / %  Mean Mean No. of 
name, of age measurement depressed depression follow- events 
country study instrument1 and score (SD) up time ACM / 
cut-off score (days) CVE 
D.A. Lane 1997 288 / 75% standardized criteria for Ml other life-threat. med. 63 BDI 1A � 10 89 / 31% 7.72 (6.26) ACM: 976 ACM: 38 
i l ln.; cogn. impairm.; CVE:na CVE: na 
UK 46,47 Ml result of CABG or 
angiogr.; unable to 
communicate; too i l l  
L. Pilote 1996 553 / 81% acute Ml; surv. up to 24 phys. unable to respond 60 BDI 1 �10 193 / 35% 9.07 (7.93) ACM: 350 ACM: 32 
hours after hosp. adm.; to quest.; unable to CVE: 205 CVE: 222 
Canada 48 adm. through emergency communicate 
dept. 
K. Parakh, R.C. 1995 284 / 57% standardized criteria for Ml other life-threat. med. 65 SCID MDD: 29 / BDI: 5.76 ACM: 2428 ACM: 153 
Ziegelstein i l ln.; cogn. impairm.; 10% (6.15) CVE: na CVE: na 
too i l l  BDI 1A �10 BDI: 56 / 20% 
USA 49 
C. Rafanel l i  1995 61 / 85% standardized criteria for Ml; nr 59 modified SCID 7 I 11% na na (24 ACM: 4 
first Ml (minor and major months) CVE: 22 
Italy 32 depression 
H. Sato 1998 1042 / 80% standardized criteria for Ml in-hosp. mort.; other 63 ZSDS � 40 438 / 42% 38.03 na (12 ACM: na 
OACIS major psych. disord.; (9.07) months) CVE: 283 
Japan 51 unable to communicate 
R.P. Steeds 1999 131 / 33% Ml; age < 75 nr 60 BDI-II � 14 52 / 40% 12.42 ACM: 457 ACM: 11 
(9.09) CVE: na CVE: na 
UK 52 
S.L. Grace 1997 468 / 72% confirmed Ml; age � 18 too il l; unable to 61 BDI 1A � 10 136 / 28% 7.93 (7.22) na (12 ACM: 29 3 
communicate months) CVE: 101 [lJ 
Canada 53 QJ 
270 / 84% standardized criteria for Ml; 96/ 36% na (120 C. Welin 1985 nr 56 ZSDS � 40 36.76 ACM: 65 [lJ 
first Ml; age < 65 (8.58) months) CVE: 73 � 
Sweden 54 .:;;· 
1 Depression measurement instrument used in the current individual patient data meta-analysis. -g 
2 Part of the non-depressed control group came from an ancillary study and part of the patients in the non-depressed control group had low social support. Depressed patients 
were oversampled for the purpose of the study. o· 
3 Number of patients included in I PD-meta-analysis. 
::l 
[lJ 
Abbreviations: ACM: All-cause mortality; ACS: acute coronary syndrome; BDI: Beck Depression Inventory; BDI-FS: Beck Depression Inventory Fast Scale; CIDI: Composite 
International Diagnostic Interview; CVE: cardiovascular events; DepreMI: Depression after Myocardial Infarction; ENRICHD: Enhancing Recovery in Coronary Heart Disease; -c 
HADS-D: Hospital Anxiety and Depression Scale-Depression subscale; HRV: heart rate variabi l ity; MDD: major depression disorder; Ml: myocardial infarction; MIND-IT: 
Myocardial Infarction and Depression Intervention Trial; na: not available; nr: not reported; OACIS: Osaka Acute Coronary Insufficiency Study; Pl: primary investigator; SCID: ::::, 
I-' 5l CXl Structured Clinical Interview for DSM; SD: standard deviation; ZSDS: Zung Self-rating Depression Scale w .:;;· 
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Study characteristics 
The 16 participating studies originated from 9 different countries. The mean sample size 
was 615 patients per study (SD 711), ranging from 61 to 2,889 patients. Studies originated 
from 1985 to 2006. Mean age per study ranged from 56-65 years (m=61), and the mean 
percentage of males ranged from 33%-85% (m=72%). All studies included Ml patients based 
on standardized diagnostic criteria. Most of the exclusion criteria concerned life-threatening 
illnesses or psychiatric disorders other than depression, Ml due to a surgical procedure (e.g. 
CABG, valve replacement, etc.), or cognitive or communication difficulties. 
Depression was measured with a self-report depression questionnaire, a structured 
clinical interview, or both. The self-report depression scales that were used included the 
BDl-lA, BDI-II, BDI-Fast Screen (FS), the depression subscale of the Hospital Anxiety and 
Depression Rating Scale (HADS-D), and Zung Self-rating Depression Scale (SDS). Structured 
clinical interviews included the Depression Interview and Structured Hamilton (DISH), the 
Composite International Diagnostic Interview (CIDI), and the Structured Clinical Interview 
for DSM Disorders (SCIO). The percentage of depressed patients was lower when based on 
diagnostic interviews (11%-15%) than when based on elevated symptoms on self-report 
questionnaires {17%-69%). Follow-up time ranged from 350 to 2,428 days (1 - 6.7 years), 
with a mean of 1,151 days (3.2 years). 
Patient characteristics 
Individual patient data were combined for 10,175 Ml patients. 4,043 patients (40%) had a 
major depression, or elevated symptoms of depression and 6,132 patients {60%) were not 
depressed 2• Nineteen percent of patients had a history of one or more Mis prior to the 
index Ml, 23% had low LVEF, and 18% had a Killip class higher than I. Twenty-one percent of 
those measured had comorbid diabetes, 45% were (ever) smokers, and the mean BMI was 
27 (Table 2). 
Adjusted association between post-Ml depression and prognosis: Cox regression analyses 
Base model (adjusted for age and sex) 
Figure 2 shows survival curves for the two outcomes all-cause mortality and cardiovascular 
events, with separate lines for depressed and non-depressed patients, and adjusted for age 
and sex. Rates of all-cause mortality were stable over time, and were consistently higher 
for depressed patients than for non-depressed patients. The rate of cardiovascular events 
was highest soon after the Ml, and became relatively stable after about 1 year. The rate of 
cardiovascular events was higher for depressed than for non-depressed patients. 
2 Note t hat some studies may have oversampled depressed patients, so t hese numbers may overrepresent 
depression percentages in Ml patients. 
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Table 2: Baseline patient characteristics by depression status 




Age 60.5 (12.2) 61.4 (11.6) <0.001 10,171 
Sex (% male) 63.3 75.7 <0.001 10,175 
Employment status (% employed) 43.1 46.6 0.004 6,528 
Partner status (% with partner) 63.7 73.7 <0.001 6,412 
Cardiac disease severity 
History of Ml (% yes) 21.8 17.0 <0.001 9,646 
LVEF (% of patients <40%) 27.0 21.3 0.001 3,505 
Killip class (% poor) 21.6 15.7 <0.001 7,532 
PTCA (%) 48.7 43.6 <0.001 7,679 
History of PTCA (%) 13.4 9.3 <0.001 4,830 
CABG (%) 11.5 8.5 <0.001 8,139 
History of CABG (%) 11.4 8.2 <0.001 4,849 
Thrombolysis (%) 32.5 34.8 0.037 8,065 
Congestive HF (%) 29.0 12.3 <0.001 6,104 
Other risk factors 
Diabetes (%) 27.8 17.3 <0.001 10,060 
Smoking (%) 43.1 45.6 0.017 9,942 
BMI  (mean, (SD)) 27.6 (5.6) 26.7 (4.5) <0.001 7,188 
Hyperlipidemia / 48.7 45.5 0.004 8,405 
hypercholesterolemia (%) 
Hypertension (%) 31.0 35.8 <0.001 8,301 
History of hypertension (%) 55.2 44.4 <0.001 5,348 
Medication use 
Hypolipidemics (%) 42.7 44.7 0.230 4,004 
Beta-blockers (%) 68.7 74.0 <0.001 8,833 
Aspirin (%) 86.3 87.8 0.051 7,561 
Calcium-channel blockers / 19.3 14.9 <0.001 7,056 
antagonists (%) 
ACE-inhibitors (%) 48.1 49.6 0.160 8,550 
Antidepressant use (%) 10.1 3.2 <0.001 5,507 
ACE: angiotensin converting-enzyme; BMI: body mass index; CABG: coronary artery bypass graft; HF :  heart failure; 
LVEF:  left ventricular ejection fraction; M l :  myocardial infarction; PTCA: percutaneous transluminal coronary 
angioplasty; SD:  standard deviation 
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Figure 2: survival curves al l-cause mortality and cardiovascular events adjusted for age and sex 
Al l-cause mortal ity 
0 
adjusted for age and sex 
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Left panel: a l l-cause mortality survival curves based on 10 studies and 7691 patients. Right panel: cardiovascular events survival curves 
based on 7 studies and 6616 patients. 
Table 3: Hazard ratios for all-cause mortality, unadjusted and adjusted for cardiac disease severity 
and other health-related variables 
HR unadjusted1 HR adjusted1 % change N / n studies2 
(95% CI) (95% Cl) 
Sociodemographic variables 
Age, sex3 1.26 (1.18-1.35)***  1.32 (1.26-1.38)***  +17% 7,628 I 10 
Cardiac disease severity 
variables 
History of Ml 1.32 (1.26-1.39)***  1.29 (1.24-1.36)***  -8% 7,543 I 10 
LVEF (low vs normal) 1.30 (1.23-1.39)***  1.25 (1.18-1.33)***  -15% 3,115 / 5 
Ki l l ip class (I vs II, Ill or IV) 1.31 (1.25-1.38)***  1.25 (1.18-1.32)***  -19% 5,924 / 6 
General health variables 
Diabetes 1.31 (1.25-1.38)***  1.29 (1.22-1.36)***  -7% 7,587 I 10 
Smoking 1.33 (1.27-1.39)***  1.33 (1.27-1.39)***  -1% 7,485 I 10 
BMI 1.34 (1.27-1.41)***  1.34 (1.28-1.41)* **  0% 6,133 / 7  
Model including all variables 
(Age, sex) history of Ml, LVEF, 1.33 (1.23-1.44)***  1.23 (1.15-1.31)***  -28% 2,226 / 3 
Ki l l ip class, diabetes, smoking, 
BMI 
(Age, sex) history of Ml, LVEF, 1.32 (1.24-1.40)***  1.22 (1.13-1.31)***  -29% 2,400 / 3 
Killip class 
ACM: al l-cause mortality; BMI: body mass index; Cl : confidence interval; HR :  hazard ratio; LVEF:  left ventricular 
ejection fraction; Ml : myocardial infarction 
Note that column 2 represents unadjusted HRs, based on analyses including only those patients that had scores 
available for the variables concerned 
1 depression is included in al l the models as a continuous variable (z-score) 
2 depending on availability of these variables in each study 
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The base Cox regression model for all-cause mortality (adjusted for age and sex) produced 
an HR for depression (z-scores) of 1.32 per SD (95%CI 1 .26-1.38, p<0.001). Adjustment for 
age and sex increased the strength of the association between post-Ml depression and all­
cause mortality by 17% (see Table 3). 
In the cardiovascular events model the HR (adjusted for age and sex) for depression 
(z-scores) was 1 .19 per SD (95% Cl 1. 14-1.24, p<0.001). Adjustment for age and sex did 
not substantially alter the strength of the association between post-Ml depression and 
cardiovascular events (Table 4). 
Table 4: Hazard ratios for cardiovascular events, unadjusted and adjusted for cardiac disease severity 
and other health-related variables 
HR unadjusted1 HR adjusted1 % change N / n studies2 
(95% CI) (95% CI) 
Sociodemographic variables 
Age, sex3 1.18 (1.13-1.23)***  1.19 (1.14-1.24)***  +2% 6,556 I 7 
Cardiac disease severity 
variables 
History of Ml 1.19 (1.13-1.24)***  1.17 (1.12-1.22)***  -9% 6,475 / 7  
LVEF (low vs normal) 1.18 (1.12-1.25)***  1.16 (1.10-1.23)***  -10% 2,904 / 5 
Killip class (I vs II, Ill or IV) 1.17 (1.12-1.22)***  1.15 (1.11-1.20)***  -12% 5,410 I 5 
General health variables 
Diabetes 1.19 (1.14-1.24)***  1.17 (1.13-1.22)***  -7% 6,522 / 7 
Smoking 1.19 (1.13-1.24)***  1.19 (1.13-1.24)***  0% 6,416 / 7 
BMI 1.18 (1.12-1.25)***  1.18 (1.12-1.25)* * *  0% 5,757 I 5 
Model including al l  variables 
(Age, sex) history of Ml, LVEF, 1.17 (1.05-1.30)**  1.12 (1.01-1.25)* -25% 1,962 / 2 
Kil lip class, diabetes, smoking, 
BMI 
(Age, sex) history of Ml, LVEF, 1.17 (1.09-1.26)***  1.13 (1.07-1.19)***  -21% 2,178 / 3 
Killip class 
BMI: body mass index; Cl : confidence interval; CVE:  cardiovascular events; HR :  hazard ratio; LVEF :  left ventricular 
ejection fraction; Ml : myocardial infarction 
Note that column 2 represents unadjusted HRs, based on analyses including only those patients that had scores 
available for the variables concerned 
1 depression is included in all the models as a continuous variable (z-score) 
2 depending on availability of these variables in each study 
3 the model including depression, age, and sex is the comparison model 






All three cardiac disease severity variables explained a substantial portion of the association 
between post-Ml depression and all-cause mortality, with the dichotomized variables for 
Killip class and LVEF explaining 19% and 15%, respectively, and history of Ml explaining 
8%. Of the general health variables diabetes, smoking, and BMI, only diabetes explained 
a considerable part (7%) of the association between post-Ml depression and all-cause 
mortality. Table 3 is a summary of the results of unadjusted and adjusted analyses. 
For cardiovascular events, all three variables relating to cardiac disease severity explained 
a substantial portion of the association with post-Ml depression, with the dichotomized 
variables for Killip class and LVEF explaining 12% and 10%, respectively, and history of Ml 
explaining 9%. Of the general health variables diabetes, smoking, and BMI, again only 
diabetes explained a considerable part (7%) of the association (Table 4). 
Multivariable models 
The following results are based upon the three studies that included all variables (i.e., history 
of Ml, Killip class, LVEF, diabetes, smoking, and BMI). When combining all general health 
and disease severity related variables in one model, the adjusted HR for all-cause mortality 
was 1.23, compared to 1.33 unadjusted, an attenuation of 28%. All variables except sex 
and BMI independently explained part of the association between post-Ml depression and 
prognosis. Figure 3 (top panel) is a survival curve of the model adjusted for age, sex, history 
of Ml, LVEF, Killip class, diabetes, BMI, and smoking. Note that this figure is based on the 
three studies only that contained all these variables. 
Adjusting for the three cardiac disease-related variables only, the HR for all-cause mortality 
was 1.22 compared to 1.32 unadjusted, an attenuation of 29%. This means that the 
cardiac disease-related variables are responsible for nearly all of the attenuation in the full 
model. Model fit improved when age, sex, history of Ml, LVEF, Killip class, and diabetes 
were subsequently added. Model fit did not improve after further adjustment for BMI and 
smoking. 
For cardiovascular events, when combining all general health and disease severity-related 
variables in one model, the adjusted HR was 1.12, compared to 1.17 unadjusted, an 
attenuation of 25%. All variables except BMI independently explained part of the association 
between post-Ml depression and prognosis. Figure 3 (bottom panel) is a survival curve of 
the model adjusted for age, sex, history of Ml, LVEF, Killip class, diabetes, BMI, and smoking. 
Note that this figure is based on the two studies only that contained all these variables. 
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Figure 3: Survival curves al l-cause mortality and cardiovascular events for the base and ful ly adjusted 
models 
All-cause mortality 
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Top panel: All-cause mortality survival curves based on 3 studies and 2239 patients. Bottom panel: Cardiovascular 
events survival curves based on 2 studies and 1973 patients. 
Adjusting for the three cardiac disease-related variables only, the HR for cardiovascular 
events was 1.13 compared to 1.17 unadjusted, an attenuation of 21%. This means that 
the cardiac disease-related variables were responsible for most of the attenuation in the 
full model. Congruent with the all-cause mortality analyses, model fit improved when 
subsequently adjusting for age, sex, history of Ml, LVEF, Killip class, and diabetes. Model fit  
did not improve after further adjustment for BMI and smoking. 
Adjusted association between post-Ml depression and prognosis: logistic regression 
analyses 
Five studies (2,468 patients) did not have time-to-event data, and therefore logistic 
regression analyses were performed in addition to the Cox regression analyses. Of the 
8,366 patients who had depression z-scores as well as outcome data on all-cause mortality, 
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1, 136 patients (14%) died. Of 3,206 depressed patients, 636 (12%) died, and of 3,206 non­
depressed patients, 500 (16%) died. Of the 8,878 patients who had depression z-scores 
as well as outcome data on cardiovascular events, 3,067 experienced a fatal or non-fatal 
cardiac event (35%). Of 3,747 depressed patients, 1,449 (39%) experienced a fatal or non­
fatal cardiac event, and of 5,135 non-depressed patients, 1, 168 (32%) experienced an event. 
Base model (adjusted for age and sex). 
The base logistic regression model for all-cause mortality (adjusted for age and sex) 
produced an OR for depression (z-scores) of 1.41 per SD (95%Cl=l.34-1.49, p<0.001) (Table 
5). Adjustment for age and sex increased the strength of the association between post -Ml 
depression and all-cause mortality by 18%. 
Table 5:  Odds ratios for all-cause mortality, unadjusted and adjusted for cardiac disease severity and 
health related variables 
OR unadjusted1 OR adjusted1 % change N / n studies2 
{95% CI) {95% CI) 
Sociodemographic variables 
Age, sex***  1.33 (1.25-1.41}* * *  1.41 (1.34-1.49}* * *  +18% 8.362 / 12 
General health variables 
Diabetes 1.41 (1.33-1.48}* * *  1.37 (1.30-1.45}***  -7% 8273 / 12 
Smoking 1.42 (1.35-1.49}* * *  1.42 (1.34-1.49}* * *  -1% 8192 / 12 
BMI 1.43 (1.35-1.52}***  1.40 (1.35-1.52}** *  0% 6132 / 7 
Cardiac disease severity 
variables 
History of Ml 1.41 (1.33-1.487}* * *  1.37 (1.30-1.44)* * *  -8% 8007 I 11 
LVEF 1.36 (1.25-1.49)* * *  1.31 (1.21-1.43} ***  -12% 3330 / 6 
Killip class 1.40 (1.33-1.48)* * *  1.35 (1.26-1.44} ***  -13% 6367 / 7 
Model Including al l  variables 
(Age, sex )  history of Ml, LVEF, 1.37 (1.18-1.59}* * *  1.24 (1.07-1.44)* * *  -30% 2225 / 3 
Killip class, diabetes, smoking, 
BMI 
(Age, sex } history of Ml, LVEF, 1.36 (1.24-1.50)* * *  1.27 (1.17-1.37)***  -25% 2399 / 3 
Killip class 
ACM: all-cause mortality; BMI: body mass index; Cl : confidence interval; HR :  hazard ratio; LVEF :  left ventricular 
ejection fraction; Ml :  myocardial infarction 
1 depression is included in all the models as a continuous variable (z-score) 
2 depending on availability of these variables in each study 
3 the model including depression, age, and sex is the comparison model 
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The OR for depression in the cardiovascular events model (adjusted for age and sex) for 
depression (z-scores) was 1.25 per SD (95%Cl=l. 19-1.32, p<0.001) (Table 6). Adjustment 
for age and sex did not substantially alter the strength of the association between post-Ml 
depression and cardiovascular events. 
Table 6: Odds ratios for cardiovascular events, unadjusted and adjusted for cardiac disease severity 
and health related variables 
OR unadjusted1 OR adjusted1 % change N / n studies2 
(95% CI) (95% CI) 
Sociodemographic variables 
Age, sex 1.25 (1.19-1.31)***  1.25 (1.19-1.32)***  +1% 8,878 / 11 
General health variables 
Diabetes 1.25 (1.19-1.32)***  1.24 (1.18-1.29)***  -6% 8,770 I 11 
Smoking 1.25 (1.20-1.31)* * *  1.26 (1.20-1.32)***  0% 8,654 / 11 
BMI 1.25 (1.16-1.35)* * *  1.25 (1.16-1.35)***  0% 6,759 I 6 
Cardiac disease severity 
variables 
History of Ml 1.24 (1.17-1.32)* * *  1.23 (1.16-1.29)***  -7% 8,415 / 10 
LVEF 1.26 (1.18-1.35)* * *  1.24 (1.15-1.34)***  -8% 3,123 / 6 
Killip class 1.24 (1.16-1.32)* * *  1.22 (1.16-1.28)***  -7% 6,874 / 7  
Model Including al l  variables 
(Age, sex) history of Ml, LVEF, 1.24 (1.07-1.44)**  1.18 (1.00-1.40,) -23% 1,964 / 2 
Killip class, diabetes, smoking, p=0.053 
BMI 
(Age, sex) history of Ml,  LVEF, 1.23 (1.17-1.30)***  1.19 (1.12-1.26)***  -19% 2,181 / 3 
Killip class 
BMI :  body mass index; Cl : confidence interval; CVE: cardiovascular events; HR :  hazard ratio; LVEF :  left ventricular 
ejection fraction; Ml: myocardial infarction 
1 depression is included in all the models as a continuous variable (z-score) 
2 depending on availability of these variables in each study 
3 t he model including depression, age, and sex is the comparison model 
* * *  p<0.001 
** p<0.01 
* p<0.05 
Univariate logistic models 
For the all-cause mortality and cardiovascular events analyses, the variables diabetes, 
history of Ml, LVEF and Killip class each explained a substantial part (�more than 5%) of the 
association between post-Ml depression and all-cause mortality and improved model fit. 
The variables smoking and BMI did not add to the model (Tables 5 and 6). 
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Multivariable logistic model 
When all variables were added to the model at once, 3 studies and 2,225 patients remained, 
and the adjusted OR for depression was 1.24 per SD (95% Cl=l .07-1.44, p<0.001) in the 
all-cause mortality model. The added variables explained 30% of the association between 
post-Ml depression and all-cause mortality. When including the variables relating to cardiac 
disease severity only (i.e., history of Ml, LVEF, Killip class), the OR was 1 .27 per SD (95% Cl = 
1. 17-1.37, p<0.001). These variables explained 25% of the association (Table 5). 
The complete model for cardiovascular events included 2 studies and 1964 patients, and 
resulted in an OR for depression of 1. 18 per SD (95%Cl=l .00-l.39, p=0.053). The variables 
explained 23% of the association between post-Ml depression and cardiovascular events. 
The association was no longer significant after adjusting for all variables. When including 
the variables relating to cardiac disease severity only (history of Ml, LVEF, Killip class), the 
OR was 1 .19 per SD (95%CI = 1. 12-1.26, p<0.001). These variables explained 19% of the 
association (Table 6). 
Participation 
Of the 30 studies that were included in the summary data meta-analyses, the authors of 14 
studies participated and contributed their data. In addition, 2 studies that were published 
after the summary data meta-analysis contributed their data. Combining all available studies 
resulted in inclusion of 51% (10,175 of 19,859) of eligible patients. 
To estimate the impact of non-participation of studies on the association, 2-year ORs for 
post- Ml depression were compared for included and excluded studies, as 2-year follow-up 
data were available for most studies. For comparison purposes, this was done on the studies 
that were included in the original summary data meta-analysis. For excluded studies that 
reported on all-cause mortality, the unadjusted OR was 1.98 (95%CI 1.62-2.42, p<0.001) 
and for included studies, the unadjusted OR was 2.45 (95%CI 1.46-4.14, p<0.001), with no 
significant difference. However, for cardiovascular events, the ORs of excluded and included 
studies differed significantly (p=0.04), with an unadjusted OR of 1 .83 (95%CI 1.40-2.39, 
p<0.001) for excluded studies and 1.34 (95%CI 1 .17-1.54, p<0.001) for included studies. 
Discussion 
Main results 
The association between post-Ml depression and all-cause mortality and cardiovascular 
events was partly attenuated, but remained significant, after adjustment for cardiac 
disease severity and other health variables. In Cox regression analyses, adjusting for cardiac 
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disease severity, i.e. history of Ml, LVEF and Killip class, resulted in an attenuation of 29% 
in the all-cause mortality model and 21% in the cardiovascular events model. Adjustment 
for the health-related variables smoking and BMI did not result in an attenuation of the 
association between post-Ml depression and all-cause mortality or cardiovascular events, 
but adjustment for diabetes attenuated the association for both outcomes by 7%. In logistic 
regression analyses, results were similar, 
The fact that, after attenuation for variables indicating cardiac disease severity, the 
association between post-Ml depression and prognosis remains can mean several things. 
First, adjustments for more variables indicating disease severity may results in stronger 
attenuation. Second, other mechanisms than disease severity are likely to be involved in the 
association. For example, depression has been associated with changes in ANS functioning, 
and in HPA-axis activity 11•57•58• In addition, increased inflammation 11•59 and platelet reactivity 
11•60•61 have been associated with depression. As these physiological processes may be 
particularly disturbed in depressed Ml patients and they are all involved in the development 
and progression of cardiovascular disease, they may be mechanisms through which 
depression in Ml patients can affect prognosis. 
In addition to physiological mechanisms, psychological mechanisms may be involved. 
Depression in Ml patients has been associated with a range of behaviors that are unhealthy 
and may increase the risk of mortality and new cardiac events. Depressed patients have poor 
medication adherence 62•64, and low adherence to rehabilitation programs 65• Moreover, they 
display more generally unhealthy behaviors, such as maintaining a high-fat diet, smoking, 
and a lack of physical exercise 66-68• In addition to physiological mechanisms, psychological 
mechanisms may be involved. Depression in Ml patients has been associated with a range 
of behaviors that are unhealthy and may increase the risk of mortality and new cardiac 
events. Depressed patients have poor medication adherence 62-64, and poor adherence to 
rehabilitation programs 65• Moreover, they display more generally unhealthy behaviors, such 
as maintaining a high-fat diet, smoking, and a lack of physical exercise 66-68• 
These unhealthy behaviors may be the result of psychological mechanisms associated with 
depression. For example, low self-efficacy in depressed cardiac patients may imply they 
are less likely to believe they can control and influence their prognosis, for example by 
changing unhealthy behavior patterns. In a sample of heart failure patients, low self-efficacy 
was associated with poor adherence 69, and in another study, low self-efficacy predicted 
poor self-management behaviors in Ml patients 70• Interestingly, self-efficacy appears to 
be associated with poor adherence and health status independently of depression 59·11• 
However, evidence also suggests that the association between self-efficacy and worsened 
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prognosis is caused by worse cardiac disease severity in patients with low self-efficacy 72, 
which is consistent with the confounding role of disease severity in the association between 
depression and prognosis. 
The attenuation after adjusting for LVEF and Killip class was somewhat stronger for all-cause 
mortality than for cardiovascular events in both time-to-event {LVEF 15 vs 10%, Killip class 
19 vs. 12%) and logistic {LVEF 12 vs. 8%, Killip class 13 vs. 7%) regression analyses. This is 
unexpected, as these variables appear to be more strongly related to cardiac disease than 
to all-cause mortality and would therefore be expected to explain more of the association 
between depression and cardiac outcomes than of the association between depression and 
all-cause mortality. Potentially, however, poor Killip class and low LVEF, symptoms of heart 
failure, are markers of poor health in general. Heart failure is often comorbid with other 
serious health problems, such as lung disease, obesity and diabetes, with 40% of heart 
failure patients having more than 5 comorbid conditions 73• Any of these health problems 
may escalate and cause mortality, not just cardiac disease 73• This may explain why adjusting 
for LVEF and Killip class attenuates the association between depression and all-cause 
mortality more than it does the association between depression and cardiovascular events, 
as patients with low LVEF or Killip class have a higher risk of dying early of any cause, not just 
cardiac causes, than do patients with normal LVEF or Killip class. 
Results in the context of previous studies 
The attenuation of the association between post-Ml depression and cardiac prognosis after 
adjustment is a consistent finding in studies in this field 4,15-17, but identifying the factors that 
cause this attenuation has proven to be difficult thus far. In the summary data meta-analysis 
preceding this IPD meta-analysis 5, reported analyses adjusting for a number of factors, 
including disease severity-related variables, attenuated the association between post-Ml 
depression and prognosis by on average 21%. However, adjusted analyses were reported in 
a limited number of studies only, using different sets of variables, and adjustment was done 
for several variables at once, making it impossible to see to what extent individual variables 
were responsible for attenuation. The fully adjusted model in this IPD meta-analysis 
resulted in slightly higher attenuation than the summary data meta-analysis. Similar, but 
higher, attenuation was found in another summary data meta-analysis by Nicholson et al. 4• 
They reported that a pooled OR of adverse outcomes in depressed versus non-depressed Ml 
patients, adjusted for diverse variables, was attenuated by 41%. So overall, it appears that 
in this study we have identified the disease specific variables that are responsible for the 
largest portion of the attenuation known so far. 
194 
IPD meta-analysis depression and prognosis 
The summary data meta-analysis preceding this IPD meta-analysis resulted in ORs of 2.25 for 
all-cause mortality, 2.71 for cardiac mortality, and 1.59 for cardiovascular events. Similar effect 
sizes were reported in other meta-analyses 3.4. The current IPD meta-analysis resulted in HRs of 
1.32 for all-cause mortality and 1.19 for cardiovascular events. This apparent difference in the 
effect size is mainly due to the fact that these ORs and HRs are based on different analyses. The 
associations in the previous meta-analysis were based on (maximally) two-year follow-up data, 
dichotomized depression scores, and logistic regression analysis. The main associations in the 
current IPD meta-analysis are based on longer follow-up data, continuous depression scores, 
and Cox regression analyses. In previous meta-analyses, dichotomous depression scores 
were used, so the effect sizes represented the increase in risk associated with the difference 
between depressed and non-depressed patients, which is a large difference. Using continuous 
depression scores, the HR in this IPD meta-analysis represent the increase in risk associated 
with one SD increase in continuous depression scores, so the steps involved are smaller, and 
results are more precise. All these differences, and the fact that the risk of spurious results due 
to low numbers of events is small in the IPD meta-analysis, explain these apparently different 
results in the IPD meta-analysis compared to the summary data meta-analysis. As depression 
is by nature a continuous variable instead of a dichotomous variable, expressing the effect on 
prognosis per SD is more accurate than expressing it dichotomously. 
Strengths and limitations 
Individual studies often lack power to adjust for several variables, and summary data meta­
analyses are limited to combining reported data. The current IPD meta-analysis allowed 
us to investigate in detail some of the variables responsible for this attenuation. One of 
the main advantages is that time-to-event analyses could be performed. As time-to-event 
analyses combine the occurrence and timing of events 24, they are more reliable and 
stable than, for example, ORs, which are often used in summary data meta-analyses. In 
addition, adjustment for potentially confounding variables could be done systematically 
across studies, with increased power and specificity of results. This resulted in a relatively 
accurate estimate of the effect of cardiac disease severity on the association between post­
Ml depression and prognosis. 
There were also a number of limitations to this study: First, the analyses were to some extent 
l imited in power, as, in addition to not all studies participating, some of the participating 
studies did not contain all variables that were selected for analyses. For example, for 
analyses with Killip class and LVEF, a limited number of studies (6 and 5) were available. 
However, these analyses are still based on a large number of patients, and there is no other 
way to perform such analyses. Therefore they do have an added value in summarizing the 
role of these variables in the association between post-Ml depression and prognosis. 
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With regard to participation, of 30 eligible studies, 16 were included, of which the majority 
were from Western, first world countries. This level of participation is common for IPD meta­
analyses of observational studies 33• For example, Schmid et al. achieved participation of 
11 of 14 of the researchers of clinical trials 74, but Sternberg et al. achieved participation 
of 13 of 24 {54%) observational studies 75, and Wicherts et al. of 64 of 249 studies {26%) 
76
• In addition, there were no appreciable differences between eligible studies that were 
included and those that were excluded. We therefore concluded that the data available for 
this IPD meta-analysis, and the results of the analyses, are representative of Ml patients in 
first world countries, and that the benefits of analyzing IPD outweighed the potential effects 
of excluding relevant studies. 
Second, an inherent problem of IPD meta-analyses is that individual studies use different 
methods to assess relevant variables. In the current IPD meta-analysis, variables were 
harmonized across studies, with the main issue being depression measurement. However, 
such harmonization always contains the risk of combining measurements based on different 
underlying constructs 77• For depression, however, most studies used the BDI, making their 
data comparable. The other questionnaires used were the BDI-FS, HADS-D, and Zung SOS, 
which are highly correlated with the BDI. Item Response Theory methods of harmonization 
could not be used here, as they require individual depression item scores, which were not 
available for 4 of the 16 studies. Standardizing depression scores within each study may 
introduce bias by leveling out any differences in depression severity and prevalence between 
studies, which may affect the strength of the association between post-Ml depression and 
prognosis. If the strength of the association is different for patients with less severe vs. more 
severe depression, this would not be accounted for by these standardization method. We 
therefore investigated whether this bias was present in our study. To do this, a variable was 
added to the model that describes the level of depression per study (percentage depressed 
based on depression questionnaire scores), as well as an interaction variable of the 
standardized depression scores and the percentage depressed variable. If this interaction 
variable would be a significant predictor in the model, this would mean that the association 
between depression and prognosis is moderated by level of depression. This, however, was 
not the case { HR 1.00, 95% Cl 0.99-1.01, p = 0.915). We are therefore confident that this 
potential bias did not affect our results. 
Third, although LVEF, history of Ml, and Killip class are important predictors of post­
Ml mortality and morbidity, they are not the only risk factors associated with worsened 
prognosis. Other important variables that are related to disease severity, for example, heart 
rate, blood pressure, treatment with PTCA or CABG, etc. 78, could not be included in the 
analyses. Similarly, a number of non-cardiac comorbidities, such as chronic obstructive 
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pulmonary disease (COPD} and kidney disease are known to be associated with worsened 
outcomes 79• Also, the type of treatment in the acute phase and subsequent pharmacological 
treatment can affect outcomes. Finally, behavioral variables that were not incorporated in 
the model can attenuate the association. In a sample of stable CAD patients, Whooley et al. 
found that physical activity is an important confounder of the association 37• Adding these 
variables to a prediction model is likely to result in additional attenuation of the association 
between post-Ml depression and prognosis. However, related research suggests the 
association may still remain. Kronish et al., for example, found that depression after acute 
coronary syndrome (ACS} remained associated with all-cause mortality, even after adjusting 
for GRACE risk score and LVEF 80 and Meurs et al . found similar results after adjusting the 
association for GRACE risk score in Ml patients 81• 
Finally, the outcome of all-cause mortality is somewhat imprecise in investigating the 
association between post-Ml depression and prognosis. First, in some studies, cardiac deaths 
may be included in the outcome "cardiavascular events" as well as in the outcome "all-cause 
mortality". Therefore, the results of the analyses for the two outcome measures are based 
in part on the same event data. Second, as all-cause mortality includes non-cardiac cases 
of mortality, the results of this study might encompass a part of the association between 
post-Ml depression and prognosis that is not specific to cardiac disease. However, the 
reason to use all-cause mortality was that the outcome data available in studies of post-Ml 
depression often include mortality without specified causes of death. This was preferred 
over excluding studies without cardiac-specific outcome measures, as it would considerably 
reduce the number of available studies and otherwise relevant data. In addition, all-cause 
mortality includes cardiac mortality, and data on cardiac mortality and morbidity were 
analyzed separately to obtain results that were maximally specific. As all-cause mortality 
includes non-cardiac mortality, the proportion of variance in the association between post­
Ml depression and all-cause mortality explained by cardiac disease severity may be smaller 
than it would be when only cardiac mortality were included. This is because part of the 
association between post-Ml depression and all-cause mortality is non-specific for cardiac 
disease and may therefore not be affected by adjusting for cardiac disease related variables. 
Conclusions 
This study represents an important step forward in understanding the association between 
post-Ml depression and prognosis, as it is the first time that the amount of attenuation of 
this association by cardiac disease severity has been systematically quantified. Therefore, 
an important part of the inconsistencies in previous literature, due to conflicting results 
and methodological issues, has been solved. It appears more severe cardiac disease is a 
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common underlying factor resulting in both poorer prognosis and higher risk of depression. 
In addition, however, post-Ml depression remains independently associated with poorer 
cardiac prognosis, despite this attenuation. This means either that it is depression itself 
that adversely affects outcomes, or that unknown mechanisms can further explain the 
association. 
Future research should focus not only on the mechanisms through which post-Ml depression 
is associated with poorer cardiac outcomes, but also on better ways to treat post-Ml 
depression. As depression is widely recognized to be an extremely heterogeneous concept, 
with many different etiologies, symptoms profiles, and clinical courses, there currently is a 
movement towards more individualized treatments. Within such individualized depression 
care for Ml patients, integrating depression treatment and treatment of major indicators of 
cardiac disease severity could help improve prognosis, which post-Ml depression treatments 
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compl./hour or � 5 ep. of unsust. 
ventr. tach.; age < 75; LVEF > 20% 
896 / standard ized criteria for Ml 
68% 
222 / standardized criteria for Ml 
78% 
301 / standardized criteria for Ml; freq. 
82% or repet. ventr. depol. with in 6 to 
45 days of Ml 
331 / standardized criteria for Ml 
66% 
553 / standard ized criteria for Ml; 
100% male sex; age < 66 
344 / standardized criteria for Ml 
73% 
1803 standardized criteria for M l  
/ na  
Exclusion criteria 
illiterate in Engl ish; 
i nadequate eyesight; poor 
dominant hand mobility 
other life-threat. med. illn .; 
cogn. impairm.; periproc. 
Ml; unable to commun.; 
too ill; lived too far away; 
adm. reas. 
other life-threat. med. illn.; 
cogn. impairm.; periproc. 
Ml; unable to commun.; 
too i ll 
illiterate in English and 
French; death before 
2-week postrandomiz. cl inic 
visit 
other life-threat. med. illn.; 
cogn. impairm.; illiterate 
in English; too ill; in hosp. 
mortality 
nr 
age > 80; index Ml within 
28 days of preceding event 
unable to commun.; i n-
hosp. mortality; major 
psych. disorder 
Mean Depression N / %  Follow- Reason for 
age measurement depressed up time exclusion 
instrument / (days) 
cut-off score 
nr BDI, version nr; 140 / 40% 365 unable to 
cutoff nr contact 
59 BDI, version nr 290 / 32% 365 not 
/ �  10 interested 
60 BDI, version nr 66 / 31% 549 not 
/ �  10 interested 
34 / 15% 
DIS 
64 BDI, version nr 98 / 33% 732 unable to 
/ �  10 contact 




54 KSb-S / 90% 80 / 14% 183 data not iii' 
0. 
available 




na ZSDS / � 40 860 / 48% 732 data not 
available :;) � 
iii' 
N  





F i r s t  a u t h o r ;  s t u d y  
S t a r t  N / %  I n c l u s i o n  c r i t e r i a  
E x c l u s i o n  c r i t e r i a  
M e a n  D e p r e s s i o n  N / %  F o l l o w - R e a s o n  f o r  
�  
n a m e ;  c o u n t r y  
o f  m a l e  
m e a s u r e m e n t  d e p r e s s e d  u p t i m e  
e x c l u s i o n  a g e  
s t u d y  
i n s t r u m e n t /  ( d a y s )  
c u t - o ff  s c o r e  
J . S .  R u m s f e l d  
8 9  
1 9 9 9  6 3 4 /  s t a n d a r d i z e d  c r i t e r i a  f o r  M l ;  M l  
v a l v u l a r  o r  c o n g e n .  h e a r t  
6 5  M O S - D  /  �  0 . 0 6  1 4 3  /  2 3 %  4 8 8  u n a b l e  t o  
E P H E S U S  
7 2 %  
c o m p l i c .  b y  L V  d y s f u n c t i o n  a n d  f a i l u r e ;  d i u r e t i c s  o t h e r  t h a n  c o n t a c t  
U S A  
h e a r t  f a i l u r e  e p l e r e n o n e  
P .  S i l v e r s t o n e  
9 0  
1 9 8 4  1 0 8 /  M l  
n r  6 3  M A D R S / �  1 4  4 8 /  4 4 %  8  
u n a b l e  t o  
U K  
7 5 %  
c o n t a c t  
K . G .  S m o l d e r e n  
9 1  
2 0 0 3  2 3 4 7  
s t a n d a r d i z e d  c r i t e r i a  f o r  M l ;  a g e  
t r a n s f e r  f r o m  o t h e r  f a c .  6 1  P H Q /  �  1 0  5 1 6  /  2 2 %  1 4 6 0  d a t a  n o t  
P R E M I E R  
/ 6 8 %  �  1 8  >  2 4  h o u r s  a f t e r  M l ;  
a v a i l a b l e  
U S A  
i n c a r c e r a t e d ;  u n a b l e  t o  
c o m m u n .  
C .  S (l) r e n s e n  
9 2  
1 9 9 9  7 6 1 /  s t a n d a r d i z e d  c r i t e r i a  f o r  M l  o t h e r  l i f e - t h r e a t .  m e d .  
5 9  
M D I  /  c u t o f f  n r  7 3  I  1 0 %  3 6 5  u n a b l e  t o  
D e n m a r k  
7 6 %  
i l l n . ;  a g e >  7 6 ;  m a j o r  c o n t a c t  
p s y c h .  d i s o r d e r ;  u n a b l e  t o  
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D e n m a r k  
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The aims of this discussion are to provide an overview of the main results of the systematic 
reviews and meta-analyses on depression in patients with cancer and Ml, as well as to 
discuss the strengths and limitations of the analytic methods applied. In addition, the wider 
context in which these studies are embedded, and alternative explanations and theories are 
discussed. It ends with the implications and final conclusions. 
Screening for depression and distress in patients with cancer 
Results of the systematic reviews on screening for depression and distress indicated there 
is little evidence that screening improves psychological outcomes in cancer patients. These 
findings are in line with those of previous studies in other patient groups 1-3, as evidence from 
RCTs is relatively scarce in all settings. The N ICE {UK), for example, recommended against 
screening in primary care settings because of a lack of evidence of its efficacy 4• Even if there 
had been more research to evaluate, the fact that screening alone does not improve depression 
or distress outcomes is not unexpected, as screening is only the first step towards improved 
outcomes, and treatment is the next essential element. Despite this, recommendations for 
screening often do not include recommendations for the management and treatment of 
patients who screen positive. As screening does not automatically result in increased referral 
rates or depression and distress treatment rates in cancer patients 5•6, screening programs 
need subsequent treatment programs. Some institutions, therefore, recommend screening 
only when integrated depression or distress management is available 7•8• 
Significant problems were detected in all three stages (screening accuracy assessment, 
treatment evaluation, and screening program evaluation) of research into the routine screening 
for depression or distress. First, accuracy of most screening instruments is not optimal, with 
high false positive rates. Similar false positive rates were found for depression screening 
instruments in patients with cardiovascular disease 3, and diabetes 9 • False positive screening 
diagnoses can result in unnecessary, high-cost, and stressful follow-up assessment and 
treatment. In addition, the methodology of the majority of accuracy studies is questionable. 
Instead of being based on standard cut-off scores, cut-off scores are often selected to maximize 
accuracy within study samples, which are generally small and contain few depression cases. 
This limits generalizability of the accuracy results to a wider cancer population. Furthermore, 
the studies on accuracy of screening typically include patients who are already diagnosed with 
depression or elevated distress, and potentially are already undergoing treatment, resulting 
in an overestimation of the accuracy of screening instruments. Such patients that are already 
diagnosed would not usually be screened in practice. 
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In treatment studies, most studies included cancer patients, regardless of whether or 
not they had elevated symptoms of distress or major depression. This tends to decrease 
estimates of treatment effects, as patients without psychological problems are unlikely 
to improve with treatment. For this thesis, therefore, only studies that included patients 
with elevated distress or depression were selected, but this reduced the number of studies 
available for evaluation. In addition, even in patients with elevated distress or depression, 
treatment effects were mostly modest. This is in line with an overview of the results of a 
number of meta-analyses on antidepressant and psychological treatment efficacy in primary 
care, which additionally show that treatment is mainly efficient for patients with severe 
symptoms of depression and distress 1. 
With regard to the evaluation of screening programs, the main problem is that most studies 
are not proper screening trials. Many studies investigating screening are not RCTs. First, many 
do not include a control group of patients who receive usual care without screening, which 
means in such studies, no objective evaluation of the additional benefit of screening can be 
made, as psychological support or pharmaceutical treatment is often already available to 
cancer patients as part of standard care. In other studies, sequential cohort designs are used, 
which are not randomized. Second, many studies screen for multiple problems with multiple 
instruments, both psychological and physical, which makes it impossible to determine the 
effects of screening for depression or distress alone. Third, many studies assess patients, 
but do not use a defined depression or distress cut-off score to determine which patients 
receive further assessment and treatment, so do not actually screen. Instead, referrals are 
based on nurse or clinician judgment, which is more subjective and dependent upon the 
amount of time and attention they can spend on psychological symptoms. 
Recommendations for or against routine screening need careful consideration and a solid 
evidence-base, as screening without definite benefits is not without harms. To begin with, 
patients who screen positive, but are not depressed or distressed (around 50% in this thesis), 
may become stressed by their diagnosis, and may be submitted to unnecessary treatment. 
Patients who incorrectly screen negative (around 10% in this thesis) may be denied access to 
treatment, even though they might need it. Also, patients' subjective needs for psychosocial 
support are not always congruent with their screening diagnosis, as many patients who 
screen negative want help, and many patients who screen positive do not. For example, in a 
study by Sollner et al., 40% of patients who screened negative for distress expressed a need 
for psychosocial suppport 10• Conversely, several studies investigated acceptance of referral 
and found that between 50% and 75% of positively screened patients did not accept referral 
10-13. Moreover, many patients who suffer from depression or distress, and who desire help, 
are likely to already receive treatment. Palmer et al. found that 64% of cancer patients with 
a psychiatric diagnosis already received psychotropic medication 14• 
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In summary, the main problem identified by the systematic reviews on screening for 
depression and distress in cancer patients is the lack of high-quality RCT's that are 
methodologically sound to support recommendations for or against routine screening in 
cancer patients. This lack of evidence means that no definite conclusions can be drawn and 
no recommendations can be made for routine screening in cancer patients. Data were too 
scarce or heterogeneous (for example due to different screening instruments, treatments, 
or patient groups) to be quantitavely combined. 
Post-Ml depression and cardiac prognosis 
The two summary data meta-analyses in this thesis provided an overview of current 
knowledge as well as more detailed insight into the nature and strength of the association 
between post-Ml depression and (cardiac) prognosis. The summary overview of the 
prognostic association of depression with outcomes showed that depressed post-Ml 
patients have an increased risk of 2.25 of all-cause mortality, 2.71 of cardiac mortality, and 
1.59 of cardiac events, and suggested that adjusting for disease severity may attenuate this 
risk with between 4-65%. 
A number of potential mechanisms are involved in the association between depression and 
cardiac outcomes. One of these mechanisms, inflammation, was investigated in depressed 
and non-depressed patients with stable and acute CHD, including Ml. It was concluded that, 
although there was a moderate association between inflammation (CRP) and depression in 
CHD patients, the role of inflammation in explaining the association is probably relatively 
small. Similar findings in otherwise healthy community-based samples and clinically 
depressed patients, in cardiac patients, and in cancer patients, were reported by Howren 
et al., who in addition found an association with interleukin-6 15• The role of inflammation 
in explaining worsened prognosis in CHD and Ml patients might be further investigated 
by adjusting the association for inflammation, but such inflammation data, or adjusted 
analyses, are rarely available. 
Other research into potential mechanisms has aimed at, for example, the differential 
effects of somatic and affective depressive symptoms, at differences between a new onset 
post-Ml depression and recurrent depression, and at changes in HPA-axis and the ANS. A 
fairly consistent finding is that somatic/affective depressive symptoms are more strongly 
associated with adverse outcomes than cognitive/affective symptoms 16-19• This may be 
due to the fact that somatic depressive symptoms overlap with physical symptoms of CAD, 
so in fact may represent cardiac disease severity rather than depression. However, as the 
association remains after adjusting for cardiac disease severity in other studies 18•19, the 
same as in the current thesis, symptom overlap cannot fully explain the association. This 
means depression can still be an independent predictor of worsened cardiac outcomes. 
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Another distinction is made between new onset depression and recurrent depression in Ml 
patients, in which new onset depression is generally thought to be more strongly associated 
with cardiac events 20-22• However, not all studies find evidence for this distinction 23, and a 
recent systematic review concluded there is no consistent evidence to support this theory 
24• More important for predicting outcomes may be whether depressive symptoms after an 
Ml persist or not 21• 
Other mechanisms may be abnormal HPA-axis activity and a deregulated {ANS) in patients 
with depression, which is associated with increased risk of new cardiac events in Ml patients 
25,26 • Deregulation of the autonomic nervous system results in, for example, increased 
inflammatory and coagulatory processes, as well as low heart rate variability {HRV), all 
of which are processes involved in myocardial ischemia 26 • Evidence exists for low HRV 
as a potential mechanism for adverse outcomes in depressed Ml patients 27• Similarly, 
Musselman et al. found depressed Ml patients exhibit increased platelet reactivity 28• If such 
mechanisms are involved, depression may have a directly causal association with prognosis. 
Furthermore, non-causal, factors that are associated with both physical illness and 
depression may explain part of the association. Comorbidity, such as diabetes, obesity and 
lung disease, is common in Ml patients, and patients with higher comorbidity are likely 
to have more symptoms of depression as well as a higher risk of adverse outcomes 29• In 
the IPD meta-analysis in this thesis, diabetes, for example, explained 7% of the association 
between post-Ml depression and prognosis, and diabetes is typically associated with 
elevated depression prevalence 30• A recent study found that the comorbid presence of both 
diabetes and depression in Ml patients increased the risk of mortality more strongly than 
did diabetes and depression independently 31• 
Depression is associated with unhealthy behaviors, such as smoking, lack of exercise and 
unhealthy diet 26 • The potential effects of such behaviors on the association between 
depression in cardiac patients and outcome are demonstrated by Whooley et al., who found 
that in a sample of stable CAD patients, 32% of the association was explained by different 
levels of physical activity between depressed and non-depressed patients 32• Adjusting for 
more relevant health behaviors in addition to disease severity is likely to attenuate more of 
the association between post-Ml depression and prognosis. 
The summary data meta-analyses provide an overall picture of the strength of the 
association between post-Ml depression and prognosis, and between inflammation and 
depression in CHD patients. Potential explanations for heterogeneity in the results were 
investigated in subgroup analyses, as were changes in the association over time. One of 
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the main questions in this field, to what extent disease severity confounded the association 
between post-Ml depression and prognosis, and whether depression is an independent 
predictor of prognosis after adjusting for disease severity, remained unanswered due to 
limited reporting of analyses adjusted for disease severity in original studies. This problem 
was therefore addressed by performing an IPD meta-analysis, which made it possible to 
perform analyses systematically adjusted for potentially confounding factors. In addition, 
in the summary data meta-analyses, power was limited, as it was based on the number of 
studies included (13 in the inflammation meta-analysis and 29 in the post-Ml depression 
and prognosis meta-analysis), while in the IPD meta-analysis, power is based on the total 
number of subjects available from the combined studies (over 10,000}. 
When, in the IPD meta-analysis, the association between post-Ml depression and prognosis 
was systematically adjusted for the disease severity indicators LVEF, previous Ml, Killip class, 
and other health factors, the association was substantially attenuated by around 25%, 
though depression remained a significant independent predictor of adverse outcomes. 
This indicates that disease severity plays a significant role in the association. However, 
attenuation of the association may be even larger when more disease-specific risk factors are 
added. This was investigated in a study of 6-month mortality in patients with acute coronary 
syndrome (ACS}, which includes Ml patients. Major disease-specific predictors of mortality 
were history of Ml, history of heart failure, increased pulse rate at presentation, elevated 
serum creatinine levels, low systolic blood pressure, elevated serum cardiac biomarker 
levels, percutaneous coronary intervention, and ST-segment depression on presentation 33, 
summarized as the GRACE risk score (Global Registry of Acute Coronary Events). In another 
study of Ml patients, Meurs et al. found that the GRACE risk score was associated with 
somatic symptoms of post-Ml depression only, not with cognitive symptoms. After adjusting 
for the GRACE risk score, the association between somatic symptoms of depression and 
cardiac events was attenuated, but remained as strong as the association between the 
GRACE risk score and cardiac events itself 34• 
Although IPD meta-analysis greatly increased the reliability of the results, one of the main 
limitations was that not all relevant studies could be included, as data from a number of 
research groups (14 of 30} were not available. Another limitation was that not all studies 
measured the same variables related to disease severity, or used different measurement 
instruments. Harmonization of data resulted in loss of at least some information. For example, 
some studies assessed all 4 levels of Killip class, while others only distinguished between 
good (I} and poor Killip class (II, Ill, and IV }. For analyses, therefore, Killip class in studies 
measuring 4 levels had to be dichotomized as well. Additionally, not all studies measured 
relevant risk factors, as discussed above, such as creatinine and cardiac enzyme levels, or 
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blood pressure. This means that for the main analyses, these factors could not be included 
in the prediction model, resulting in a potentially underestimation of attenuation. Finally, 
IPD meta-analysis is time-consuming and requires the cooperation of many researchers, but 
its possibilities in answering important questions may well outweigh the effort. 
Systematic reviews and meta-analyses in investigating depression in patients with medical 
illness 
Systematic reviews and meta-analyses are considered a gold standard in research, as 
they objectively summarize and evaluate the available evidence. The studies in this thesis 
support this classification by demonstrating the value of different methods of systematic 
review and meta-analysis in investigating depression in patients with medical illness. In the 
first three chapters, the importance of systematically searching for and reviewing existing 
literature for evidence-based clinical practice recommendations became clear. The added 
value of summary data quantitative meta-analysis was demonstrated in the two chapters 
on depression in patients with Ml. The ultimate level of meta-analytic techniques was the 
performance of an IPD meta-analysis, which helped to determine the role of disease severity 
in explaining the association between post-Ml depression and cardiac prognosis. 
In addition to the advantages of systematic reviews and meta-analyses, some limitations 
are inevitab le. Most importantly, systematic reviews and meta-analyses are dependent 
upon information available in the studies they include. When studies include incomplete 
information, or when relevant studies are scarce, the conclusions drawn in the review or 
meta-analysis are limited as well. Further limitations were discussed within the context 
of the different meta-analytic techniques and disease-specific findings in the preceding 
sections. 
Clinical relevance and implications for future research 
Ideally, clinical practice is based on scientific evidence. As much research is available, often 
with conflicting results, it may be difficult to keep track of the most reliable and relevant 
research. Therefore, systematic reviews and meta-analyses are important to provide an 
overview of research and to critically evaluate available evidence, which was the main 
purpose of this thesis. 
Regarding screening for depression and distress in cancer patients, the most important 
finding is a lack of evidence to support recommendations for routine screening. Various 
ways of addressing depression and distress in cancer patients are being investigated, and 
more research is needed to assess whether routine screening will be helpful in this issue. 
However, attention to the psychological implications of cancer has already greatly increased 
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over the years, and efforts and resources may therefore better be directed at improving 
treatment of depression and distress in cancer patients who want help, instead of at 
detection. The implications go beyond the setting of cancer, but extend to other medical 
patient groups, as the same issues apply. Similar recommendations for routine screening 
have been made for other patient groups, the same screening instruments are often used, 
and the same antidepressant medication and psychological services are available. Moreover, 
the lack of studies investigating the effectiveness of routine screening compared to usual 
care is characteristic for depression and distress screening in all fields. 
Understanding the mechanisms involved in the association between post-Ml depression 
and {cardiac) prognosis may lead to improved methods of addressing post-Ml depression 
and its effects on outcome. Systematic adjustment for disease severity and other factors 
explained 25% of the association. This means that in practice, assessment of risk factors 
and treatment for improving outcomes in depressed patients need not only be aimed at 
depression, but also at clinical signs of more severe cardiac disease. When clinicians know 
which factors are associated with increased mortality in depressed Ml patients, they can 
identify patients who are most vulnerable and address these risk factors. In this thesis, it 
became clear that patients with low LVEF and poor Killip class are at higher risk of mortality. 
In addition, patients with a history of Ml and patients with comorbid diabetes are at higher 
risk. Other potentially predictive risk factors that were not included in this thesis need 
further investigation. 
To conclude, systematic reviews and meta-analyses are essential to provide an overview 
of the state of research and of which knowledge is still lacking. They can help in evaluating 
what can safely be assumed to be true in a field of research, and in directing us at what best 
to investigate next. As Sir Austin Bradford Hill wrote: 
"All scientific work is liable to be upset or modified by advancing knowledge. That 
does not confer upon us a freedom to ignore the knowledge we already have or to 
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Depression is the most prevalent psychiatric disorder in Western countries. In the general 
population, around one in 20 people suffer from a major depression. In patients with serious 
medical conditions, the prevalence of depression is even higher. This may be a result of the 
psychological consequences of the illness, as well as of physiological processes involved in 
the medical condition, which may also be involved in the development of depression. Not 
only do depressed medical patients suffer from decreased quality of life, but depression is 
also associated with worsened disease prognosis. The mechanisms involved are a complex 
interaction between psychological, biological, and behavioral factors, making it difficult to 
investigate and treat depression in medical patients. 
In this thesis, the existing evidence in two areas of research was evaluated, both demonstrating 
the problems encountered when investigating depression in medical patients, i.e. cancer 
and myocardial infarction. This was done using systematic reviews and meta-analytic 
techniques, to be able to provide the most reliable answers to essential research questions 
in these fields. The literature was systematically identified, evaluated, summarized, and 
analyzed. In patients with cancer, one of the main issues concerning depression is whether 
cancer patients would benefit from routine screening for depression or distress. This 
was investigated in two systematic review studies. In patients with myocardial infarction, 
depression has been consistently found to be associated with worse (cardiac) prognosis. 
However, the mechanisms involved, and the potential role of cardiac disease severity in 
explaining this association, need further investigation. This was done in two summary data 
meta-analyses of the existing literature, as well as an individual patient data meta-analysis 
of combined data from research groups across the world. 
Screening for depression and distress in cancer patients: systematic reviews 
In patients with cancer, depression prevalence is on average around 25%. Next to 
depression, in oncology psychological problems associated with cancer are often defined 
using the term 'distress'. This encompasses not only major depression, but also anxiety, 
adjustment disorder, and subclinical levels of these disorders. Awareness of the impact 
of depression and distress on cancer patients' quality of life, but also on their cancer 
prognosis, has increased greatly. Consequently, questions about improved detection and 
treatment of depression and distress have arisen, which resulted in recommendations for 
routine screening for depression and distress in oncology practice. However, there does 
not yet appear to be a scientific basis for these recommendations. Therefore, in this thesis, 
the literature on screening for depression and distress in cancer patients was searched, 
summarized, and critically evaluated to investigate whether recommendations for routine 
screening are warranted and will improve psychological outcomes in cancer patients. 
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Three fundamental research questions were investigated to evaluate the effects of routine 
screening. First, for a routine screening program to be effective, screening instruments need 
to be accurate. Therefore, the literature on the psychometric properties of major depression 
screening instruments, such as the Hospital Anxiety and Depression Scale, was summarized 
and evaluated. Second, available depression and distress treatment methods need to be 
effective. To assess treatment effects, studies on depression and distress treatment in cancer 
patients were searched and summarized. Finally, it was evaluated whether cancer patients 
that were enrolled in depression or distress screening programs had better psychological 
outcomes than cancer patients who only had access to care as usual, which often already 
involves some form of psychological support. 
This was done for major depression and distress separately. For major depression, the DMS­
IV or ICD-10 clinical diagnosis of major depression serves as a gold standard for screening 
instruments. For distress, no uniform definition, and therefore no gold standard, exists. 
The systematic review of research on screening for major depression in cancer patients 
(Chapter 2) resulted in 19 studies of screening accuracy, one randomized controlled trial on 
major depression treatment, and no studies on the effects of complete screening programs 
on depression outcomes. Screening accuracy varied across studies, and the main finding 
concerning accuracy was that studies identify different optimal cut-off scores and have small 
samples of patients, making it difficult to generalize results to other cancer patient groups. 
The depression treatment study found moderate effects, which is common for depression 
treatment methods in general. There were no randomized controlled trials comparing the 
effects of a depression screening program to treatment as usual, which leaves the essential 
question unanswered. 
Similar conclusions were drawn from the systematic review on distress screening in cancer 
patients (Chapter 3). Fourteen randomized controlled trials on distress treatment were 
found, assessing pharmacological, psychotherapy and collaborative care interventions. 
Treatment effects on distress were generally small to moderate. The effects of distress 
screening compared to treatment as usual on psychological outcomes were investigated in 
one study, in which no improvements were found. 
In these systematic reviews, the evidence was either too heterogeneous (screening 
instrument accuracy) or the evidence was too scarce (treatment and screening effects) to 
quantitatively summarize in a meta-analysis. Moreover, the methodology of many studies on 
diagnostic accuracy was found to be less than ideal (Chapter 4). Most studies that assess the 
accuracy of depression screening instruments include patients who are already diagnosed 
or treated for depression. In clinical practice, these patients would not be screened, and 
including them in screening studies can lead to inflated estimates of screening accuracy. 
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In summary, both the systematic reviews on depression screening and on distress screening 
demonstrated that there is currently no evidence that routine screening for depression and 
distress benefits cancer patients. In addition, routine screening for depression or distress 
poses potential harms. Patients may be incorrectly labeled, either as depressed/distressed, 
or not depressed/distressed. This may result in additional distress, patients being submitted 
to unnecessary treatments, or being denied treatments they need. Furthermore, the costs 
for routine screening may better be invested in improving depression and distress treatment 
when such screening is not effective. To be able to make recommendations, or to advise 
against routine screening, evidence from randomized controlled studies on depression or 
distress screening programs that include depression or distress treatment compared with 
treatment as usual is essential. 
Depression and myocardial infarction: meta-analyses 
When a systematic literature search yields enough comparable studies, results may ideally be 
summarized using meta-analytic techniques. The methods, advantages, and disadvantages 
of such techniques in psychosomatic research were set out in Chapter 5. Meta-analysis can 
quantitatively summarize results, investigate relevant confounders and mediators, as well as 
provide ideas for future research. 
To investigate the mechanisms and strength of the association between post myocardial 
infarction depression and prognosis, two regular, summary data meta-analyses were 
performed, as well as one individual patient data meta-analysis of combined raw data from 
research groups across the world. 
One of the potential mechanisms between post myocardial infarction depression and 
prognosis, inflammation, was investigated in Chapter 6. Inflammation is a potential 
mechanism explaining the association between depression and coronary heart disease, as it 
is involved in the development and progression of coronary heart disease. This meta-analysis 
included both patients with acute coronary heart disease (including myocardial infarction) 
and patients with stable coronary heart disease, and investigated whether depression in 
coronary heart disease patients was associated with inflammation. Results of studies on 
the inflammation markers C-reactive protein and interleukin-6 were meta-analyzed, which 
revealed that depression in patients with coronary heart disease is associated with small to 
moderate elevations in C-reactive protein levels, but not with elevated interleukin-6 levels. 
Based on this meta-analysis, the evidence for inflammation as a major mechanism between 
depression and coronary heart disease appears weak. 
Next, the strength of, and potential confounders in the association between post myocardial 
infarction and worsened prognosis were investigated in two meta-analyses. An overview of 
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25 years of studies investigating the strength of the association between post myocardial 
infarction depression and prognosis was provided in Chapter 7. Outcomes of included studies 
were all-cause mortality, cardiac mortality, and cardiac events within 2 years after the initial 
myocardial infarction. A total of 29 studies were identified, including 16,889 patients. Post­
Ml depression was associated with an increased risk of 2.25 (OR) of all-cause mortality, 2.71 
(OR) of cardiac mortality, and 1.59 (OR) of new cardiac events. The size of these increased 
risks proved robust in subgroup analyses but declined over the years for cardiac events. 
Previous studies have demonstrated that the association between post myocardial infarction 
depression and prognosis may in part be explained by the severity of the underlying cardiac 
disease. To investigate this in more detail, an individual patient data meta-analysis was 
performed (Chapter 8). The advantages of this method compared to summary data meta­
analyses are that a single model for analyses can be applied to all studies, more detailed 
analyses of the effects of individual variables on the association can be performed, and the 
power of the analyses is greatly increased, increasing reliability of the results. 
Sixteen research groups participated and shared their databases of individual patient 
data. This resulted in a combined database of 10,175 patients. As time-to-event data were 
available, hazard ratios as well as odds ratios could be calculated. Analyses were adjusted 
for a number of variables indicating disease severity and other health related risk factors. As 
they were measured routinely in most studies, left ventricular ejection fraction, Killip class, 
and history of myocardial infarction were selected to represent cardiac disease severity. 
In addition, comorbid diabetes, smoking, and body mass index were added to the model 
as they are also considered major risk factors for cardiovascular disease. Left ventricular 
ejection fraction and Killip class explained the largest part of the association, and body mass 
index and smoking did not explain anything. Adjusting for all these variables in one model, 
which is not possible when using summary data only, resulted in an attenuation of around 
25% of the association between post myocardial infarction depression and prognosis. After 
this adjustment, depression remained independently associated with prognosis. 
Conclusions 
The systematic reviews on depression and distress screening in cancer patients not only 
served to summarize existing evidence, but also stressed that the evidence that screening 
benefits patients is too limited and heterogeneous to justify recommendations for routine 
screening. 
The meta-analyses on depression in patients with myocardial infarction summarized the 
existing evidence and indicate that depression is associated with a 1.6 to 2.7 times increased 
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risk of adverse outcomes. The mechanism of inflammation does not appear to be involved 
in this association. In addition, the individual patient data meta-analysis investigated the 
effects of individual variables representing disease severity that potentially confound the 
association in a detailed way that could not be done before in summary data meta-analyses. 
Severity of cardiac disease explained part of the association. 
This thesis demonstrates how systematic reviews and meta-analyses can provide an 
overview, summary, and re-analysis of existing evidence, and how they can provide 






Depressie is de meest voorkomende psychiatrische aandoening in Westerse landen. In de 
algemene bevolking lijdt ongeveer 1 op de 20 mensen aan een ernstige depressie. Onder 
mensen die een ernstige medische aandoening hebben is deze prevalentie nog hoger. 
Dit kan het gevolg zijn van de psychologische consequenties van de ziekte, maar ook van 
fysiologische processen die een rol spelen bij de ziekte, en die ook een rol kunnen spelen bij 
het ontstaan van depressie. Medische patienten met een depressie hebben niet alleen een 
verminderde kwaliteit van leven, maar depressie is ook geassocieerd met een verslechterde 
prognose van de ziekte. De mechanismen die hierbij betrokken zijn, zijn een complexe 
interactie tussen psychologische, biologische en gedragsfactoren, waardoor het lastig is om 
depressie bij medische patienten te onderzoeken en behandelen. 
In dit proefschrift zijn de bestaande resultaten uit twee onderzoeksgebieden geevalueerd, 
welke beide een �orbeeld zijn van de problemen die ontstaan bij het onderzoeken van 
depressie in medische patienten, namelijk het onderzoek bij patienten met kanker en met 
een myocard infarct. Oit is gedaan door middel van systematisch literatuuronderzoek en 
meta-analytische technieken, om de meest betrouwbare antwoorden op de essentiele 
vragen uit deze onderzoeksgebieden te kunnen geven. Relevante literatuur is systematisch 
ge'identificeerd, geevalueerd, ' · samengevat en geanalyseerd. Een van de grootste 
vraagstukken betreffende depressie in patienten met kanker is of deze patienten er baat bij 
hebben om systematisch gescreend te warden voor depressie of distress. Dit is onderzocht 
in twee systematische literatuurstudies. In patienten met een myocard infarct wordt 
consistent gevonden dat een depressie is geassocieerd met een slechtere (hart) prognose. 
De mechanismen hierachter, en de mogelijke rol van de ernst van de hartziekte in het 
verklaren van dit verband, moeten verder warden onderzocht. Dit is gedaan in twee meta­
analyses gebaseerd op samengevatte data gerapporteerd in bestaande artikelen, evenals in 
een meta-analyse gebaseerd op oorspronkelijke, individuele patientgegevens afkomstig van 
onderzoeksgroepen over de hele wereld. 
Screen en voordepressie en distress in patienten met kanker: systematische literatuurstudies 
De prevalentie van depressie in patienten met kanker is ongeveer 25%. Naast depressie 
warden psychologische problemen in de oncologie vaak aangeduid met de term 'distress'. 
Deze term omvat niet a Ileen ernstige depressie, maar ook angststoornis, aanpassingsstoornis 
en subklinische psychologische klachten. Het beset van de gevolgen van depressie en 
distress voor de kwaliteit van leven, maar ook voor de prognose van patienten met 
kanker is enorm gegroeid. Daardoor zijn er vragen gerezen over verbeterde detectie en 
behandeling van depressie en distress, wat heeft geresulteerd in aanbevelingen voor het 
systematisch screenen voor depressie en distress in de oncologie. Er lijken echter nag geen 
wetenschappelijke gronden te zijn voor deze aanbevelingen. Oaarom is in dit proefschrift de 
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literatuur betreffende screenen voor depressie en distress ge"identificeerd, samengevat en 
kritisch geevalueerd, om te onderzoeken of de aanbevelingen voor systematisch screenen 
terecht zijn en of screenen een positief effect heeft op de psychologische uitkomsten van 
patienten met kanker. 
Om de effecten van systematisch screenen te evalueren zijn drie fundamentele 
onderzoeksvragen onderzocht. Ten eerste kan een screeningsprogramma alleen succesvol 
zijn als de instrumenten waarmee wordt gescreend accuraat zijn. Daarom is de literatuur 
over de psychometrische eigenschappen van meetinstrumenten voor ernstige depressie, 
zoals de Hospital Anxiety and Depression Scale, samengevat en geevalueerd. Ten tweede 
moeten de beschikbare behandelmethoden voor depressie en distress effectief zijn. 
Om de effecten van behandeling te onderzoeken werden studies naar behandeling van 
depressie en distress in patienten met kanker ge"identificeerd en sam�ngevat. Ten slotte 
is er onderzocht of patienten met kanker die meededen aan een screeningsprogramma 
betere psychologische uitkomsten hadden dan patienten die alleen toegang hadden tot de 
gebruikelijke zorg, die vaak oak een vorm van psychologische hulp bevat. 
Dit is apart gedaan voor ernstige depressie en distress. De DSM-IV en ICD-10 diagnose voor 
ernstige depressie gelden als gouden standaard voor instrumenten voor depressiescreening. 
Voor distress bestaat geen uniforme definitie, en daarom oak geen gouden standaard. 
De systematische literatuurstudie naar het screenen voor ernstige depressie in patienten 
met kanker (Hoofdstuk 2), resulteerde in 19 artikelen over de accuraatheid van screenen, 
een gerandomiseerde en gecontroleerde studie naar de behandeling van ernstige depressie, 
en geen artikelen over de effecten van complete screeningsprogramma's op depressie­
uitkomsten. De accuraatheid van screenen verschilde per studie, en de belangrijkste 
bevindingen betreffende deze accuraatheid was dat studies verschillende optimale cut-off 
scores vinden, en dat het aantal patienten per studie klein is. Hierdoor zijn de resultaten 
moeilijk te generaliseren naar andere groepen patienten met kanker. In het onderzoek 
over de behandeling van depressie werden matige effecten gevonden, wat gebruikelijk is 
voor behandelmethoden van depressie in het algemeen. Er waren geen gerandomiseerde, 
gecontroleerde studies die de effecten van een screeningsprogramma voor depressie 
vergeleken met de effecten van gebruikelijke behandeling, waardoor de belangrijkste vraag 
onbeantwoord blijft. 
Soortgelijke conclusies werden getrokken uit de systematische literatuurstudie naar het 
screen en voor distress bij patienten met ka n ker (Hoofdstuk 3). Er werden 14 gera ndom iseerde, 
gecontroleerde studies gevonden naar de behandeling van distress, waarin farmacologische, 
psychotherapeutische en ge"integreerde zorginterventies werden onderzocht. De effecten 
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van behandeling van distress waren over het algemeen klein tot matig. De effecten van 
screenen voor distress vergeleken met de gebruikelijke behandeling werden in een studie 
onderzocht, waarin geen verbeterde psychologische uitkomsten werden gevonden. 
In deze systematische literatuuronderzoeken was het bewijs of te heterogeen (accuraatheid 
van screeningsinstrumenten), of te schaars (effecten van behandeling en screenen) om 
kwantitatief samen te vatten in een meta-analyse. Bovendien was de methodologie van 
veel studies over de diagnostische accuraatheid van screeningsinstrumenten niet optimaal 
(Hoofdstuk 4). De meeste studies die de accuraatheid van meetinstrumenten voor ernstige 
depressie meten includeren patienten die al gediagnosticeerd of onder behandeling 
zijn voor ernstige depressie. In de klinische praktijk zullen deze patienten niet warden 
gescreend en door ze te includeren in studies over screenen kan de accuraatheid van de 
screeningsinstrumenten warden overschat. 
Depressie en myocard infarct: meta-analyses 
Als een systematisch literatuuronderzoek genoeg vergelijkbare studies oplevert, kunnen de 
resultaten het beste warden samengevat door middel van meta-analytische technieken. 
De methoden, voordelen en nadelen van deze technieken in psychosomatisch onderzoek 
zijn besproken in Hoofdstuk 5. In een meta-analyse kunnen resultaten kwantitatief warden 
samengevat, kunnen relevante confounders en mediatoren warden onderzocht en kunnen 
ideeen voor vervolgonderzoek warden gevormd. 
Om de mechanismen achter, en de sterkte van het verband tussen depressie na een 
myocard infarct en prognose te onderzoeken, werden twee meta-analyses gebaseerd 
op samengevatte data gedaan, evenals een meta-analyse gebaseerd op oorspronkelijke, 
individuele patientgegevens van onderzoeksgroepen over de hele wereld. 
Een van de mogelijke mechanismen achter de associatie tussen depressie na een myocard 
infarct en prognose, inflammatie, werd onderzocht in Hoofdstuk 6. lnflammatie kan mogelijk 
het verband tussen depressie en hart- en vaatziekten verklaren, omdat het betrokken is bij 
zowel de ontwikkeling als voortgang van hart- en vaatziekten, evenals bij depressie. In deze 
meta-analyse werden zowel patienten met acute hartklachten (inclusief myocard infarct) en 
patienten met stabiele hartklachten ge'includeerd. Er werd onderzocht of depressie in deze 
patienten was geassocieerd met inflammatie. De resultaten van de inflammatiemarkers 
C-reactief prote'ine en interleukine-6 konden warden gecombineerd in meta-analyses, 
waaruit bleek dat depressie in patienten met hart- en vaatziekten geassocieerd was met 
matig verhoogde niveaus van C-reactief prote'ine, maar niet met verhoogde niveaus van 
interleukine-6. Op basis van deze meta-analyse is het bewijs voor inflammatie als belangrijk 
mechanisme in het verband tussen depressie en hart- en vaatziekten zwak. 
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De sterkte van de associatie tussen depressie na een myocard infarct en verslechterde 
prognose, en mogelijke confounders in deze associatie, zijn onderzocht in twee meta­
analyses. Een overzicht van 25 jaar onderzoek in studies die de sterkte van het verband tussen 
depressie na een myocard infarct en prognose onderzochten werd gegeven in Hoofdstuk 7. 
De uitkomsten van de ge·includeerde studies waren algehele mortaliteit, cardiale mortaliteit 
en cardiale events binnen twee jaar na het oorspronkelijke myocard infarct. In totaal werden 
29 studies gevonden, met bij elkaar 16,889 patienten. In meta-analyses bleek dat depressie 
na een myocard infarct is geassocieerd met een vergroot risico op algehele mortaliteit van 
2,25 (OR), cardiale mortaliteit van 2, 71 (OR) en nieuwe cardiale events van 1,59 (OR). De 
sterkte van deze verhoogde risico's bleek robuust in subgroepanalyses, maar verminderde 
over de tijd voor cardiale events. 
Eerdere studies lieten zien dat het verband tussen depressie na een myocard infarct en 
prognose mogelijk deels wordt verklaard door de ernst van de onderliggende hartziekte. 
Om dit gedetailleerder te kunnen onderzoeken is een meta-analyse van oorspronkelijke, 
individuele patientgegevens gedaan (Hoofdstuk 8). De voordelen van deze methode, 
vergeleken met meta-analyses gebaseerd op samengevatte data, zijn dat er een model 
voor de analyses op data van alle studies kan worden toegepast, dat er meer gedetailleerde 
analyses over de effecten van individuele variabelen op het verband kunnen worden 
gedaan, en dat de statistische power van de analyses aanzienlijk groter is, waardoor de 
betrouwbaarheid van de resultaten eveneens groter is. 
Zestien onderzoeksgroepen namen deel en stelden hun databestanden met individuele 
patientgegevens beschikbaar. Dit leverde een gecombineerde dataset van 10,175 patienten 
op. Omdat time-to-event gegevens beschikbaar waren, konden zowel hazard ratios als odds 
ratios worden berekend. De analyses werden gecorrigeerd voor een aantal variabelen die 
de ernst van de hartziekte aangeven en voor andere gezondheidsgerelateerde variabelen. 
Omdat left ventricular ejection fraction, Killip class en geschiedenis van myocard infarct 
standaard waren gemeten in de meeste studies, werden deze variabelen geselecteerd om 
de ernst van de hartziekte te vertegenwoordigen. Daarnaast werden diabetes, roken en 
body mass index toegevoegd aan het model omdat deze variabelen oak gezien worden 
als belangrijke risicofactoren voor hart- en vaatziekten. Left ventricular ejection fraction 
en Killip class verklaarden het grootste deel van het verband, en body mass index en 
roken verklaarden niets. Na correctie voor al deze variabelen in een model, wat in meta­
analyses gebaseerd op samengevatte data niet mogelijk is, verdween 25% van het verband 
tussen depressie na een myocard infarct en prognose. Na deze correctie bleef depressie 




De systematische literatuurstudies over screen en voor depressie en distress in patienten met 
kanker vatten niet alleen het bestaande onderzoek samen, maar benadrukken ook dat het 
bewijs dat patienten met kanker baat hebben bij deze screening te beperkt en heterogeen 
is om het systematisch screenen aan te kunnen bevelen. 
De meta-analyses over depressie bij mensen met een myocard infarct vatten het bestaande 
onderzoek samen en geven aan dat depressie geassocieerd is met een 1,6 tot 2, 7 keer 
grater risico op een slechte prognose. lnflammatie lijkt niet bij dit verband betrokken te 
zijn. Daarnaast zijn in de meta-analyse van individuele patientgegevens de effecten van 
variabelen die de ernst van de hartziekten representeren en mogelijk confounders zijn in het 
verband op een dusdanig gedetailleerde manier onderzocht die niet eerder mogelijk was in 
meta-analyses gebaseerd op samengevatte data. De ernst van de hartziekte verklaarde een 
deel van het verband. 
Dit proefschrift laat zien dat systematische literatuurstudies en meta-analyses een overzicht, 
samenvatting en zelfs re-analyses kunnen bieden van bestaande onderzoeksresultaten, en 
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